nimodipine has been researched along with Hemorrhage, Subarachnoid in 394 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic review and network meta-analysis (NMA) were conducted to explore the optimal administration route of nimodipine for treatment subarachnoid hemorrhage." | 9.41 | The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis. ( Hu, Y; Lei, G; Rao, Z, 2023) |
| "These results are consistent with a beneficial effect of locally delivered nimodipine (EG-1962) on SD after aSAH in more severely injured patients who are at risk of delayed cerebral ischemia related to SD." | 9.41 | Effect of Locally Delivered Nimodipine Microparticles on Spreading Depolarization in Aneurysmal Subarachnoid Hemorrhage. ( Alchbli, A; Carlson, AP; Hänggi, D; Macdonald, RL; Shuttleworth, CW, 2021) |
| "A sustained release microparticle formulation of nimodipine (EG-1962) was developed for treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 9.34 | NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage. ( Aldrich, EF; Bleck, T; Carlson, AP; Darsaut, TE; Diringer, MN; Etminan, N; Grubb, R; Hänggi, D; Ko, NU; Macdonald, RL; Mayer, SA; Ng, D; Strange, P; Suarez, JI; Wong, GK, 2020) |
| "Nimodipine is the only drug approved in the treatment of aneurysmal subarachnoid hemorrhage (aSAH) in many countries." | 9.30 | Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimo ( Aldrich, EF; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Macdonald, RL; Mayer, SA; Ng, D; Saville, BR; Schmutzhard, E, 2019) |
| "We conducted a randomized, open-label, phase 1/2a, dose-escalation study of intraventricular sustained-release nimodipine (EG-1962) to determine safety, tolerability, pharmacokinetics, and clinical effects in aneurysmal subarachnoid hemorrhage." | 9.24 | Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid ( Aldrich, F; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Hoh, BL; Macdonald, RL; Mayer, SA; Mocco, J; Steiger, HJ, 2017) |
| "Our objective was to compare the effectiveness of intravenous and enteral nimodipine in preventing poor outcome from delayed cerebral ischemia in patients with subarachnoid hemorrhage." | 9.22 | A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis. ( Boscolo, A; Cacco, N; Carere, A; Correale, C; De Cassai, A; Diana, P; Disarò, L; Geraldini, F; Munari, M; Navalesi, P; Zampirollo, S, 2022) |
| "The aim of this study was to evaluate serum nimodipine concentrations in patients with aneurysmal subarachnoid hemorrhage (SAH) after parenteral therapy and a following course of enteral administration." | 9.20 | Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. ( Abboud, T; Andresen, H; Czorlich, P; Duehrsen, L; Koeppen, J; Regelsberger, J; Stenzig, J; Westphal, M, 2015) |
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 9.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| "The calcium antagonist nimodipine has been shown to reduce the incidence of ischemic complications following aneurysmal subarachnoid hemorrhage (SAH)." | 9.14 | Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. ( Cronqvist, M; Kronvall, E; Nilsson, OG; Romner, B; Säveland, H; Undrén, P, 2009) |
| "The efficacy of intra-arterial administration of nimodipine (IAN) in patients with severe vasospasm after aneurysmal subarachnoid hemorrhage (SAH) remains unproved." | 9.13 | Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. ( Beseoglu, K; Hänggi, D; Steiger, HJ; Turowski, B; Yong, M, 2008) |
| "The prophylactic use of nimodipine in patients with aneurysmal subarachnoid hemorrhage reduces the risk of ischemic brain damage." | 9.12 | Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. ( Briegel, J; Kunz, M; Prueckner, S; Schmid-Elsaesser, R; Steiger, HJ; Zausinger, S, 2006) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 9.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "Nimodipine has been shown to improve neurological outcome after subarachnoid hemorrhage (SAH); the mechanism of this improvement, however, is uncertain." | 9.11 | The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage. ( Abrahams, JM; Bloom, S; Grady, MS; Heuer, GG; LeRoux, PD; Maloney-Wilensky, E; Smith, MJ; Stiefel, MF, 2004) |
| "To assess the cost-effectiveness ratio of nimodipine administration after aneurysmal subarachnoid hemorrhage (SAH) and surgery." | 9.09 | Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery. ( Karinen, P; Koivukangas, J; Koivukangas, P; Ohinmaa, A; Ohman, J, 1999) |
| "A prospective, randomized, double-blind, placebo-controlled study of nimodipine used to treat traumatic subarachnoid hemorrhage (tSAH) was conducted in 21 German neurosurgical centers between January 1994 and April 1995." | 9.08 | Traumatic subarachnoid hemorrhage and its treatment with nimodipine. German tSAH Study Group. ( Braakman, R; Harders, A; Kakarieka, A, 1996) |
| "A total of 213 patients with verified aneurysmal subarachnoid hemorrhage (SAH) of Grades I to III (Hunt and Hess classification) were enrolled in a double-blind placebo-controlled trial to determine the effect of intravenous nimodipine on delayed ischemic deterioration and computerized tomography (CT)-visualized infarcts after SAH and surgery." | 9.07 | Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. ( Heiskanen, O; Ohman, J; Servo, A, 1991) |
| "We studied platelet function in 41 patients with subarachnoid hemorrhage who were randomized to receive either nimodipine or placebo in a double-blind fashion." | 9.06 | Effect of nimodipine on platelet function in patients with subarachnoid hemorrhage. ( Hillbom, M; Juvela, S; Kaste, M, 1990) |
| "To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes (death and severe disability) after subarachnoid haemorrhage." | 9.06 | Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. ( Foy, PM; Humphrey, PR; Illingworth, R; Lang, DA; Murray, GD; Nelson, R; Pickard, JD; Richards, P; Shaw, MD; Teasdale, GM, 1989) |
| "The effect of intravenous nimodipine on the incidence of mortality and delayed ischemic neurological deficits of patients after aneurysmal subarachnoid hemorrhage (SAH) and surgery was studied in a prospective double-blind placebo-controlled trial." | 9.06 | Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. ( Heiskanen, O; Ohman, J, 1988) |
| "We enrolled 75 consecutive patients admitted with subarachnoid hemorrhages in a randomized, double-blind, placebo-controlled trial to determine the effect of early intervention with nimodipine on outcome and cerebral blood flow." | 9.06 | Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. ( Dorrance, D; Lowe, D; Mee, E; Neil-Dwyer, G, 1988) |
| "The present studies show that nimodipine prevents and/or improves permanent ischemic neurological deficits in patients with subarachnoid hemorrhage." | 9.06 | Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage. ( Battye, R; Porto, L; Ryman, T; Strugo, V; Taquoi, G; Tettenborn, D, 1987) |
| "We enrolled 125 neurologically normal patients with intracranial aneurysms in a multi-institution, prospective, double-blind, randomized, placebo-controlled trial within 96 hours of their subarachnoid hemorrhage, to determine whether treatment with the calcium blocker nimodipine would prevent or reduce the severity of ischemic neurologic deficits from arterial spasm." | 9.05 | Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. ( Ahn, HS; Allen, GS; Battye, R; Bertsch, LA; Boisvert, DP; Boone, SC; Chou, SN; Crabbe, RA; Dorsey, FC; Hundley, MB; Ingram, CR; Johnson, RK; Kelly, DL; Lavik, PJ; Mellits, DE; Preziosi, TJ; Rosenbloom, SB; Strom, JA; Transou, CR; Weir, BK, 1983) |
| "Experimental and clinical studies have been performed to investigate the validity of a pharmacological approach to prevent delayed ischemic neurologic deficit from vasospasm after subarachnoid hemorrhage: the calcium channel blocker nimodipine was administered intravenously and perivascularly." | 9.05 | Preventive nimodipine and acute aneurysm surgery. Heading for the control of complications after aneurysmal subarachnoid hemorrhage. ( Auer, LM, 1985) |
| " Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia." | 9.01 | Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage. ( Cowart, JB; Freeman, WD; James, C; Peacock, SH; Reid, JM; Turnbull, MT, 2019) |
| "The authors report findings from a metaanalysis of all published randomized trials of prophylactic nimodipine used in patients who have experienced subarachnoid hemorrhage (SAH)." | 8.79 | Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. ( Barker, FG; Ogilvy, CS, 1996) |
| " We propose a meta-analytical evaluation of published clinical trials on nimodipine, a dihydropiridin calcium antagonist, in subarachnoid hemorrhage and in ischemic stroke." | 8.79 | From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders. ( Di Mascio, R; Marchioli, R; Tognoni, G, 1994) |
| "Nimodipine, a calcium-channel antagonist with a relatively selective vasodilatory effect on cerebral blood vessels, has recently been approved for improvement of neurologic deficits due to spasm following subarachnoid hemorrhage." | 8.77 | Nimodipine in the treatment of subarachnoid hemorrhage. ( Tietze, KJ; Yasuda, SU, 1989) |
| "Nimodipine has recently been approved for the treatment of cerebral ischemia caused by subarachnoid hemorrhage." | 8.77 | Nimodipine in subarachnoid hemorrhage. ( DiPalma, JR, 1989) |
| "The chemistry, pharmacology, pharmacokinetics, adverse effects, dosage, and availability of nimodipine are discussed, and the clinical use of nimodipine in preventing and treating cerebral arterial spasm in patients with subarachnoid hemorrhage is reviewed." | 8.77 | Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage. ( Welty, TE, 1987) |
| "Nimodipine improves outcomes following aneurysmal subarachnoid hemorrhage (aSAH) and current guidelines suggest that patients with aSAH receive nimodipine for 21 days." | 8.31 | Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study. ( Almohaish, S; Ammar, AA; Ammar, MA; Armahizer, MJ; Barra, ME; Barthol, CA; Binning, MJ; Blunck, JR; Brophy, GM; Brown, CS; Burgess, SV; Buschur, PL; Cantin, A; Clark, SL; Cook, AM; Delucilla, L; Fox, N; Hamilton, LA; Hefny, FR; Hintze, TD; Kaupp, K; Keegan, SP; Mahmoud, LN; Mahmoud, SH; Naydin, S; Ngan, Z; Owusu-Guha, J; Panos, NG; Perreault, MM; Peters, DM; Rowe, AS; Sandler, M; Shewmaker, J; Tesoro, EP; Traeger, J; Wieruszewski, ED, 2023) |
| "Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous subarachnoid hemorrhage (SAH)." | 8.31 | Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage. ( Altmann, K; Beer, R; Helbok, R; Ianosi, BA; Kindl, P; Kofler, M; Lindner, A; Pfausler, B; Putnina, L; Rass, V; Schiefecker, AJ, 2023) |
| "The only established pharmacological treatment option improving outcomes for patients suffering from subarachnoid hemorrhage (SAH) is the L-type-calcium channel inhibitor nimodipine." | 8.31 | Nimodipine Reduces Microvasospasms After Experimental Subarachnoid Hemorrhage. ( Harapan, BN; Lin, X; Plesnila, N; Schwarting, J; Terpolilli, NA, 2023) |
| "The selective intra-arterial nimodipine application for the treatment of cerebral vasospasm (CVS) in patients after spontaneous subarachnoid hemorrhage (sSAH) is widely employed." | 8.12 | Radiation exposure in the intra-arterial nimodipine therapy of subarachnoid hemorrhage related cerebral vasospasm. ( Bos, D; Deuschl, C; Dörner, N; Forsting, M; Guberina, N; Jabbarli, R; Kleinschnitz, C; Li, Y; Opitz, M; Radbruch, A; Sure, U; Uslar, E; Wetter, A; Zensen, S, 2022) |
| "Nimodipine improves outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 8.12 | Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage. ( Blake, C; Dai, X; Furie, KL; Mahmoud, L; Mahta, A; Reznik, ME; Thompson, BB; Wendell, LC; Zullo, AR, 2022) |
| "Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown." | 8.12 | Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022) |
| "Intra-arterial nimodipine (IAN) injections are performed in refractory delayed cerebral ischemia (DCI) related to cerebral vasospasm (CVS) after spontaneous subarachnoid hemorrhage (sSAH), but the clinical benefits are inconclusive and angiographic treatment failure is observed." | 8.12 | Analysis of Angiographic Treatment Response to Intra-Arterial Nimodipine Bolus Injection in Patients with Medically Refractory Cerebral Vasospasm After Spontaneous Subarachnoid Hemorrhage. ( Ditz, C; Küchler, J; Neumann, A; Schacht, H; Schramm, P; Tronnier, VM, 2022) |
| "The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters." | 8.12 | Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. ( Chakrabarti, D; Konar, SK; Kotwal, A; Radhakrishnan, M; Ramalingaiah, AH; Shukla, D; Srinivasaiah, B; Sundaram, M, 2022) |
| "This study aimed to discuss the influence of nimodipine+ulinastatin on the neurological function and inflammatory reaction in patients with cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH)." | 8.02 | Influence of nimodipine combined with ulinastatin on neurological function and inflammatory reaction in patients with cerebral vasospasm after subarachnoid hemorrhage. ( Chen, M; Liu, H; Wei, X; Zhang, Q; Zou, W, 2021) |
| "Randomized-controlled trials and meta-analyses showed nimodipine use after aneurysmal subarachnoid hemorrhage (aSAH) leads to reduction in incidence of cerebral infarction, persistent neurological deficits, and poor outcomes." | 8.02 | Nimodipine after aneurysmal subarachnoid hemorrhage: Fourteen-day course for patients that meet criteria for early hospital discharge. ( Burke, RM; Chen, CJ; Kalani, MYS; Mastorakos, P; Myers, KM; Nguyen, JM; Park, MS; Sokolowski, JD; Soldozy, S, 2021) |
| " Here we describe a patient with subarachnoid hemorrhage treated with nimodipine, which resulted in marked bradycardia with junctional atrioventricular heart block." | 7.96 | Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage. ( Freeman, WD; James, CL; Turnbull, MT, 2020) |
| "Our findings suggest that nimodipine administration via enteral feeding tubes may be associated with vasospasm and DCI in subarachnoid hemorrhage patients secondary to reduced exposure." | 7.96 | The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage. ( Abdallah, YEH; Isse, FA; Mahmoud, SH, 2020) |
| "Current guidelines recommend the administration of nimodipine for the prevention of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH)." | 7.91 | Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage? ( Hernández-Durán, S; Malinova, V; Mielke, D; Rohde, V, 2019) |
| "Fifty-three percent of patients developed new cerebral infarction after intraarterial nimodipine and additional PTA in selected cases." | 7.91 | Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk? ( Adami, D; Berkefeld, J; Konczalla, J; Pfeilschifter, W; Platz, J; Wagner, M; Weidauer, S, 2019) |
| "Oral nimodipine is used for prophylaxis and treatment of delayed cerebral ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage (SAH)." | 7.91 | Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage. ( Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019) |
| "To determine adherence to nimodipine administration in patients admitted with aneurysmal subarachnoid hemorrhage (aSAH)." | 7.91 | Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage. ( Clark, SL; Hajizadeh Barfejani, A; Rabinstein, AA; Wijdicks, EFM, 2019) |
| "Long-term continuous intra-arterial nimodipine infusion (CIAN) is a rescue therapy option in cases of severe refractory cerebral vasospasm (CV) following acute non-traumatic subarachnoid hemorrhage (SAH)." | 7.88 | Side Effects of Long-Term Continuous Intra-arterial Nimodipine Infusion in Patients with Severe Refractory Cerebral Vasospasm after Subarachnoid Hemorrhage. ( Bele, S; Flessa, J; Graf, B; Kieninger, M; Lindenberg, N; Redel, A; Schneiker, A; Schuierer, G; Silbereisen, V; Wendl, C, 2018) |
| "Guidelines for aneurysm subarachnoid hemorrhage (aSAH) management recommend treatment with nimodipine to all patients to reduce delayed cerebral ischemia (DCI) and poor clinical outcome." | 7.88 | Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage. ( Liengudom, A; Samseethong, T; Suansanae, T; Suthisisang, C; Veerasarn, K, 2018) |
| "Intra-arterial (IA) administration of nimodipine has been shown to be an effective treatment for subarachnoid hemorrhage-related cerebral vasospasm." | 7.85 | Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ( Brockmann, C; Brockmann, MA; Groden, C; Hesser, J; Neumaier-Probst, E; Schubert, R; Seker, F, 2017) |
| "For the treatment and prevention of delayed cerebral ischemia after subarachnoid hemorrhage, the vasodilating agent nimodipine (NDP) is widely employed." | 7.85 | Effect of Intra-Arterial and Intravenous Nimodipine Therapy of Cerebral Vasospasm After Subarachnoid Hemorrhage on Cerebrovascular Reactivity and Oxygenation. ( Birkenhauer, U; Diedler, J; Ernemann, U; Hockel, K; Schuhmann, MU; Steiner, J, 2017) |
| " In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH." | 7.83 | Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study. ( Brüning, R; Ehlert, A; Heindel, W; Hesselmann, V; Jacobs, AH; Manthei, G; Pluta, RM; Ringelstein, EB; Schmidt, C; Stummer, W; Wölfer, J, 2016) |
| "The incidence of cerebral infarction and poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH) is reduced by oral nimodipine but acute effects of the drug may include a significant decrease in mean arterial blood pressure (MAP)." | 7.83 | Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage. ( Diesing, D; Sandow, N; Sarrafzadeh, A; Vajkoczy, P; Wolf, S, 2016) |
| "Oral nimodipine is standard therapy for patients suffering an aneurysmal subarachnoid hemorrhage (aSAH)." | 7.83 | Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients. ( Bales, J; Cho, S; Joffe, AM; Khandelwal, N; Korab, G; Tran, TK, 2016) |
| "A case of probable nimodipine-induced hypoxemia in a patient undergoing treatment for aneurysmal subarachnoid hemorrhage (SAH) is reported." | 7.81 | Hypoxemia associated with nimodipine in a patient with an aneurysmal subarachnoid hemorrhage. ( Baker, M; Bastin, MT; Cook, AM; Fraser, J; Hessel, E, 2015) |
| "Records of children with a confirmed diagnosis of subarachnoid hemorrhage who received nimodipine between January 1, 2005 and August 31, 2013 were reviewed." | 7.81 | Nimodipine for the prevention of cerebral vasospasm after subarachnoid hemorrhage in 12 children. ( Heffren, J; McIntosh, AM; Reiter, PD, 2015) |
| "Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage." | 7.81 | Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. ( Ahtola-Sätilä, T; Forsback, AP; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Simola, O; Tarkia, M, 2015) |
| "In thirty patients with aneurysmal subarachnoid hemorrhage and refractory vasospasm continuous infusion of nimodipine was started on the neurosurgical intensive care unit." | 7.80 | Continuous selective intra-arterial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage. ( Jedlicka, S; Lumenta, CB; Merker, P; Ott, S; Peter, M; Pudenz, C; Schürer, L; Wolf, S, 2014) |
| "We sought to explore whether topical administration of nimodipine improves the abnormal cerebral perfusion following subarachnoid hemorrhage (SAH) in pigs." | 7.79 | Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs. ( Jia, F; Jiang, JY; Wang, F; Yin, YH, 2013) |
| "Nimodipine is the only medication shown to improve outcomes after aneurysmal subarachnoid hemorrhage (SAH)." | 7.78 | Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. ( Badjatia, N; Carpenter, AM; Chen, H; Choi, HA; Claassen, J; Connelly, ES; Gilmore, E; Ko, SB; Lee, D; Lee, K; Mayer, SA; Paik, M; Schmidt, JM, 2012) |
| "Nimodipine improved outcome in patients with subarachnoid hemorrhage (SAH) although hypotension limited the dose that could be administered systemically." | 7.78 | Cisternal sustained release dihydropyridines for subarachnoid hemorrhage. ( Ai, J; Cook, DJ; Kan, S; Kasuya, H; Macdonald, RL, 2012) |
| "To investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH)." | 7.78 | Local delivery of nimodipine by prolonged-release microparticles-feasibility, effectiveness and dose-finding in experimental subarachnoid hemorrhage. ( Bege, N; Beseoglu, K; Eicker, S; Etminan, N; Frauenknecht, K; Hänggi, D; Heiroth, HJ; Kamp, MA; Kissel, T; Macht, S; Perrin, J; Sommer, C; Steiger, HJ, 2012) |
| "the aim of this study was to assess and to compare the ability of intrathecal flunarizine and nimodipine to prevent vasospasm in a rabbit model of subarachnoid hemorrhage (SAH)." | 7.77 | Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. ( Civelek, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Secer, HI; Solmaz, I; Temiz, C, 2011) |
| "This study evaluated the efficacy of intra-arterial nimodipine infusion for symptomatic vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 7.77 | Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. ( Cho, WS; Hang, MH; Jung, C; Kang, HS; Kim, JE; Know, BJ; Kwon, OK; Oh, CW; Son, YJ, 2011) |
| "We investigated the effect of ebselen relative to nimodipine in an animal model of subarachnoid hemorrhage." | 7.76 | Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats. ( Acikgoz, B; Acikgoz, S; Ankarali, H; Bahadir, B; Bektas, S; Gul, S; Hanci, V; Kalayci, M; Ugurbas, E, 2010) |
| "To explore the dose-response effects of topical administration of nimodipine on cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rabbits." | 7.75 | Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits. ( Jiang, JY; Luo, QZ; Pan, YH; Wang, F; Wang, Y; Yin, YH, 2009) |
| "Sixty-five male Wistar rats were randomized into 4 groups: the control sham-operated group, the control subarachnoid hemorrhage-only group, and the treatment groups receiving 5 or 10 microL/hour of intracisternal nimodipine continuously for 5 days via subcutaneously implanted Alzet osmotic pumps (Durect Corp." | 7.75 | Dose-related efficacy of a continuous intracisternal nimodipine treatment on cerebral vasospasm in the rat double subarachnoid hemorrhage model. ( Beseoglu, K; Eicker, S; Hänggi, D; Nawatny, J; Perrin, J; Rapp, M; Sommer, C; Steiger, HJ; Turowski, B, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 7.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "Nimodipine therapy has become a standard component of the treatment regimen used in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 7.70 | The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage. ( Toyota, BD, 1999) |
| " and oral administration of nimodipine the concentration-time profiles of the drug and its enantiomers were studied in seven patients with subarachnoid hemorrhage." | 7.70 | Studies on concentration-time profiles of nimodipine enantiomers following intravenous and oral administration of nimodipine in patients with subarachnoid hemorrhage. ( Gaarskaer, FB; Jakobsen, P; Mikkelsen, EO; Voldby, B; Wanner-Olsen, H, 2000) |
| "Isolated pial arteries from a previously well-characterized model of experimental subarachnoid hemorrhage (SAH) in baboon were tested for their contractile response to 5-hydroxytryptamine (5-HT), norepinephrine (NE), and prostaglandin F2 alpha (PGF2 alpha) and the effect of the calcium antagonist, nimodipine." | 7.68 | Changes in contractile response and effect of a calcium antagonist, nimodipine, in isolated intracranial arteries of baboon following experimental subarachnoid hemorrhage. ( Chang, JY; Delgado, T; Owman, C; Sahlin, C; Salford, LG; Svendgaard, NA, 1990) |
| "Nimodipine was included in the treatment of four patients who had previously presented subarachnoid hemorrhage; cerebral circulation has been assayed by means of "Tomophygmographie cérébrale ultra-sonore"." | 7.67 | [Nimodipine and cerebrovascular circulation. Initial results apropos of 4 cases of subarachnoid hemorrhage]. ( Feiss, P; Lepetit, JM; Moreau, JJ; Ravon, R; Texier, JJ, 1989) |
| "Arachidonic acid metabolites are under investigation as possible vasoactive agents involved in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage." | 7.67 | Effect of nimodipine on arachidonic acid metabolites after subarachnoid hemorrhage. ( Baena, Y; Gaetani, P; Grignani, G; Pacchiarini, L; Rodriguez, R, 1987) |
| "In a pilot study of 6 patients with subarachnoid hemorrhage caused by a ruptured intracranial (grade IV (Hunt and Hess) aneurysm the hemodynamics and plasma-nimodipine concentrations have been observed during a 3-week period of treatment." | 7.67 | Nimodipine treatment of subarachnoid hemorrhage. ( Jakobsen, P; Jensen, F; Laursen, J; Mikkelsen, E, 1988) |
| "Eighty-four patients were treated early with nimodipine intravenously, and thereafter orally, up to 21 days after aneurysmal subarachnoid hemorrhage." | 7.67 | Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results. ( Bolander, H; Carlsson, H; Pellettieri, L; Sjölander, U, 1988) |
| "Nimodipine is being used with increasing frequency in the prevention or treatment of vasospasm due to subarachnoid hemorrhage." | 7.67 | Nimodipine-treated subarachnoid hemorrhage associated with acute pseudo-obstruction of the colon. ( Sharp, A; Soto, B; Torrealba, G, 1987) |
| "The efficacy and tolerability of the dihydropyridine calcium antagonist nimodipine (BAY e 9736) in the prophylaxis of ischemic neurological deficits after subarachnoid hemorrhage were investigated in 171 patients in an open, prospective, multicenter study." | 7.67 | Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhage. ( Adelt, D; Ammerer, HP; Baumann, H; Böker, DK; Grotenhuis, JA; Istaitih, AR; Jaksche, H; Karnick, R; Kazner, E; Sprung, C, 1985) |
| "Intravenous Nimodipine was administered to 109 patients (65 female and 44 male) with either pre- or post-operative progressive neurological deterioration from cerebral vasospasm following subarachnoid hemorrhage from a ruptured aneurysm." | 7.67 | Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage. Clinical results of a multicenter study. ( Auer, LM; Böker, DK; Gaab, M; Jaksche, H; Koos, WT; Kostron, H; Meinig, G; Muizelaar, JP; Perneczky, A; van der Werf, AJ, 1985) |
| "The pharmacokinetics of Nimodipine were studied in healthy volunteers and in patients with subarachnoid hemorrhage (SAH) following cerebral aneurysm rupture." | 7.67 | Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ( Ahr, G; Auer, LM; Rämsch, KD; Tettenborn, D, 1985) |
| "Careful observation of blood pressure and heart rate in patients with subarachnoid hemorrhage during therapy with nimodipine showed that blood pressure decreases mainly in hypertensive patients during the first hours of therapy or when treatment is started immediately with 2 mg per hour instead of the recommended initial dose of 1 mg per hour." | 7.67 | Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage. ( Düdden, P; Dycka, J; Tettenborn, D; Volberg, E, 1985) |
| "Effect of a calcium antagonist, isopropyl-(2-methoxyethyl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5- pyridinedicarboxylate (nimodipine) on the cerebral vasospasm after experimental subarachnoid hemorrhage (SAH) was studied in ten adult cats." | 7.66 | Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarachnoid hemorrhage in cats. ( Fukuuchi, Y; Gotoh, F; Kobari, M; Muramatsu, F; Okayasu, H; Suzuki, N; Tanaka, K, 1982) |
| "Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high morbidity and mortality." | 6.80 | NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage. ( Aldrich, F; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Hoh, BL; Macdonald, RL; Mayer, SA; Miller, M; Mocco, J; Steiger, HJ; Strange, P, 2015) |
| "Cerebral vasospasm is a common complication of subarachnoid hemorrhage." | 6.72 | Side effects of continuous intra-arterial infusion of nimodipine for management of resistant cerebral vasospasm in subarachnoid hemorrhage patients: A systematic review. ( Bilotta, F; Sarria-Santamera, A; Viderman, D, 2021) |
| "In patients with aneurysmal subarachnoid hemorrhage (SAH), delayed ischemic cerebral dysfunction (DID or symptomatic vasospasm) with subsequent fixed neurological dysfunction (FND) is a frequent and most feared complication induced by the hemorrhage." | 6.66 | Cerebral vasospasm and calcium channel blockade. Nimodipine treatment in patients with aneurysmal subarachnoid hemorrhage. ( Andersson, KE; Brandt, L; Ljunggren, B; Säveland, H; Vinge, E, 1986) |
| "The effective reduction of delayed cerebral ischemia (DCI), a main contributor for poor outcome following aneurysmal subarachnoid hemorrhage (SAH), remains challenging." | 6.52 | Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. ( Burton, K; Davis, C; Etminan, N; Hänggi, D; Macdonald, RL; Steiger, HJ, 2015) |
| "A short overview on trials in subarachnoid hemorrhage, head injury, ischemic stroke and cerebral resuscitation is given in this paper." | 6.39 | Clinical experiences with nimodipine in cerebral ischemia. ( Fritze, J; Kakarieka, A; Schakel, EH, 1994) |
| "Severe refractory cerebral vasospasm (CV) is a major cause of disability and death in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 5.72 | Continuous intra-arterial nimodipine infusion as rescue treatment of severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Anthofer, J; Bele, S; Bruendl, E; Kieninger, M; Schebesch, KM; Schmidt, NO; Wendl, C; Zeman, F, 2022) |
| "Nimodipine treatment provides SAH patients with short-term neurological benefits." | 5.72 | Nimodipine Attenuates Early Brain Injury by Protecting the Glymphatic System After Subarachnoid Hemorrhage in Mice. ( Cui, X; Hou, C; Li, J; Liu, Q; Ren, W; Wang, B; Wang, W; Yang, X; Zhang, H, 2022) |
| "Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a." | 5.56 | Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis. ( Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020) |
| "The prevalence of takotsubo syndrome (TTS) in patients with subarachnoid hemorrhage (SAH) is much higher than in the general population." | 5.56 | Takotsubo syndrome after nimodipine-induced hypotension treated with norepinephrine in a female with subarachnoid hemorrhage. ( Baszko, A; Elikowski, W; Fertała, N; Ganowicz-Kaatz, T; Małek-Elikowska, M; Piestrzeniewicz, R; Smól, S; Zawodna, M, 2020) |
| "We report a 39-year-old male with an aneurysmal subarachnoid hemorrhage without hydrocephalus, in whom a right choroidal aneurysm was early excluded by endovascular coil insertion." | 5.51 | [Continuous intra arterial nimodipine for vasospasm secondary to subarachnoid hemorrhage. Report of one case]. ( Contreras, L; Cordovez, J; Ducci, H; Galvez, M; Mena, F; Reccius, A; Regueira, T; Soto, L; Torres, F, 2019) |
| "Cerebral vasospasm (CV) and delayed cerebral ischemia (DCI) are major factors that limit good outcome in patients with spontaneous subarachnoid hemorrhage (SAH)." | 5.51 | The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia-continuous selective intracarotid nimodipine therapy in awake patients without sedation. ( Brand, C; Braun, M; Kapapa, T; König, R; Özpeynirci, Y; Paľa, A; Pedro, MT; Schmitz, B; Schneider, M; Wirtz, CR, 2019) |
| "Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most important complication that effects the mortality and morbidity of patients with intracranial aneurysm." | 5.46 | Comparison of the Effects and Mechanism of the Curcumin with Different Drugs in Experimental Vasospasm After Subarachnoid Hemorrhage. ( Aydin, HE; Baycu, C; Bektur, NE; Kilic, FS; Oner, S; Ozbek, Z, 2017) |
| " Key to the effective administration of continuous intra-arterial nimodipine is multimodal neuromonitoring and the individual adaptation of dosage and time of infusion for each patient." | 5.42 | Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results. ( Bele, S; Brawanski, A; Bründl, E; Hochreiter, A; Kieninger, M; Proescholdt, MA; Schebesch, KM; Scheitzach, J; Schneiker, A; Schödel, P; Schuierer, G; Wendl, C, 2015) |
| "A systematic review and network meta-analysis (NMA) were conducted to explore the optimal administration route of nimodipine for treatment subarachnoid hemorrhage." | 5.41 | The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis. ( Hu, Y; Lei, G; Rao, Z, 2023) |
| "These results are consistent with a beneficial effect of locally delivered nimodipine (EG-1962) on SD after aSAH in more severely injured patients who are at risk of delayed cerebral ischemia related to SD." | 5.41 | Effect of Locally Delivered Nimodipine Microparticles on Spreading Depolarization in Aneurysmal Subarachnoid Hemorrhage. ( Alchbli, A; Carlson, AP; Hänggi, D; Macdonald, RL; Shuttleworth, CW, 2021) |
| "Nimodipine treatment in cerebral vasospasm is useful." | 5.37 | Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Civelek, E; Isikay, I; Kircelli, A; Narin, F; Onal, MB; Solmaz, I; Ugurel, S; Yakupoglu, H, 2011) |
| "Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously." | 5.37 | Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011) |
| "Nimodipine is an effect-proven agent in CVS, but dotarizine may take place of it." | 5.37 | Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Civelek, E; Erdogan, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Solmaz, I; Tehli, O, 2011) |
| "Nimodipine is a potent drug for vessel relaxation, but side effects may preclude a sufficient dose." | 5.37 | Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. ( Coburger, J; Henkes, H; Hopf, N; Musahl, C; Vajda, Z, 2011) |
| "Cerebral vasospasm complicating aneurysmal subarachnoid hemorrhage is a well-known medical entity." | 5.37 | Resistant vasospasm in subarachnoid hemorrhage treated with continuous intraarterial nimodipine infusion. ( Barth, H; Doukas, A; Jansen, O; Maslehaty, H; Mehdorn, HM; Petridis, AK, 2011) |
| "Traumatic subarachnoid hemorrhage is a common finding following traumatic brain injury." | 5.35 | Experimental subarachnoid hemorrhage in the rat: influences of nimodipine. ( Brinker, T; Herrmann, B; Samii, M; Thomas, S, 2008) |
| "A sustained release microparticle formulation of nimodipine (EG-1962) was developed for treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 5.34 | NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage. ( Aldrich, EF; Bleck, T; Carlson, AP; Darsaut, TE; Diringer, MN; Etminan, N; Grubb, R; Hänggi, D; Ko, NU; Macdonald, RL; Mayer, SA; Ng, D; Strange, P; Suarez, JI; Wong, GK, 2020) |
| "Nimodipine is the only drug approved in the treatment of aneurysmal subarachnoid hemorrhage (aSAH) in many countries." | 5.30 | Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimo ( Aldrich, EF; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Macdonald, RL; Mayer, SA; Ng, D; Saville, BR; Schmutzhard, E, 2019) |
| "Nimodipine treatment was associated with a significant increase of survival (11." | 5.29 | [Comparison of 2 consecutive series of aneurysmal subarachnoid hemorrhage with or without nimodipine and study of the temperature curve]. ( Bazin, A; Bernard, MH; Bertault, R; Gomis, P; Graftieaux, JP; Peruzzi, P; Rousseaux, P; Scherpereel, B, 1993) |
| "Operative interventions in subarachnoid hemorrhages caused by brain vessel aneurysm require meticulous dissection of the latter." | 5.29 | [Controlled hypotension against a background of nimodipine during an operation on neurosurgical patients with hypertension]. ( Karadimov, D, 1995) |
| "Nimodipine was then discontinued and, 48 hours later, when the middle cerebral artery velocity was still in the same range, CO2 vasoreactivity was tested again." | 5.28 | Effect of nimodipine on cerebrovascular response to CO2 in asymptomatic individuals and patients with subarachnoid hemorrhage: a transcranial Doppler ultrasound study. ( Nirkko, AC; Seiler, RW, 1990) |
| "Nimodipine has proven to be effective in preventing this complication in a majority of patients studied, with hypotension the most severe adverse effect." | 5.28 | Nimodipine: the use of calcium antagonists to prevent vasospasm following subarachnoid hemorrhage. ( Sosnowski, C, 1990) |
| "Twenty-four patients with subarachnoid hemorrhage due to rupture of a supratentorial aneurysm underwent surgery within 72 hours after subarachnoid hemorrhage." | 5.27 | Thromboxane B2 levels in serum during continuous administration of nimodipine to patients with aneurysmal subarachnoid hemorrhage. ( Andersson, KE; Brandt, L; Ljunggren, B; Vinge, E, 1988) |
| "We conducted a randomized, open-label, phase 1/2a, dose-escalation study of intraventricular sustained-release nimodipine (EG-1962) to determine safety, tolerability, pharmacokinetics, and clinical effects in aneurysmal subarachnoid hemorrhage." | 5.24 | Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid ( Aldrich, F; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Hoh, BL; Macdonald, RL; Mayer, SA; Mocco, J; Steiger, HJ, 2017) |
| "INTRODUCTION: Enteral nimodipine provides a neuroprotective effect in patients who have experienced an aneurysmal subarachnoid hemorrhage (aSAH)." | 5.22 | Nimodipine in Clinical Practice: A Pharmacological Update. ( Aiyagari, V; Clough, B; Griffin, T; Gunter, E; Tenii, J; Wee, C, 2022) |
| "One of the challenges in bringing new therapeutic agents (since nimodipine) in for the treatment of cerebral ischemia associated with aneurysmal subarachnoid hemorrhage (aSAH) is the incongruence in therapeutic benefit observed between phase II and subsequent phase III clinical trials." | 5.22 | Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage. ( Broderick, JP; Cassarly, CN; Huang, W; Ishfaq, MF; Lobanova, I; Macdonald, RL; Martin, RH; Qureshi, AI; Suarez, JI, 2022) |
| "Nimodipine and cilostazol are likely the most effective treatments in preventing morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage." | 5.22 | Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials. ( Ahmadvand, S; Amin-Hanjani, S; Dayyani, M; Grotta, JC; Guyatt, GH; Sadeghirad, B; Wang, Y; Zabihyan, S, 2022) |
| "Our objective was to compare the effectiveness of intravenous and enteral nimodipine in preventing poor outcome from delayed cerebral ischemia in patients with subarachnoid hemorrhage." | 5.22 | A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis. ( Boscolo, A; Cacco, N; Carere, A; Correale, C; De Cassai, A; Diana, P; Disarò, L; Geraldini, F; Munari, M; Navalesi, P; Zampirollo, S, 2022) |
| "The aim of this study was to evaluate serum nimodipine concentrations in patients with aneurysmal subarachnoid hemorrhage (SAH) after parenteral therapy and a following course of enteral administration." | 5.20 | Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. ( Abboud, T; Andresen, H; Czorlich, P; Duehrsen, L; Koeppen, J; Regelsberger, J; Stenzig, J; Westphal, M, 2015) |
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 5.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| "The calcium antagonist nimodipine has been shown to reduce the incidence of ischemic complications following aneurysmal subarachnoid hemorrhage (SAH)." | 5.14 | Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. ( Cronqvist, M; Kronvall, E; Nilsson, OG; Romner, B; Säveland, H; Undrén, P, 2009) |
| "The efficacy of intra-arterial administration of nimodipine (IAN) in patients with severe vasospasm after aneurysmal subarachnoid hemorrhage (SAH) remains unproved." | 5.13 | Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. ( Beseoglu, K; Hänggi, D; Steiger, HJ; Turowski, B; Yong, M, 2008) |
| "The prophylactic use of nimodipine in patients with aneurysmal subarachnoid hemorrhage reduces the risk of ischemic brain damage." | 5.12 | Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. ( Briegel, J; Kunz, M; Prueckner, S; Schmid-Elsaesser, R; Steiger, HJ; Zausinger, S, 2006) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 5.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "Nimodipine has been shown to improve neurological outcome after subarachnoid hemorrhage (SAH); the mechanism of this improvement, however, is uncertain." | 5.11 | The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage. ( Abrahams, JM; Bloom, S; Grady, MS; Heuer, GG; LeRoux, PD; Maloney-Wilensky, E; Smith, MJ; Stiefel, MF, 2004) |
| "To assess the cost-effectiveness ratio of nimodipine administration after aneurysmal subarachnoid hemorrhage (SAH) and surgery." | 5.09 | Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery. ( Karinen, P; Koivukangas, J; Koivukangas, P; Ohinmaa, A; Ohman, J, 1999) |
| "A prospective, randomized, double-blind, placebo-controlled study of nimodipine used to treat traumatic subarachnoid hemorrhage (tSAH) was conducted in 21 German neurosurgical centers between January 1994 and April 1995." | 5.08 | Traumatic subarachnoid hemorrhage and its treatment with nimodipine. German tSAH Study Group. ( Braakman, R; Harders, A; Kakarieka, A, 1996) |
| "A total of 213 patients with verified aneurysmal subarachnoid hemorrhage (SAH) of Grades I to III (Hunt and Hess classification) were enrolled in a double-blind placebo-controlled trial to determine the effect of intravenous nimodipine on delayed ischemic deterioration and computerized tomography (CT)-visualized infarcts after SAH and surgery." | 5.07 | Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. ( Heiskanen, O; Ohman, J; Servo, A, 1991) |
| "We studied platelet function in 41 patients with subarachnoid hemorrhage who were randomized to receive either nimodipine or placebo in a double-blind fashion." | 5.06 | Effect of nimodipine on platelet function in patients with subarachnoid hemorrhage. ( Hillbom, M; Juvela, S; Kaste, M, 1990) |
| "To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes (death and severe disability) after subarachnoid haemorrhage." | 5.06 | Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. ( Foy, PM; Humphrey, PR; Illingworth, R; Lang, DA; Murray, GD; Nelson, R; Pickard, JD; Richards, P; Shaw, MD; Teasdale, GM, 1989) |
| "The effect of intravenous nimodipine on the incidence of mortality and delayed ischemic neurological deficits of patients after aneurysmal subarachnoid hemorrhage (SAH) and surgery was studied in a prospective double-blind placebo-controlled trial." | 5.06 | Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. ( Heiskanen, O; Ohman, J, 1988) |
| "We enrolled 75 consecutive patients admitted with subarachnoid hemorrhages in a randomized, double-blind, placebo-controlled trial to determine the effect of early intervention with nimodipine on outcome and cerebral blood flow." | 5.06 | Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. ( Dorrance, D; Lowe, D; Mee, E; Neil-Dwyer, G, 1988) |
| "The present studies show that nimodipine prevents and/or improves permanent ischemic neurological deficits in patients with subarachnoid hemorrhage." | 5.06 | Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage. ( Battye, R; Porto, L; Ryman, T; Strugo, V; Taquoi, G; Tettenborn, D, 1987) |
| "Nimodipine has been shown to improve outcomes following aneurysmal subarachnoid hemorrhage." | 5.05 | Nimodipine Pharmacokinetic Variability in Various Patient Populations. ( Isse, FA; Ji, X; Mahmoud, SH, 2020) |
| "We enrolled 125 neurologically normal patients with intracranial aneurysms in a multi-institution, prospective, double-blind, randomized, placebo-controlled trial within 96 hours of their subarachnoid hemorrhage, to determine whether treatment with the calcium blocker nimodipine would prevent or reduce the severity of ischemic neurologic deficits from arterial spasm." | 5.05 | Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. ( Ahn, HS; Allen, GS; Battye, R; Bertsch, LA; Boisvert, DP; Boone, SC; Chou, SN; Crabbe, RA; Dorsey, FC; Hundley, MB; Ingram, CR; Johnson, RK; Kelly, DL; Lavik, PJ; Mellits, DE; Preziosi, TJ; Rosenbloom, SB; Strom, JA; Transou, CR; Weir, BK, 1983) |
| "Experimental and clinical studies have been performed to investigate the validity of a pharmacological approach to prevent delayed ischemic neurologic deficit from vasospasm after subarachnoid hemorrhage: the calcium channel blocker nimodipine was administered intravenously and perivascularly." | 5.05 | Preventive nimodipine and acute aneurysm surgery. Heading for the control of complications after aneurysmal subarachnoid hemorrhage. ( Auer, LM, 1985) |
| " Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia." | 5.01 | Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage. ( Cowart, JB; Freeman, WD; James, C; Peacock, SH; Reid, JM; Turnbull, MT, 2019) |
| " Nimodipine is administered to maintain a euvolemic state and prevent delayed cerebral ischemia (DCI)." | 4.90 | Treatment of subarachnoid hemorrhage. ( Diringer, MN; Raya, AK, 2014) |
| " Clinical trials in subarachnoid hemorrhage have led to approval of nimodipine for oral and intravenous use, but other drugs, such as clazosentan, hydroxymethylglutaryl CoA reductase inhibitors (statins) and magnesium, have not shown consistent clinical efficacy." | 4.88 | Intracranial drug delivery for subarachnoid hemorrhage. ( Leung, M; Macdonald, RL; Tice, T, 2012) |
| "Nimodipine (Nimotop), HMG Co-A reductase inhibitor (statins) and enoxaparin (Lovenox) were the only drugs with level-1 evidence available for the treatment of vasospasm from aneurysmal subarachnoid hemorrhage as defined by the US Preventative Services Task Force." | 4.85 | Evidence-based pharmacotherapy for cerebral vasospasm. ( Boulos, AS; Deshaies, EM; Drazin, D; Popp, AJ, 2009) |
| "The authors report findings from a metaanalysis of all published randomized trials of prophylactic nimodipine used in patients who have experienced subarachnoid hemorrhage (SAH)." | 4.79 | Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. ( Barker, FG; Ogilvy, CS, 1996) |
| " We propose a meta-analytical evaluation of published clinical trials on nimodipine, a dihydropiridin calcium antagonist, in subarachnoid hemorrhage and in ischemic stroke." | 4.79 | From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders. ( Di Mascio, R; Marchioli, R; Tognoni, G, 1994) |
| "Clinical management of patients affected by subarachnoid hemorrhage has been modified by the use of nimodipine." | 4.78 | Update on calcium antagonists in cerebrovascular diseases. ( Argentino, C; De Michele, M; Fieschi, C; Frontoni, M; Sacchetti, ML; Toni, D, 1991) |
| "Nimodipine, a calcium-channel antagonist with a relatively selective vasodilatory effect on cerebral blood vessels, has recently been approved for improvement of neurologic deficits due to spasm following subarachnoid hemorrhage." | 4.77 | Nimodipine in the treatment of subarachnoid hemorrhage. ( Tietze, KJ; Yasuda, SU, 1989) |
| "Nimodipine has recently been approved for the treatment of cerebral ischemia caused by subarachnoid hemorrhage." | 4.77 | Nimodipine in subarachnoid hemorrhage. ( DiPalma, JR, 1989) |
| "The chemistry, pharmacology, pharmacokinetics, adverse effects, dosage, and availability of nimodipine are discussed, and the clinical use of nimodipine in preventing and treating cerebral arterial spasm in patients with subarachnoid hemorrhage is reviewed." | 4.77 | Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage. ( Welty, TE, 1987) |
| "Nimodipine improves outcomes following aneurysmal subarachnoid hemorrhage (aSAH) and current guidelines suggest that patients with aSAH receive nimodipine for 21 days." | 4.31 | Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study. ( Almohaish, S; Ammar, AA; Ammar, MA; Armahizer, MJ; Barra, ME; Barthol, CA; Binning, MJ; Blunck, JR; Brophy, GM; Brown, CS; Burgess, SV; Buschur, PL; Cantin, A; Clark, SL; Cook, AM; Delucilla, L; Fox, N; Hamilton, LA; Hefny, FR; Hintze, TD; Kaupp, K; Keegan, SP; Mahmoud, LN; Mahmoud, SH; Naydin, S; Ngan, Z; Owusu-Guha, J; Panos, NG; Perreault, MM; Peters, DM; Rowe, AS; Sandler, M; Shewmaker, J; Tesoro, EP; Traeger, J; Wieruszewski, ED, 2023) |
| "Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous subarachnoid hemorrhage (SAH)." | 4.31 | Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage. ( Altmann, K; Beer, R; Helbok, R; Ianosi, BA; Kindl, P; Kofler, M; Lindner, A; Pfausler, B; Putnina, L; Rass, V; Schiefecker, AJ, 2023) |
| "A total of 40 rabbits were used to make subarachnoid hemorrhage model and were divided into three groups - a control group, nimodipine group, and tadalafil group." | 4.31 | Vasodilatory effects of tadalafil in an animal model of cerebral vasospasm: Comparative analysis with oral nimodipine. ( Byoun, HS; Il Won, Y; Lim, J; Park, B; Park, KH; Youm, JY, 2023) |
| "The only established pharmacological treatment option improving outcomes for patients suffering from subarachnoid hemorrhage (SAH) is the L-type-calcium channel inhibitor nimodipine." | 4.31 | Nimodipine Reduces Microvasospasms After Experimental Subarachnoid Hemorrhage. ( Harapan, BN; Lin, X; Plesnila, N; Schwarting, J; Terpolilli, NA, 2023) |
| "The selective intra-arterial nimodipine application for the treatment of cerebral vasospasm (CVS) in patients after spontaneous subarachnoid hemorrhage (sSAH) is widely employed." | 4.12 | Radiation exposure in the intra-arterial nimodipine therapy of subarachnoid hemorrhage related cerebral vasospasm. ( Bos, D; Deuschl, C; Dörner, N; Forsting, M; Guberina, N; Jabbarli, R; Kleinschnitz, C; Li, Y; Opitz, M; Radbruch, A; Sure, U; Uslar, E; Wetter, A; Zensen, S, 2022) |
| "Nimodipine improves outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 4.12 | Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage. ( Blake, C; Dai, X; Furie, KL; Mahmoud, L; Mahta, A; Reznik, ME; Thompson, BB; Wendell, LC; Zullo, AR, 2022) |
| "Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown." | 4.12 | Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022) |
| "Intra-arterial nimodipine (IAN) injections are performed in refractory delayed cerebral ischemia (DCI) related to cerebral vasospasm (CVS) after spontaneous subarachnoid hemorrhage (sSAH), but the clinical benefits are inconclusive and angiographic treatment failure is observed." | 4.12 | Analysis of Angiographic Treatment Response to Intra-Arterial Nimodipine Bolus Injection in Patients with Medically Refractory Cerebral Vasospasm After Spontaneous Subarachnoid Hemorrhage. ( Ditz, C; Küchler, J; Neumann, A; Schacht, H; Schramm, P; Tronnier, VM, 2022) |
| "The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters." | 4.12 | Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. ( Chakrabarti, D; Konar, SK; Kotwal, A; Radhakrishnan, M; Ramalingaiah, AH; Shukla, D; Srinivasaiah, B; Sundaram, M, 2022) |
| "This study aimed to discuss the influence of nimodipine+ulinastatin on the neurological function and inflammatory reaction in patients with cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH)." | 4.02 | Influence of nimodipine combined with ulinastatin on neurological function and inflammatory reaction in patients with cerebral vasospasm after subarachnoid hemorrhage. ( Chen, M; Liu, H; Wei, X; Zhang, Q; Zou, W, 2021) |
| "Randomized-controlled trials and meta-analyses showed nimodipine use after aneurysmal subarachnoid hemorrhage (aSAH) leads to reduction in incidence of cerebral infarction, persistent neurological deficits, and poor outcomes." | 4.02 | Nimodipine after aneurysmal subarachnoid hemorrhage: Fourteen-day course for patients that meet criteria for early hospital discharge. ( Burke, RM; Chen, CJ; Kalani, MYS; Mastorakos, P; Myers, KM; Nguyen, JM; Park, MS; Sokolowski, JD; Soldozy, S, 2021) |
| " Here we describe a patient with subarachnoid hemorrhage treated with nimodipine, which resulted in marked bradycardia with junctional atrioventricular heart block." | 3.96 | Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage. ( Freeman, WD; James, CL; Turnbull, MT, 2020) |
| "Our findings suggest that nimodipine administration via enteral feeding tubes may be associated with vasospasm and DCI in subarachnoid hemorrhage patients secondary to reduced exposure." | 3.96 | The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage. ( Abdallah, YEH; Isse, FA; Mahmoud, SH, 2020) |
| "Current guidelines recommend the administration of nimodipine for the prevention of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH)." | 3.91 | Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage? ( Hernández-Durán, S; Malinova, V; Mielke, D; Rohde, V, 2019) |
| "Fifty-three percent of patients developed new cerebral infarction after intraarterial nimodipine and additional PTA in selected cases." | 3.91 | Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk? ( Adami, D; Berkefeld, J; Konczalla, J; Pfeilschifter, W; Platz, J; Wagner, M; Weidauer, S, 2019) |
| "Oral nimodipine is used for prophylaxis and treatment of delayed cerebral ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage (SAH)." | 3.91 | Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage. ( Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019) |
| "To determine adherence to nimodipine administration in patients admitted with aneurysmal subarachnoid hemorrhage (aSAH)." | 3.91 | Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage. ( Clark, SL; Hajizadeh Barfejani, A; Rabinstein, AA; Wijdicks, EFM, 2019) |
| "Long-term continuous intra-arterial nimodipine infusion (CIAN) is a rescue therapy option in cases of severe refractory cerebral vasospasm (CV) following acute non-traumatic subarachnoid hemorrhage (SAH)." | 3.88 | Side Effects of Long-Term Continuous Intra-arterial Nimodipine Infusion in Patients with Severe Refractory Cerebral Vasospasm after Subarachnoid Hemorrhage. ( Bele, S; Flessa, J; Graf, B; Kieninger, M; Lindenberg, N; Redel, A; Schneiker, A; Schuierer, G; Silbereisen, V; Wendl, C, 2018) |
| "Guidelines for aneurysm subarachnoid hemorrhage (aSAH) management recommend treatment with nimodipine to all patients to reduce delayed cerebral ischemia (DCI) and poor clinical outcome." | 3.88 | Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage. ( Liengudom, A; Samseethong, T; Suansanae, T; Suthisisang, C; Veerasarn, K, 2018) |
| "Oral nimodipine is an established prophylactic agent for cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 3.85 | Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment. ( Albanna, W; Clusmann, H; Conzen, C; Höllig, A; Müller, M; Reinsch, M; Schneider, T; Schubert, GA; Weiss, M; Wiesmann, M, 2017) |
| "Intra-arterial (IA) administration of nimodipine has been shown to be an effective treatment for subarachnoid hemorrhage-related cerebral vasospasm." | 3.85 | Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ( Brockmann, C; Brockmann, MA; Groden, C; Hesser, J; Neumaier-Probst, E; Schubert, R; Seker, F, 2017) |
| "For the treatment and prevention of delayed cerebral ischemia after subarachnoid hemorrhage, the vasodilating agent nimodipine (NDP) is widely employed." | 3.85 | Effect of Intra-Arterial and Intravenous Nimodipine Therapy of Cerebral Vasospasm After Subarachnoid Hemorrhage on Cerebrovascular Reactivity and Oxygenation. ( Birkenhauer, U; Diedler, J; Ernemann, U; Hockel, K; Schuhmann, MU; Steiner, J, 2017) |
| " In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH." | 3.83 | Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study. ( Brüning, R; Ehlert, A; Heindel, W; Hesselmann, V; Jacobs, AH; Manthei, G; Pluta, RM; Ringelstein, EB; Schmidt, C; Stummer, W; Wölfer, J, 2016) |
| "The incidence of cerebral infarction and poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH) is reduced by oral nimodipine but acute effects of the drug may include a significant decrease in mean arterial blood pressure (MAP)." | 3.83 | Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage. ( Diesing, D; Sandow, N; Sarrafzadeh, A; Vajkoczy, P; Wolf, S, 2016) |
| "Nimodipine is the only drug approved for use by the Food and Drug Administration for improving outcome after aneurysmal subarachnoid hemorrhage (SAH)." | 3.83 | A Site-Specific, Sustained-Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage. ( Burton, K; Davis, C; Etminan, N; Faleck, HJ; Hänggi, D; Heshmati, P; Hudson, B; Johnson, M; Macdonald, RL; Peet, MM; Steiger, HJ; Stella, A; Tice, T; Turner, M, 2016) |
| "Oral nimodipine is standard therapy for patients suffering an aneurysmal subarachnoid hemorrhage (aSAH)." | 3.83 | Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients. ( Bales, J; Cho, S; Joffe, AM; Khandelwal, N; Korab, G; Tran, TK, 2016) |
| "A case of probable nimodipine-induced hypoxemia in a patient undergoing treatment for aneurysmal subarachnoid hemorrhage (SAH) is reported." | 3.81 | Hypoxemia associated with nimodipine in a patient with an aneurysmal subarachnoid hemorrhage. ( Baker, M; Bastin, MT; Cook, AM; Fraser, J; Hessel, E, 2015) |
| "Records of children with a confirmed diagnosis of subarachnoid hemorrhage who received nimodipine between January 1, 2005 and August 31, 2013 were reviewed." | 3.81 | Nimodipine for the prevention of cerebral vasospasm after subarachnoid hemorrhage in 12 children. ( Heffren, J; McIntosh, AM; Reiter, PD, 2015) |
| "Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage." | 3.81 | Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. ( Ahtola-Sätilä, T; Forsback, AP; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Simola, O; Tarkia, M, 2015) |
| "In thirty patients with aneurysmal subarachnoid hemorrhage and refractory vasospasm continuous infusion of nimodipine was started on the neurosurgical intensive care unit." | 3.80 | Continuous selective intra-arterial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage. ( Jedlicka, S; Lumenta, CB; Merker, P; Ott, S; Peter, M; Pudenz, C; Schürer, L; Wolf, S, 2014) |
| "Nimodipine is well characterized for the management of SAH (subarachnoid hemorrhage) and has been shown to promote a better outcome and less DIND (delayed ischemic neurological deficits)." | 3.80 | Investigation of the neuroprotective impact of nimodipine on Neuro2a cells by means of a surgery-like stress model. ( Bork, K; Dehghani, F; Herzfeld, E; Horstkorte, R; Scheller, C; Simmermacher, S; Strauss, C, 2014) |
| "We sought to explore whether topical administration of nimodipine improves the abnormal cerebral perfusion following subarachnoid hemorrhage (SAH) in pigs." | 3.79 | Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs. ( Jia, F; Jiang, JY; Wang, F; Yin, YH, 2013) |
| "Nimodipine is the only medication shown to improve outcomes after aneurysmal subarachnoid hemorrhage (SAH)." | 3.78 | Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. ( Badjatia, N; Carpenter, AM; Chen, H; Choi, HA; Claassen, J; Connelly, ES; Gilmore, E; Ko, SB; Lee, D; Lee, K; Mayer, SA; Paik, M; Schmidt, JM, 2012) |
| "Nimodipine improved outcome in patients with subarachnoid hemorrhage (SAH) although hypotension limited the dose that could be administered systemically." | 3.78 | Cisternal sustained release dihydropyridines for subarachnoid hemorrhage. ( Ai, J; Cook, DJ; Kan, S; Kasuya, H; Macdonald, RL, 2012) |
| "To investigate the effect of locally applied nimodipine prolonged-release microparticles on angiographic vasospasm and secondary brain injury after experimental subarachnoid hemorrhage (SAH)." | 3.78 | Local delivery of nimodipine by prolonged-release microparticles-feasibility, effectiveness and dose-finding in experimental subarachnoid hemorrhage. ( Bege, N; Beseoglu, K; Eicker, S; Etminan, N; Frauenknecht, K; Hänggi, D; Heiroth, HJ; Kamp, MA; Kissel, T; Macht, S; Perrin, J; Sommer, C; Steiger, HJ, 2012) |
| "the aim of this study was to assess and to compare the ability of intrathecal flunarizine and nimodipine to prevent vasospasm in a rabbit model of subarachnoid hemorrhage (SAH)." | 3.77 | Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. ( Civelek, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Secer, HI; Solmaz, I; Temiz, C, 2011) |
| "the aim of this study was to assess and to compare the ability of intrathecal nicergoline and nimodipine in prevention of cerebral vasospasm in a rabbit model of subarachnoid hemorrhage (SAH)." | 3.77 | The effects of intrathecal nicergoline and nimodipine in cerebral vasospasm: an experimental study in rabbits. ( Civelek, E; Erdogan, E; Gonul, E; Kircelli, A; Onal, MB; Ongoru, O; Solmaz, I; Ugurel, S, 2011) |
| "This study evaluated the efficacy of intra-arterial nimodipine infusion for symptomatic vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 3.77 | Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. ( Cho, WS; Hang, MH; Jung, C; Kang, HS; Kim, JE; Know, BJ; Kwon, OK; Oh, CW; Son, YJ, 2011) |
| "For endovascular treatment of vasospasm after aneurysmal subarachnoid hemorrhage (aSAH), an intraarterial treatment course with the calcium channel antagonist nimodipine infused for 30 min is proposed." | 3.76 | Continuous selective intraarterial infusion of nimodipine for therapy of refractory cerebral vasospasm. ( Landscheidt, JF; Lumenta, CB; Martin, H; Rodiek, SO; Schürer, L; Wolf, S, 2010) |
| "We investigated the effect of ebselen relative to nimodipine in an animal model of subarachnoid hemorrhage." | 3.76 | Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats. ( Acikgoz, B; Acikgoz, S; Ankarali, H; Bahadir, B; Bektas, S; Gul, S; Hanci, V; Kalayci, M; Ugurbas, E, 2010) |
| "To explore the dose-response effects of topical administration of nimodipine on cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rabbits." | 3.75 | Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits. ( Jiang, JY; Luo, QZ; Pan, YH; Wang, F; Wang, Y; Yin, YH, 2009) |
| "Sixty-five male Wistar rats were randomized into 4 groups: the control sham-operated group, the control subarachnoid hemorrhage-only group, and the treatment groups receiving 5 or 10 microL/hour of intracisternal nimodipine continuously for 5 days via subcutaneously implanted Alzet osmotic pumps (Durect Corp." | 3.75 | Dose-related efficacy of a continuous intracisternal nimodipine treatment on cerebral vasospasm in the rat double subarachnoid hemorrhage model. ( Beseoglu, K; Eicker, S; Hänggi, D; Nawatny, J; Perrin, J; Rapp, M; Sommer, C; Steiger, HJ; Turowski, B, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 3.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "Between August 2001 and January 2004 we treated nine acute subarachnoid hemorrhage (SAH) patients with a combination of stents and platinum coils." | 3.73 | [Stenting plus coiling: dangerous or helpful?]. ( Dörfler, A; Forsting, M; Gizewski, E; Stolke, D; Wanke, I, 2005) |
| "Nimodipine is a therapy that reduces morbidity and mortality in patients with subarachnoid hemorrhage (SAH), though the mechanisms by which it does so are not well understood." | 3.73 | Dynamic CT perfusion imaging in subarachnoid hemorrhage-related vasospasm. ( Chen, FX; Eastwood, JD; Laslo, AM; Lee, TY, 2006) |
| "The efficacy of nimodipine was examined in a murine model of subarachnoid hemorrhage (SAH)." | 3.73 | Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. ( Borel, CO; Laskowitz, DT; Lombard, FW; Mesis, RG; Vitek, MP; Wang, H; Warner, DS; Yates, R, 2006) |
| "Nimodipine therapy has become a standard component of the treatment regimen used in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 3.70 | The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage. ( Toyota, BD, 1999) |
| " and oral administration of nimodipine the concentration-time profiles of the drug and its enantiomers were studied in seven patients with subarachnoid hemorrhage." | 3.70 | Studies on concentration-time profiles of nimodipine enantiomers following intravenous and oral administration of nimodipine in patients with subarachnoid hemorrhage. ( Gaarskaer, FB; Jakobsen, P; Mikkelsen, EO; Voldby, B; Wanner-Olsen, H, 2000) |
| "Nimodipine is commonly used to improve neurological outcomes after subarachnoid hemorrhage." | 3.70 | Nimodipine-induced acute hypoxemia: case report. ( Coplin, WM; Devlin, JW; Murry, KR; Rengachary, SS; Wilson, RF, 2000) |
| " It is well-known, that the calcium channel blocker nimodipine reduces the incidence of cerebral infarction and ischaemic dysfunction after SAH." | 3.69 | The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat. ( Gjerris, F; Hauerberg, J; Juhler, M; Rasmussen, G, 1995) |
| "To determine the incidence of induced systemic hypotension in patients after aneurysmal subarachnoid haemorrhage (SAH) and nimodipine treatment 87 consecutive cases were reviewed." | 3.69 | Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. ( Chioléro, R; de Tribolet, N; Porchet, F, 1995) |
| "During recent years, the management of subarachnoid hemorrhage (SAH) has changed, resulting in an increase in early operations and routine administration of nimodipine." | 3.68 | Cerebral hemodynamics in subarachnoid hemorrhage evaluated by transcranial Doppler sonography. Part 1. Reliability of flow velocities in clinical management. ( Fahlbusch, R; Gönner, F; Laumer, R; Priem, R; Steinmeier, R; Vogtmann, T, 1993) |
| "The study evaluated the effectiveness of the combination of nimodipine and cyclosporine A vs nimodipine alone in the prevention of delayed neurologic deficit in 82 (31 plus 51) patients in whom intracranial aneurysms were clipped within 72 h after subarachnoid haemorrhage." | 3.68 | A strategy for analyzing multiple parameters with application to aneurysmal SAH patients all of them clipped but treated with and without cyclosporine. ( Andrychowski, J; Barczewska, M; Bojarski, P; Dziewiecki, C; Pastuszko, M; Ryba, M, 1993) |
| "A case is reported in which intravenous nimodipine therapy was associated with severe acute pulmonary hypertension in a patient with a subarachnoid haemorrhage." | 3.68 | Pulmonary vasoconstriction following intravenous nimodipine. ( Lovell, AT; Smith, M, 1992) |
| "We studied adenosine diphosphate-induced platelet aggregation and the associated release of thromboxane B2 in 49 patients with subarachnoid hemorrhage in relation to angiographic vasospasm." | 3.68 | Angiographic vasospasm and release of platelet thromboxane after subarachnoid hemorrhage. ( Heiskanen, O; Juvela, S; Kaste, M; Ohman, J; Servo, A, 1991) |
| "To prevent and treat the ischemic complications due to the vasospasm, this report suggest the management of aneurysmal subarachnoid haemorrhage by the association of antifibrinolytics (tranexamic acid) to lower the risk of rebleeding, calcium channel blockers (nimodipine), and the keeping of an effective total blood volume (thanks to volume expansion and dopamine)." | 3.68 | [Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume]. ( Berard, JP; Cavaroc, G; Greil, P; Gutknecht, JL; Halberstadt, J; Irthum, B; Planchon, E, 1990) |
| "Isolated pial arteries from a previously well-characterized model of experimental subarachnoid hemorrhage (SAH) in baboon were tested for their contractile response to 5-hydroxytryptamine (5-HT), norepinephrine (NE), and prostaglandin F2 alpha (PGF2 alpha) and the effect of the calcium antagonist, nimodipine." | 3.68 | Changes in contractile response and effect of a calcium antagonist, nimodipine, in isolated intracranial arteries of baboon following experimental subarachnoid hemorrhage. ( Chang, JY; Delgado, T; Owman, C; Sahlin, C; Salford, LG; Svendgaard, NA, 1990) |
| "Sixty-five patients with ruptured aneurysms were operated upon within 48 to 72 hours after subarachnoid hemorrhage (SAH) and were treated with a regimen of intra- and postoperative nimodipine for the prevention of symptomatic vasospasm." | 3.67 | Acute operation and preventive nimodipine improve outcome in patients with ruptured cerebral aneurysms. ( Auer, LM, 1984) |
| "Nimodipine was given as an intracarotid slow bolus injection in six patients with subarachnoid hemorrhage (SAH) due to rupture of a cerebral aneurysm, with angiographically demonstrated vasospasm." | 3.67 | Intracarotid slow bolus injection of nimodipine during angiography for treatment of cerebral vasospasm after SAH. A preliminary report. ( Bettag, W; Dabir, K; Fiebach, BJ; Grotenhuis, JA, 1984) |
| "Nimodipine was included in the treatment of four patients who had previously presented subarachnoid hemorrhage; cerebral circulation has been assayed by means of "Tomophygmographie cérébrale ultra-sonore"." | 3.67 | [Nimodipine and cerebrovascular circulation. Initial results apropos of 4 cases of subarachnoid hemorrhage]. ( Feiss, P; Lepetit, JM; Moreau, JJ; Ravon, R; Texier, JJ, 1989) |
| "Fifty four patients (33 male and 21 female, mean age 47) with spontaneous aneurysmal subarachnoid hemorrhages have been tested by repeated TCD: 25 of them were systematically administered intravenous Nimodipine when admitted at hospital, the 29 others constituted a reference group." | 3.67 | [Value of transcranial Doppler in the monitoring of aneurysmal subarachnoid hemorrhage treated with calcium inhibitors]. ( Auque, J; Burdin, D; Ducrocq, X; Girard, A; Hepner, H; Lepoire, J; Marchal, JC; Pincemaille, B, 1989) |
| "Arachidonic acid metabolites are under investigation as possible vasoactive agents involved in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage." | 3.67 | Effect of nimodipine on arachidonic acid metabolites after subarachnoid hemorrhage. ( Baena, Y; Gaetani, P; Grignani, G; Pacchiarini, L; Rodriguez, R, 1987) |
| "In a pilot study of 6 patients with subarachnoid hemorrhage caused by a ruptured intracranial (grade IV (Hunt and Hess) aneurysm the hemodynamics and plasma-nimodipine concentrations have been observed during a 3-week period of treatment." | 3.67 | Nimodipine treatment of subarachnoid hemorrhage. ( Jakobsen, P; Jensen, F; Laursen, J; Mikkelsen, E, 1988) |
| "Eighty-four patients were treated early with nimodipine intravenously, and thereafter orally, up to 21 days after aneurysmal subarachnoid hemorrhage." | 3.67 | Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results. ( Bolander, H; Carlsson, H; Pellettieri, L; Sjölander, U, 1988) |
| "Nimodipine is being used with increasing frequency in the prevention or treatment of vasospasm due to subarachnoid hemorrhage." | 3.67 | Nimodipine-treated subarachnoid hemorrhage associated with acute pseudo-obstruction of the colon. ( Sharp, A; Soto, B; Torrealba, G, 1987) |
| "During opiate anesthesia (standardized dosage of fentanyl) for operation of cerebral aneurysms after subarachnoid hemorrhage, different hemodynamic, respiratory, metabolic, and endocrine parameters were determined before (1 in Fig." | 3.67 | [Effect of the calcium antagonist nimodipine on hemodynamics, gas exchange and endocrine parameters in opiate anesthesia]. ( Adams, HA; Börner, U; Gips, H; Hempelmann, G; Marck, P; Müller, H; Otto, O, 1987) |
| "A consecutive series of 100 individuals with aneurysmal subarachnoid hemorrhage were subjected to early aneurysm operation followed by subsequent intravenous administration of the calcium antagonist nimodipine during the critical period for symptomatic vasospasm." | 3.67 | Delayed ischemic deterioration in patients with early aneurysm operation and intravenous nimodipine. ( Brandt, L; Ljunggren, B; Messeter, K; Säveland, H, 1986) |
| "The efficacy of the calcium channel blocker nimodipine in the prevention of chronic cerebral vasospasm (VSP) and delayed ischemia after subarachnoid hemorrhage (SAH) in monkeys was examined in a blind, randomized, placebo-controlled trial." | 3.67 | Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings. ( Boisvert, D; Cook, D; Krueger, C; Norris, S; Nosko, M; Overton, T; Weir, B, 1985) |
| "The effect of nimodipine on the in vitro reactivity of cerebral vessels after subarachnoid hemorrhage (SAH) was studied." | 3.67 | Nimodipine and chronic vasospasm in monkeys: Part 2. Pharmacological studies of vessels in spasm. ( Cook, D; Krueger, C; Norris, S; Nosko, M; Weir, B, 1985) |
| "The efficacy and tolerability of the dihydropyridine calcium antagonist nimodipine (BAY e 9736) in the prophylaxis of ischemic neurological deficits after subarachnoid hemorrhage were investigated in 171 patients in an open, prospective, multicenter study." | 3.67 | Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhage. ( Adelt, D; Ammerer, HP; Baumann, H; Böker, DK; Grotenhuis, JA; Istaitih, AR; Jaksche, H; Karnick, R; Kazner, E; Sprung, C, 1985) |
| "Intravenous Nimodipine was administered to 109 patients (65 female and 44 male) with either pre- or post-operative progressive neurological deterioration from cerebral vasospasm following subarachnoid hemorrhage from a ruptured aneurysm." | 3.67 | Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage. Clinical results of a multicenter study. ( Auer, LM; Böker, DK; Gaab, M; Jaksche, H; Koos, WT; Kostron, H; Meinig, G; Muizelaar, JP; Perneczky, A; van der Werf, AJ, 1985) |
| "The pharmacokinetics of Nimodipine were studied in healthy volunteers and in patients with subarachnoid hemorrhage (SAH) following cerebral aneurysm rupture." | 3.67 | Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ( Ahr, G; Auer, LM; Rämsch, KD; Tettenborn, D, 1985) |
| "Careful observation of blood pressure and heart rate in patients with subarachnoid hemorrhage during therapy with nimodipine showed that blood pressure decreases mainly in hypertensive patients during the first hours of therapy or when treatment is started immediately with 2 mg per hour instead of the recommended initial dose of 1 mg per hour." | 3.67 | Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage. ( Düdden, P; Dycka, J; Tettenborn, D; Volberg, E, 1985) |
| "Effect of a calcium antagonist, isopropyl-(2-methoxyethyl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5- pyridinedicarboxylate (nimodipine) on the cerebral vasospasm after experimental subarachnoid hemorrhage (SAH) was studied in ten adult cats." | 3.66 | Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarachnoid hemorrhage in cats. ( Fukuuchi, Y; Gotoh, F; Kobari, M; Muramatsu, F; Okayasu, H; Suzuki, N; Tanaka, K, 1982) |
| " Cerebral vasospasm (CV) after aneurysmal subarachnoid hemorrhage (aSAH) is still a problem." | 3.11 | Clinical Outcome in Cerebral Vasospasm Patients Treated with and without Intra-Arterial Nimodipine Infusion. ( Nimmannitya, P; Noiphithak, R; Punyarat, P; Tantongtip, D; Yindeedej, V, 2022) |
| "Cerebral vasospasm is one of the frequent complications that can occur following subarachnoid hemorrhage (SAH)." | 3.01 | Cerebral Vasospasm: Practical Review of Diagnosis and Management. ( Artico, M; Berger, JM; Caramuta, M; Longhitano, Y; Maconi, A; Piccolella, F; Romenskaya, T; Saviano, A; Savioli, G; Taurone, S; Zanza, C, 2023) |
| "Poor outcomes in Subarachnoid Hemorrhage (SAH) are in part due to a unique form of secondary neurological injury known as Delayed Cerebral Ischemia (DCI)." | 3.01 | Cortical Spreading Depolarization and Delayed Cerebral Ischemia; Rethinking Secondary Neurological Injury in Subarachnoid Hemorrhage. ( Bischof, H; Diedrich, D; Gomez, F; Laudanski, K; Mehra, A, 2023) |
| "Aneurysmal subarachnoid hemorrhage (aSAH) is a severe subtype of stroke occurring at a relatively young age with a significant socioeconomic impact." | 2.82 | Therapeutic Approaches for Cerebrovascular Dysfunction After Aneurysmal Subarachnoid Hemorrhage: An Update and Future Perspectives. ( Grasso, G; Torregrossa, F, 2022) |
| "Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high morbidity and mortality." | 2.80 | NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage. ( Aldrich, F; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Hoh, BL; Macdonald, RL; Mayer, SA; Miller, M; Mocco, J; Steiger, HJ; Strange, P, 2015) |
| " If a sufficient absorption could be achieved with enterally administered nimodipine, this would be more feasible dosage form and result in a significant reduction in pharmaceutical costs given that the parenteral formulation of nimodipine currently used is tenfold more expensive than the enteral formulation." | 2.73 | Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study. ( Helin-Tanninen, M; Koivisto, T; Kokki, H; Lehtola, S; Lehtonen, M; Rinne, J; Soppi, V, 2007) |
| "Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition associated with the development of early brain injury (EBI) and delayed cerebral ischemia (DCI)." | 2.72 | Non-steroidal anti-inflammatory drugs in the pathophysiology of vasospasms and delayed cerebral ischemia following subarachnoid hemorrhage: a critical review. ( Jancalek, R; Joukal, M; Mackerle, Z; Solar, P, 2021) |
| "Cerebral vasospasm is a common complication of subarachnoid hemorrhage." | 2.72 | Side effects of continuous intra-arterial infusion of nimodipine for management of resistant cerebral vasospasm in subarachnoid hemorrhage patients: A systematic review. ( Bilotta, F; Sarria-Santamera, A; Viderman, D, 2021) |
| " Tirilazad mesylate at dosage levels of up to 6 mg/kg per day for 8 to 10 days following SAH did not improve the overall outcome in patients with aneurysmal SAH in this trial." | 2.68 | A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. ( Alves, WM; Apperson-Hansen, C; Haley, EC; Kassell, NF; Maile, MH, 1997) |
| "Nimodipine treatment was associated with a significant reduction of delayed ischemic deterioration (all operation group combined, nimodipine vs." | 2.66 | Timing of operation for ruptured supratentorial aneurysms: a prospective randomized study. ( Heiskanen, O; Ohman, J, 1989) |
| "Nimodipine treatment was associated with a significantly better outcome (p less than 0." | 2.66 | Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. ( Benoit, BG; Disney, LB; Gentili, F; Grace, M; Holness, RO; Khan, MI; Mohr, G; Petruk, KC; Weir, BK; West, M, 1988) |
| "SAH due to cerebral aneurysm and receiving 21 days of treatment)." | 2.66 | Early intervention with nimodipine in subarachnoid haemorrhage. ( Dorrance, D; Lowe, D; Mee, E; Neil-Dwyer, G, 1987) |
| "In patients with aneurysmal subarachnoid hemorrhage (SAH), delayed ischemic cerebral dysfunction (DID or symptomatic vasospasm) with subsequent fixed neurological dysfunction (FND) is a frequent and most feared complication induced by the hemorrhage." | 2.66 | Cerebral vasospasm and calcium channel blockade. Nimodipine treatment in patients with aneurysmal subarachnoid hemorrhage. ( Andersson, KE; Brandt, L; Ljunggren, B; Säveland, H; Vinge, E, 1986) |
| "Nimodipine was found to be more potent, both in the chamber and in the live dog experiments." | 2.66 | Role of calcium antagonists in cerebral arterial spasm. ( Allen, GS, 1985) |
| "Nimodipine was given intravenously over ten days (30 micrograms/kg bodyweight/hour) and thereafter orally over four days in diminishing dosages." | 2.65 | [Clinical experiences with nimodipine (Bay e 9736)]. ( Grunert, V; Kostron, H; Russegger, L; Twerdy, K, 1984) |
| "Aneurysmal subarachnoid hemorrhage (aSAH) represents 3% of all strokes in the US." | 2.58 | Investigational drugs for vasospasm after subarachnoid hemorrhage. ( Freeman, WD; Pizzi, MA; Tallarico, RT, 2018) |
| "Large-vessel cerebral vasospasm has been challenged as the sole causal mechanism; new hypotheses now focus on the early brain injury, microcirculatory dysfunction, impaired autoregulation, and spreading depolarization." | 2.53 | Management of delayed cerebral ischemia after subarachnoid hemorrhage. ( Francoeur, CL; Mayer, SA, 2016) |
| "The effective reduction of delayed cerebral ischemia (DCI), a main contributor for poor outcome following aneurysmal subarachnoid hemorrhage (SAH), remains challenging." | 2.52 | Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. ( Burton, K; Davis, C; Etminan, N; Hänggi, D; Macdonald, RL; Steiger, HJ, 2015) |
| "Outcome of patients with aneurysmal subarachnoid hemorrhage (SAH) has improved over the last decades." | 2.49 | SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials. ( Cusimano, MD; Etminan, N; Hanggi, D; Hasan, D; Ilodigwe, D; Jaja, B; Lantigua, H; Le Roux, P; Lo, B; Louffat-Olivares, A; Macdonald, RL; Mayer, S; Molyneux, A; Quinn, A; Schenk, T; Schweizer, TA; Singh, J; Spears, J; Todd, M; Torner, J; Vergouwen, MD; Wong, GK, 2013) |
| "This process, known as cerebral vasospasm, is the most common cause of DCI after SAH." | 2.48 | Management of delayed cerebral ischemia after subarachnoid hemorrhage. ( Koenig, MA, 2012) |
| "196), and the difference in recurrent haemorrhage and adverse reactions between the nimodipine and placebo groups was not statistically significant (nimodipine group versus placebo group, recurrent haemorrhage P = 0." | 2.47 | Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage. ( He, GH; Liu, GJ; Luo, J; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ; Zhang, LP, 2011) |
| "Aneurysmal subarachnoid hemorrhage (SAH) accounts for a significant percentage of morbidity and mortality among patients admitted to neurosurgical centers throughout the world." | 2.46 | Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. ( Cook, AM; Ramsey, CN; Weant, KA, 2010) |
| "Resolution of ongoing cerebral vasospasm can be achieved by either dilating constricted vessels or optimizing hemodynamics." | 2.43 | Detecting and treating microvascular ischemia after subarachnoid hemorrhage. ( Sakowitz, OW; Unterberg, AW, 2006) |
| "Among patients with symptomatic cerebral vasospasm around 1/3 fully recover in 1/3 of cases persistent neurological deficit remains and 1/3 of the patients die." | 2.41 | [Cerebral vasospasm after subarachnoid hemorrhage. Current possibilities of prevention and treatment]. ( Danilewicz, B; Stachura, K, 2002) |
| "A short overview on trials in subarachnoid hemorrhage, head injury, ischemic stroke and cerebral resuscitation is given in this paper." | 2.39 | Clinical experiences with nimodipine in cerebral ischemia. ( Fritze, J; Kakarieka, A; Schakel, EH, 1994) |
| "Nimodipine treatment given before experimental ischemic insult, resulting from either vascular occlusion or intracranial hemorrhage or after subarachnoid hemorrhage, maintained or improved blood flow and minimized the severity of subsequent brain damage." | 2.38 | Efficacy of nimodipine in cerebral ischemia or hemorrhage. ( Graham, DI; Harper, AM; McCulloch, J; Mendelow, AD; Teasdale, G, 1990) |
| "Early surgery on cerebral aneurysms is advocated in order to prevent rebleeding and for early removal of blood clot from the basal cisterns." | 2.37 | [Vascular spasm and cerebral ischemia after meningeal hemorrhage caused by rupture of an aneurysm]. ( Van der Werf, AJ, 1986) |
| "The current management of subarachnoid hemorrhage (SAH) in the urban Chinese population remains unclear and the relevant literature is still lacking." | 1.91 | Current management of subarachnoid hemorrhage in a northern urban Chinese population: a multi-center surveillance study. ( Cheng, GJ; Li, RM; Lv, L; Ma, N; Zhang, JF; Zhang, L; Zhang, WS, 2023) |
| "Severe refractory cerebral vasospasm (CV) is a major cause of disability and death in patients with aneurysmal subarachnoid hemorrhage (SAH)." | 1.72 | Continuous intra-arterial nimodipine infusion as rescue treatment of severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Anthofer, J; Bele, S; Bruendl, E; Kieninger, M; Schebesch, KM; Schmidt, NO; Wendl, C; Zeman, F, 2022) |
| "Nimodipine treatment provides SAH patients with short-term neurological benefits." | 1.72 | Nimodipine Attenuates Early Brain Injury by Protecting the Glymphatic System After Subarachnoid Hemorrhage in Mice. ( Cui, X; Hou, C; Li, J; Liu, Q; Ren, W; Wang, B; Wang, W; Yang, X; Zhang, H, 2022) |
| "Delayed cerebral ischemia (DCI) contributes to poor outcomes after subarachnoid hemorrhage (SAH)." | 1.72 | Large practice variations in diagnosis and treatment of delayed cerebral ischemia after subarachnoid hemorrhage. ( Coert, BA; Coutinho, JM; Horn, J; Post, R; Tjerkstra, MA; van den Berg, R; Vandertop, WP; Verbaan, D, 2022) |
| "Patients with refractory cerebral vasospasm treated with intra-arterial nimodipine during 2009-2020 at Sahlgrenska University Hospital were retrospectively reviewed." | 1.72 | Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid haemorrhage - neurological and radiological outcome. ( Nilsson, D; Rentzos, A; Samuelsson, J; Sunila, M, 2022) |
| "Nimodipine is a dihydropyridine calcium channel blocker that exhibits higher selectivity toward cerebral blood vessels compared with other members of the same class." | 1.62 | Enantioselective assay of nimodipine in human plasma using liquid chromatography-tandem mass spectrometry. ( Isse, FA; Le, T; Mahmoud, SH, 2021) |
| " Dose-response curves for the 5-HT-induced contraction (from 0." | 1.62 | The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats. ( Crespo, MJ; García, L; Morales, M; Román, M, 2021) |
| "After spontaneous subarachnoid hemorrhage (sSAH), cerebral vasospasm (CVS) is a common complication, potentially resulting in infarction mainly responsible for a poor outcome." | 1.56 | Transluminal balloon angioplasty for cerebral vasospasm after spontaneous subarachnoid hemorrhage: A single-center experience. ( Boppel, T; Ditz, C; Küchler, J; Leppert, J; Neumann, A; Schacht, H; Schramm, P, 2020) |
| " In cases of spontaneous subarachnoid hemorrhage (sSAH) and symptomatic cerebral vasospasm (sCVS), multiple intra-arterial treatments (IATs) can be potentially useful for the functional outcome, even if the prognosis is initially poor." | 1.56 | Symptomatic Cerebral Vasospasm after Spontaneous Subarachnoid Hemorrhage: Comparison of Single and Multiple Intra-arterial Treatment with Respect to the Functional Outcome. ( Aulmann, L; Ditz, C; Küchler, JN; Neumann, A; Schacht, H; Schramm, P; Tronnier, VM, 2020) |
| "Background and Purpose- Delayed cerebral infarction (DCI) is an important cause of morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 1.56 | Impact of Stereotactic Ventriculocisternostomy on Delayed Cerebral Infarction and Outcome After Subarachnoid Hemorrhage. ( Bardutzky, J; Beck, J; Buttler, J; Coenen, VA; Csok, I; Egger, K; Grauvogel, J; Niesen, WD; Reinacher, PC; Roelz, R; Rohr, E; Sajonz, B; Schaefer, JH; Scheiwe, C; Shah, MJ; Steiert, C, 2020) |
| "Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a." | 1.56 | Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis. ( Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020) |
| "The prevalence of takotsubo syndrome (TTS) in patients with subarachnoid hemorrhage (SAH) is much higher than in the general population." | 1.56 | Takotsubo syndrome after nimodipine-induced hypotension treated with norepinephrine in a female with subarachnoid hemorrhage. ( Baszko, A; Elikowski, W; Fertała, N; Ganowicz-Kaatz, T; Małek-Elikowska, M; Piestrzeniewicz, R; Smól, S; Zawodna, M, 2020) |
| "We report a 39-year-old male with an aneurysmal subarachnoid hemorrhage without hydrocephalus, in whom a right choroidal aneurysm was early excluded by endovascular coil insertion." | 1.51 | [Continuous intra arterial nimodipine for vasospasm secondary to subarachnoid hemorrhage. Report of one case]. ( Contreras, L; Cordovez, J; Ducci, H; Galvez, M; Mena, F; Reccius, A; Regueira, T; Soto, L; Torres, F, 2019) |
| "Cerebral vasospasm (CV) and delayed cerebral ischemia (DCI) are major factors that limit good outcome in patients with spontaneous subarachnoid hemorrhage (SAH)." | 1.51 | The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia-continuous selective intracarotid nimodipine therapy in awake patients without sedation. ( Brand, C; Braun, M; Kapapa, T; König, R; Özpeynirci, Y; Paľa, A; Pedro, MT; Schmitz, B; Schneider, M; Wirtz, CR, 2019) |
| "Delayed Cerebral Infarction (DCI) due to Cerebral Vasospasm (CVS) is an important contributor to poor outcome after aneurysmal subarachnoid haemorrhage (aSAH)." | 1.51 | A novel rescue therapy for cerebral vasospasm: Cisternal Nimodipine application via stereotactic catheter ventriculocisternostomy. ( Coenen, VA; Reinacher, PC; Roelz, R; Scheiwe, C, 2019) |
| "These two syndromes have similar symptoms but may have different treatments, thus highlighting the importance of a correct diagnosis." | 1.51 | Posterior reversible encephalopathy syndrome associated with reversible cerebral vasoconstriction syndrome in a patient presenting with postpartum eclampsia: A case report. ( Auliac, SC; Ayoubi, JM; Carbonnel, M; Josserand, J; Pop, A; Wang, A, 2019) |
| "Moreover, MN-08 also alleviated cerebral vasospasm in a cisterna magna single-injection model in rabbits." | 1.51 | The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models. ( Guo, B; Han, Y; Ju, J; Li, N; Li, S; Liu, Z; Luo, F; Mak, S; Sun, Y; Wang, Y; Wu, L; Yang, X; Zhang, G; Zhang, Z; Zhou, Q; Zhu, Z, 2019) |
| "Cerebral vasospasm is a major contributor to DCI and requires special attention." | 1.51 | Endovascular treatment of cerebral vasospasm after subarachnoid hemorrhage: More is more. ( Beck, J; Darkwah Oppong, M; Forsting, M; Jabbarli, R; Kaier, K; Mönninghoff, C; Pierscianek, D; Rölz, R; Shah, M; Sure, U; Taschner, C; Urbach, H, 2019) |
| "Nimodipine has improving effects on CVS in different degrees, and TCCS can be used to evaluate the therapeutic effects on CVS." | 1.46 | Evaluation function of transcranial two-dimensional and color Doppler ultrasonography (TCCS) for patients with different degrees of cerebral vasospasm before and after the nimodipine treatment. ( Li, X; Li, XN; Wang, JL; Yang, YL; Zhang, YH, 2017) |
| "Background Cerebral vasospasm (CV) is a major cause of delayed morbidity and mortality in patients with subarachnoid hemorrhage (SAH)." | 1.46 | Higher dose intra-arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a rescue therapy for refractory cerebral vasospasm. ( Dogan, R; Duman, E; Fırat, A; Karakoç, F; Pinar, HU; Yıldırım, E, 2017) |
| "Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most important complication that effects the mortality and morbidity of patients with intracranial aneurysm." | 1.46 | Comparison of the Effects and Mechanism of the Curcumin with Different Drugs in Experimental Vasospasm After Subarachnoid Hemorrhage. ( Aydin, HE; Baycu, C; Bektur, NE; Kilic, FS; Oner, S; Ozbek, Z, 2017) |
| "During the postpartum period, seizure is a significant concern." | 1.46 | Reversible cerebral vasoconstriction syndrome presenting as subarachnoid hemorrhage: A rare cause of postpartum seizure. ( Choi, YH; Lee, SH; Yun, SJ, 2017) |
| "In aneurysmal subarachnoid haemorrhage cerebral vasospasm leads to clinical worsening and poor outcome." | 1.46 | Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm. ( Doukas, A; Jansen, O; Larsen, N; Mehdorn, M; Stopfer, A; Synowitz, M; von der Brelie, C, 2017) |
| "Timely detection of impending delayed cerebral ischemia after subarachnoid hemorrhage (SAH) is essential to improve outcome, but poses a diagnostic challenge." | 1.43 | Retinal Vessel Analysis (RVA) in the Context of Subarachnoid Hemorrhage - A Proof of Concept Study. ( Albanna, W; Brockmann, MA; Clusmann, H; Conzen, C; Fuest, M; Hoellig, A; Kotliar, K; Mueller, M; Schmidt-Trucksäss, A; Schubert, GA; Seiz, M; Thomé, C; Vilser, W; Weiss, M, 2016) |
| "Milrinone was recently suggested as an invasive VSP treatment option." | 1.42 | Repeated combined endovascular therapy with milrinone and nimodipine for the treatment of severe vasospasm: preliminary results. ( Karaic, R; Kleinpeter, G; Krafft, P; Loyoddin, M; Sherif, C; Tscholakoff, D; Valentin, A; Wambacher, B, 2015) |
| "Verapamil was the most common first-line therapy in the United States, whereas nimodipine was most popular in non-U." | 1.42 | Results of an International Survey on the Investigation and Endovascular Management of Cerebral Vasospasm and Delayed Cerebral Ischemia. ( Bulsara, KR; Chen, PR; Coulthard, A; Goddard, AJ; Hollingworth, M; Söderman, M, 2015) |
| " Key to the effective administration of continuous intra-arterial nimodipine is multimodal neuromonitoring and the individual adaptation of dosage and time of infusion for each patient." | 1.42 | Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results. ( Bele, S; Brawanski, A; Bründl, E; Hochreiter, A; Kieninger, M; Proescholdt, MA; Schebesch, KM; Scheitzach, J; Schneiker, A; Schödel, P; Schuierer, G; Wendl, C, 2015) |
| "The authors describe a rare case of central auditory dysfunction induced by cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH)." | 1.39 | Partly reversible central auditory dysfunction induced by cerebral vasospasm after subarachnoid hemorrhage. ( Deggouj, N; Duprez, T; Grandin, C; Hantson, P; Lhommel, R; Ponzetto, E; van Pesch, V; Vinetti, M, 2013) |
| "Bath-related thunderclap headache (BRTH) is a rare and usually benign condition." | 1.39 | Bath-related thunderclap headache associated with subarachnoid and intracerebral hemorrhage. ( Chen, YY; Jhang, KM; Lee, KW; Lin, CH, 2013) |
| "Twenty (20) patients with SAH were treated after their ruptured aneurysms had been secured." | 1.39 | Acupuncture for cerebral vasospasm after subarachnoid hemorrhage: a retrospective case-control study. ( Bae, HS; Cho, SY; Kim, GK; Ko, CN; Koh, JS; Lee, IW; Lee, SH; Park, JM; Park, SU, 2013) |
| "Delayed cerebral ischemia (DCI) is the second most important impacting factor for functional outcome after aneurysmal subarachnoid hemorrhage (SAH) following the initial severity of the bleeding." | 1.38 | [Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: prevention, diagnostics and therapy]. ( Wartenberg, KE; Wolf, S, 2012) |
| "To determine if the age of packed red blood cells (PRBCs) is associated with adverse events or outcomes in patients with subarachnoid haemorrhage (SAH)." | 1.37 | Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage. ( Ault, ML; Duran, IM; Liebling, SM; Naidech, AM, 2011) |
| "Nimodipine treatment in cerebral vasospasm is useful." | 1.37 | Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Civelek, E; Isikay, I; Kircelli, A; Narin, F; Onal, MB; Solmaz, I; Ugurel, S; Yakupoglu, H, 2011) |
| "Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously." | 1.37 | Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011) |
| "Nimodipine is an effect-proven agent in CVS, but dotarizine may take place of it." | 1.37 | Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits. ( Civelek, E; Erdogan, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Solmaz, I; Tehli, O, 2011) |
| "The ability of subarachnoid hemorrhage (SAH) to induce vasospasm in large-diameter pial arteries has been extensively studied, although the contribution of this phenomenon to patient outcome is controversial." | 1.37 | Fundamental increase in pressure-dependent constriction of brain parenchymal arterioles from subarachnoid hemorrhage model rats due to membrane depolarization. ( Brayden, JE; Nelson, MT; Nystoriak, MA; O'Connor, KP; Sonkusare, SK; Wellman, GC, 2011) |
| "Nimodipine is a potent drug for vessel relaxation, but side effects may preclude a sufficient dose." | 1.37 | Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. ( Coburger, J; Henkes, H; Hopf, N; Musahl, C; Vajda, Z, 2011) |
| "Nonaneurysmal perimesencephalic subarachnoid hemorrhage (SAH) has usually a benign prognosis and uneventful course; however, recent reports suggest that these patients may develop severe symptomatic vasospasm." | 1.37 | Endovascular treatment of severe vasospasm in nonaneurysmal perimesencephalic subarachnoid hemorrhage. ( Dabus, G; Fuentes, K; Linfante, I; Samaniego, EA, 2011) |
| "Cerebral vasospasm complicating aneurysmal subarachnoid hemorrhage is a well-known medical entity." | 1.37 | Resistant vasospasm in subarachnoid hemorrhage treated with continuous intraarterial nimodipine infusion. ( Barth, H; Doukas, A; Jansen, O; Maslehaty, H; Mehdorn, HM; Petridis, AK, 2011) |
| " There were no serious adverse effects observed." | 1.35 | Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy. ( Beseoglu, K; Hänggi, D; Steiger, HJ; Turowski, B, 2008) |
| "Traumatic subarachnoid hemorrhage is a common finding following traumatic brain injury." | 1.35 | Experimental subarachnoid hemorrhage in the rat: influences of nimodipine. ( Brinker, T; Herrmann, B; Samii, M; Thomas, S, 2008) |
| "We describe subarachnoid hemorrhage (SAH) in a 66-year-old man, who underwent technically successful carotid stenting for a string-stenosis of the right internal carotid artery (ICA) in a presence of contralateral ICA occlusion with recurrent right hemisphere transient ischemic attacks." | 1.34 | Subarachnoid hemorrhage after carotid artery stenting. ( Kablak-Ziembicka, A; Moczulski, Z; Motyl, R; Pieniazek, P; Przewlocki, T; Tracz, W, 2007) |
| "Here we describe a patient with a thunderclap headache and a mid-basilar narrowing due to a reversible vasospasm." | 1.33 | [Idiopathic thunderclap headache: reversible vasospasm of the Arteria basilaris]. ( Bruening, R; Plendl, H; Straube, A, 2006) |
| "The patient had clinical signs of sensory aphasia, which resolved completely after one-week treatment with nimodipine." | 1.31 | Functional methods for evaluation the occurrence of delayed ischemic deficit in patients with subarachnoid hemorrhage. ( Haralanov, L; Klissurski, M; Stamenova, P, 2001) |
| "The morbidity and mortality of cerebral vasospasm is significant." | 1.31 | Contemporary management of subarachnoid hemorrhage and vasospasm: the UIC experience. ( Alp, MS; Ausman, J; Charbel, F; Corsten, L; Debrun, G; Guppy, K; Misra, M; Raja, A; Roitberg, B, 2001) |
| "Nimodipine is an established drug in the treatment of symptomatic subarachnoid haemorrhage." | 1.29 | Nimodipine levels in breast milk. ( Tonks, AM, 1995) |
| "Nimodipine infusion was started before surgery." | 1.29 | Causes of morbidity and mortality after ruptured aneurysm surgery in a series of 230 patients. The importance of control angiography. ( Creissard, P; Freger, P; Hannequin, D; Langlois, O; Proust, F, 1995) |
| "Nimodipine was administered in 231 (84%) of the 275 patients." | 1.29 | Which are the major determinants for outcome in aneurysmal subarachnoid hemorrhage? A prospective total management study from a strictly unselected series. ( Brandt, L; Säveland, H, 1994) |
| "As soon as the subarachnoid hemorrhage diagnosis is confirmed by computed tomography (or if unconfirmed, by lumbar puncture), we assume that each patient may have an aneurysm." | 1.29 | Are the calcium antagonists really useful in cerebral aneurysmal surgery? A retrospective study. ( Alhayek, G; Fournier, D; Guy, G; Menei, P; Mercier, P; Rizk, T, 1994) |
| "Nimodipine treatment was started within three days of delayed ischaemic deficit (DID) onset, at a low dose increased quickly to 30-45 ug/kg/hr, and reduced gradually over the last day or two of the course." | 1.29 | Treatment of symptomatic vasospasm with nimodipine. ( Compton, JS; Dorsch, NW, 1993) |
| "Early hydrocephalus is a risk factor of shunt-dependent late hydrocephalus (SDHC)." | 1.29 | Shunt-dependent hydrocephalus after subarachnoid haemorrhage and aneurysm surgery: timing of surgery is not a risk factor. ( Hernesniemi, J; Kari, A; Luukkonen, M; Niskanen, M; Puranen, M; Tapaninaho, A; Vapalahti, M, 1993) |
| "Nimodipine treatment was associated with a significant increase of survival (11." | 1.29 | [Comparison of 2 consecutive series of aneurysmal subarachnoid hemorrhage with or without nimodipine and study of the temperature curve]. ( Bazin, A; Bernard, MH; Bertault, R; Gomis, P; Graftieaux, JP; Peruzzi, P; Rousseaux, P; Scherpereel, B, 1993) |
| " The pharmacokinetic findings in Chinese patients are comparable to previously reported values in Caucasians." | 1.29 | Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. ( Chang, CM; Fong, KY; Fung, CF; Kou, M; Kumana, CR; Lauder, IJ; Mück, W; Yu, YL, 1993) |
| "Operative interventions in subarachnoid hemorrhages caused by brain vessel aneurysm require meticulous dissection of the latter." | 1.29 | [Controlled hypotension against a background of nimodipine during an operation on neurosurgical patients with hypertension]. ( Karadimov, D, 1995) |
| "Nimodipine was administered to 269 of the 325 patients: intravenously in 218, orally in 15, and intravenously followed by orally in 36." | 1.28 | Overall outcome in aneurysmal subarachnoid hemorrhage. A prospective study from neurosurgical units in Sweden during a 1-year period. ( Algers, G; Brandt, L; Edner, G; Hillman, J; Jakobsson, KE; Säveland, H, 1992) |
| "Among the 141 patients with subarachnoid hemorrhage but not intracerebral or intraventricular hematoma, 16 made an unfavorable outcome, ie, 11% versus 56% among patients with intracerebral hematoma/intraventricular hematoma on preoperative computed tomography scan." | 1.28 | Unfavorable outcome following early surgical repair of ruptured cerebral aneurysms--a critical review of 238 patients. ( Auer, LM, 1991) |
| "Nimodipine was then discontinued and, 48 hours later, when the middle cerebral artery velocity was still in the same range, CO2 vasoreactivity was tested again." | 1.28 | Effect of nimodipine on cerebrovascular response to CO2 in asymptomatic individuals and patients with subarachnoid hemorrhage: a transcranial Doppler ultrasound study. ( Nirkko, AC; Seiler, RW, 1990) |
| "Nimodipine has proven to be effective in preventing this complication in a majority of patients studied, with hypotension the most severe adverse effect." | 1.28 | Nimodipine: the use of calcium antagonists to prevent vasospasm following subarachnoid hemorrhage. ( Sosnowski, C, 1990) |
| " Half the animals were pretreated with an intravenous infusion of the calcium antagonistic nimodipine, in a dosage comparable with clinical levels." | 1.28 | An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage. ( Bentivoglio, P; Branston, NM; Dorsch, NW; Harris, RJ; Symon, L, 1989) |
| "Morbidity after aneurysmal subarachnoid hemorrhages is proceeding from many factors; ischemic etiology is underestimated and frequently thought to be vasospasm related only." | 1.28 | [Does nimodipine improve the outcome of perioperative complications of aneurysm rupture? Results of systematic treatment]. ( Ades, PE; Aesch, B; Buchet, S; Fabre, M; Jan, M; Lamotte, C; Rieant, JF, 1989) |
| " The effect of nimodipine on vessel caliber at this dosage was equivocal." | 1.27 | A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings. ( Boisvert, D; Castor, W; Espinosa, F; Grace, M; Overton, T; Weir, B, 1984) |
| "Nimodipine treatment significantly ameliorates mitochondrial respiratory conditions." | 1.27 | Effect of nimodipine on mitochondrial respiration in different rat brain areas after subarachnoid haemorrhage. ( Gaetani, P; Marzatico, F; Rodriguez y Baena, R; Silvani, V; Spanu, G, 1988) |
| "Following aneurysmal subarachnoid hemorrhage (SAH) many patients complain of and exhibit disturbances of a cognitive nature." | 1.27 | Does intravenous nimodipine treatment influence cognition in patients subjected to early aneurysm operation? ( Brandt, L; Ljunggren, B; Ryman, T; Säveland, H; Sonesson, B, 1988) |
| "Nimodipine was administered postoperatively by subcutaneous injection of 1 ml/0." | 1.27 | Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm. ( Grace, MG; Lewis, PJ; Nosko, MG; Tanabe, T; Weir, BK, 1988) |
| "Twenty-four patients with subarachnoid hemorrhage due to rupture of a supratentorial aneurysm underwent surgery within 72 hours after subarachnoid hemorrhage." | 1.27 | Thromboxane B2 levels in serum during continuous administration of nimodipine to patients with aneurysmal subarachnoid hemorrhage. ( Andersson, KE; Brandt, L; Ljunggren, B; Vinge, E, 1988) |
| "One nimodipine-treated patient with a preserved CO2 response, in whom operation was complicated, developed DID." | 1.27 | Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation. ( Algotsson, L; Brandt, L; Ljunggren, B; Messeter, K; Romner, B; Ryding, E; Svendgaard, NA, 1987) |
| " Cardiac index and stroke index correlated positively with nimodipine dosage (r = 0." | 1.27 | Nimodipine and chronic vasospasm in monkeys: Part 3. Cardiopulmonary effects. ( Grace, M; King, EG; Norris, SL; Nosko, M; Weir, B, 1986) |
| " Mean bioavailability was 15." | 1.27 | Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. ( Andersson, KE; Brandt, L; Ljunggren, B; Nilsson, LG; Rosendal-Helgesen, S; Vinge, E, 1986) |
| "Nimodipine was well tolerated and neither significant hypotension nor any other adverse reaction attributable to the drug was observed." | 1.27 | Nimodipine and early aneurysm operation in good condition SAH patients. ( Auer, LM; Brandt, L; Ebeling, U; Gilsbach, J; Groeger, U; Harders, A; Ljunggren, B; Oppel, F; Reulen, HJ; Saeveland, H, 1986) |
| "The overall morbidity and mortality from aneurysmal subarachnoid hemorrhage have not changed significantly over the past 30 years in spite of great progress in surgical technology and diagnostic capabilities." | 1.27 | Current management of cerebral aneurysms: is it based on facts or myths? ( Ausman, JI; Diaz, FG; Fielding, AS; Malik, GM; Son, CS, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (21.83) | 18.7374 |
| 1990's | 91 (23.10) | 18.2507 |
| 2000's | 55 (13.96) | 29.6817 |
| 2010's | 107 (27.16) | 24.3611 |
| 2020's | 55 (13.96) | 2.80 |
| Authors | Studies |
|---|---|
| Opitz, M | 1 |
| Zensen, S | 1 |
| Bos, D | 1 |
| Wetter, A | 1 |
| Kleinschnitz, C | 1 |
| Uslar, E | 1 |
| Jabbarli, R | 2 |
| Sure, U | 2 |
| Radbruch, A | 1 |
| Li, Y | 1 |
| Dörner, N | 1 |
| Forsting, M | 3 |
| Deuschl, C | 1 |
| Guberina, N | 1 |
| Chen, M | 1 |
| Zhang, Q | 1 |
| Liu, H | 1 |
| Zou, W | 1 |
| Wei, X | 1 |
| Roelz, R | 4 |
| Scheiwe, C | 4 |
| Grauvogel, J | 3 |
| Csok, I | 2 |
| Coenen, VA | 4 |
| Beck, J | 4 |
| Reinacher, PC | 4 |
| Mahmoud, L | 1 |
| Zullo, AR | 1 |
| Blake, C | 1 |
| Dai, X | 1 |
| Thompson, BB | 1 |
| Wendell, LC | 1 |
| Furie, KL | 1 |
| Reznik, ME | 1 |
| Mahta, A | 1 |
| Clough, B | 1 |
| Tenii, J | 1 |
| Wee, C | 1 |
| Gunter, E | 1 |
| Griffin, T | 1 |
| Aiyagari, V | 1 |
| Anthofer, J | 1 |
| Bele, S | 4 |
| Wendl, C | 4 |
| Kieninger, M | 4 |
| Zeman, F | 1 |
| Bruendl, E | 1 |
| Schmidt, NO | 1 |
| Schebesch, KM | 2 |
| Hou, C | 1 |
| Liu, Q | 1 |
| Zhang, H | 1 |
| Wang, W | 1 |
| Wang, B | 1 |
| Cui, X | 1 |
| Li, J | 1 |
| Ren, W | 1 |
| Yang, X | 2 |
| Yindeedej, V | 1 |
| Nimmannitya, P | 1 |
| Noiphithak, R | 1 |
| Punyarat, P | 1 |
| Tantongtip, D | 1 |
| Qureshi, AI | 1 |
| Lobanova, I | 1 |
| Huang, W | 1 |
| Ishfaq, MF | 1 |
| Broderick, JP | 1 |
| Cassarly, CN | 1 |
| Martin, RH | 1 |
| Macdonald, RL | 14 |
| Suarez, JI | 2 |
| Tjerkstra, MA | 1 |
| Verbaan, D | 1 |
| Coert, BA | 1 |
| Post, R | 1 |
| van den Berg, R | 1 |
| Coutinho, JM | 1 |
| Horn, J | 1 |
| Vandertop, WP | 1 |
| Steiger, HJ | 14 |
| Ensner, R | 1 |
| Andereggen, L | 1 |
| Remonda, L | 1 |
| Berberat, J | 1 |
| Marbacher, S | 2 |
| Torregrossa, F | 1 |
| Grasso, G | 1 |
| Schacht, H | 4 |
| Küchler, J | 3 |
| Neumann, A | 4 |
| Schramm, P | 4 |
| Tronnier, VM | 2 |
| Ditz, C | 3 |
| Dayyani, M | 1 |
| Sadeghirad, B | 1 |
| Grotta, JC | 1 |
| Zabihyan, S | 1 |
| Ahmadvand, S | 1 |
| Wang, Y | 5 |
| Guyatt, GH | 1 |
| Amin-Hanjani, S | 1 |
| Geraldini, F | 1 |
| De Cassai, A | 1 |
| Diana, P | 1 |
| Correale, C | 1 |
| Boscolo, A | 1 |
| Zampirollo, S | 1 |
| Disarò, L | 1 |
| Carere, A | 1 |
| Cacco, N | 1 |
| Navalesi, P | 1 |
| Munari, M | 1 |
| Mallereau, CH | 1 |
| Ribeiro, M | 1 |
| Ardellier, FD | 1 |
| Dannhoff, G | 1 |
| Cebula, H | 1 |
| Proust, F | 2 |
| Chibbaro, S | 1 |
| Todeschi, J | 1 |
| Kotwal, A | 1 |
| Ramalingaiah, AH | 1 |
| Shukla, D | 1 |
| Radhakrishnan, M | 1 |
| Konar, SK | 1 |
| Srinivasaiah, B | 1 |
| Chakrabarti, D | 1 |
| Sundaram, M | 1 |
| Romenskaya, T | 1 |
| Longhitano, Y | 1 |
| Piccolella, F | 1 |
| Berger, JM | 1 |
| Artico, M | 1 |
| Taurone, S | 1 |
| Maconi, A | 1 |
| Saviano, A | 1 |
| Caramuta, M | 1 |
| Savioli, G | 1 |
| Zanza, C | 1 |
| Welling, LC | 1 |
| Rabelo, NN | 1 |
| de Aguiar, LB | 1 |
| Figueiredo, EG | 1 |
| Haugh, JP | 1 |
| Turkalp, Z | 1 |
| Sivam, H | 1 |
| Gatt, S | 1 |
| Kaliaperumal, C | 1 |
| Liu, J | 1 |
| Sun, C | 1 |
| Nie, G | 1 |
| Dong, Q | 1 |
| You, J | 1 |
| Li, Q | 1 |
| Li, M | 1 |
| Zhang, JF | 1 |
| Ma, N | 1 |
| Zhang, WS | 1 |
| Cheng, GJ | 1 |
| Lv, L | 1 |
| Zhang, L | 1 |
| Li, RM | 1 |
| Crespo, MJ | 2 |
| Román, M | 2 |
| Tirado, G | 1 |
| Martins, AH | 1 |
| Ferrer-Acosta, Y | 1 |
| Martinez-Jimenez, SM | 1 |
| Mahmoud, SH | 4 |
| Hefny, FR | 1 |
| Panos, NG | 1 |
| Delucilla, L | 1 |
| Ngan, Z | 1 |
| Perreault, MM | 1 |
| Hamilton, LA | 1 |
| Rowe, AS | 1 |
| Buschur, PL | 1 |
| Owusu-Guha, J | 1 |
| Almohaish, S | 1 |
| Sandler, M | 1 |
| Armahizer, MJ | 1 |
| Barra, ME | 1 |
| Cook, AM | 3 |
| Barthol, CA | 1 |
| Hintze, TD | 1 |
| Cantin, A | 1 |
| Traeger, J | 1 |
| Blunck, JR | 1 |
| Shewmaker, J | 1 |
| Burgess, SV | 1 |
| Kaupp, K | 1 |
| Brown, CS | 1 |
| Clark, SL | 2 |
| Wieruszewski, ED | 1 |
| Tesoro, EP | 1 |
| Ammar, AA | 1 |
| Ammar, MA | 1 |
| Binning, MJ | 1 |
| Naydin, S | 1 |
| Fox, N | 1 |
| Peters, DM | 1 |
| Mahmoud, LN | 1 |
| Keegan, SP | 1 |
| Brophy, GM | 1 |
| Rass, V | 1 |
| Kindl, P | 1 |
| Lindner, A | 1 |
| Kofler, M | 1 |
| Altmann, K | 1 |
| Putnina, L | 1 |
| Ianosi, BA | 1 |
| Schiefecker, AJ | 1 |
| Beer, R | 1 |
| Pfausler, B | 1 |
| Helbok, R | 1 |
| Mehra, A | 1 |
| Gomez, F | 1 |
| Bischof, H | 1 |
| Diedrich, D | 1 |
| Laudanski, K | 1 |
| Youm, JY | 1 |
| Park, B | 1 |
| Park, KH | 1 |
| Il Won, Y | 1 |
| Byoun, HS | 1 |
| Lim, J | 1 |
| Weber, W | 1 |
| Jensen-Kondering, U | 1 |
| Berlis, A | 1 |
| Schwarting, J | 1 |
| Harapan, BN | 1 |
| Lin, X | 1 |
| Plesnila, N | 1 |
| Terpolilli, NA | 1 |
| Lei, G | 1 |
| Rao, Z | 1 |
| Hu, Y | 1 |
| Hernández-Durán, S | 1 |
| Mielke, D | 1 |
| Rohde, V | 2 |
| Malinova, V | 1 |
| Mindt, S | 1 |
| Tokhi, U | 1 |
| Hedtke, M | 1 |
| Groß, HJ | 1 |
| Hänggi, D | 16 |
| Peacock, SH | 1 |
| James, C | 1 |
| Turnbull, MT | 2 |
| Cowart, JB | 1 |
| Reid, JM | 1 |
| Freeman, WD | 3 |
| Cottenceau, V | 1 |
| Poutier, B | 1 |
| Gariel, F | 1 |
| Sauvage, N | 1 |
| Petit, L | 1 |
| Carrie, C | 1 |
| Biais, M | 1 |
| Boppel, T | 1 |
| Leppert, J | 1 |
| Aulmann, L | 1 |
| Küchler, JN | 1 |
| Schaefer, JH | 1 |
| Sajonz, B | 1 |
| Steiert, C | 1 |
| Buttler, J | 1 |
| Rohr, E | 1 |
| Shah, MJ | 1 |
| Egger, K | 1 |
| Niesen, WD | 2 |
| Bardutzky, J | 1 |
| Maher, M | 1 |
| Schweizer, TA | 2 |
| Carlson, AP | 2 |
| Alchbli, A | 1 |
| Shuttleworth, CW | 1 |
| Solar, P | 1 |
| Mackerle, Z | 1 |
| Joukal, M | 1 |
| Jancalek, R | 1 |
| James, CL | 1 |
| Isse, FA | 3 |
| Abdallah, YEH | 1 |
| Li, JW | 1 |
| Ren, SH | 1 |
| Ren, JR | 1 |
| Zhen, ZG | 1 |
| Li, LR | 1 |
| Hao, XD | 1 |
| Ji, HM | 1 |
| Chen, CT | 1 |
| Chen, CC | 1 |
| Wang, AY | 1 |
| Wu, YM | 1 |
| Chin, SC | 1 |
| Hsieh, PC | 1 |
| Yeap, MC | 1 |
| Hsu, SY | 1 |
| Lin, YJ | 1 |
| Elikowski, W | 1 |
| Małek-Elikowska, M | 1 |
| Piestrzeniewicz, R | 1 |
| Fertała, N | 1 |
| Zawodna, M | 1 |
| Ganowicz-Kaatz, T | 1 |
| Baszko, A | 1 |
| Smól, S | 1 |
| Le, T | 1 |
| Ji, X | 1 |
| McGowan, B | 1 |
| Khaira, G | 1 |
| Coghlan, MA | 1 |
| Shaibani, A | 1 |
| Alden, TD | 1 |
| Pardo, AC | 1 |
| Ko, NU | 1 |
| Darsaut, TE | 1 |
| Wong, GK | 3 |
| Etminan, N | 9 |
| Mayer, SA | 6 |
| Aldrich, EF | 2 |
| Diringer, MN | 7 |
| Ng, D | 2 |
| Strange, P | 2 |
| Bleck, T | 1 |
| Grubb, R | 1 |
| Dawley, T | 1 |
| Claus, CF | 1 |
| Tong, D | 1 |
| Rajamand, S | 1 |
| Sigler, D | 1 |
| Bahoura, M | 1 |
| Garmo, L | 1 |
| Soo, TM | 1 |
| Kelkar, P | 1 |
| Richards, B | 1 |
| Sokolowski, JD | 2 |
| Chen, CJ | 2 |
| Soldozy, S | 1 |
| Mastorakos, P | 1 |
| Burke, RM | 1 |
| Nguyen, JM | 1 |
| Myers, KM | 1 |
| Kalani, MYS | 1 |
| Park, MS | 2 |
| Regueira, T | 1 |
| Reccius, A | 1 |
| Ducci, H | 1 |
| Torres, F | 1 |
| Soto, L | 1 |
| Cordovez, J | 1 |
| Galvez, M | 1 |
| Contreras, L | 1 |
| Mena, F | 1 |
| Viderman, D | 1 |
| Sarria-Santamera, A | 1 |
| Bilotta, F | 1 |
| Morone, PJ | 1 |
| Yan, W | 1 |
| Adcock, J | 1 |
| Komalavilas, P | 1 |
| Mocco, J | 3 |
| Thompson, RC | 1 |
| Brophy, C | 1 |
| Cheung-Flynn, J | 1 |
| Schubach, F | 1 |
| Jenkner, C | 1 |
| Urbach, H | 2 |
| Taschner, C | 2 |
| Seufert, J | 1 |
| Kätzler, J | 1 |
| García, L | 1 |
| Morales, M | 1 |
| Yu, W | 1 |
| Huang, Y | 1 |
| Zhang, X | 2 |
| Luo, H | 1 |
| Chen, W | 1 |
| Jiang, Y | 1 |
| Cheng, Y | 1 |
| Samuelsson, J | 1 |
| Sunila, M | 1 |
| Rentzos, A | 1 |
| Nilsson, D | 1 |
| Albanna, W | 2 |
| Weiss, M | 2 |
| Conzen, C | 2 |
| Clusmann, H | 2 |
| Schneider, T | 1 |
| Reinsch, M | 1 |
| Müller, M | 1 |
| Wiesmann, M | 1 |
| Höllig, A | 1 |
| Schubert, GA | 2 |
| Kumar, A | 3 |
| Phalak, M | 1 |
| Harbin, M | 1 |
| Turgeon, R | 1 |
| Wang, JL | 1 |
| Li, XN | 1 |
| Zhang, YH | 1 |
| Li, X | 1 |
| Yang, YL | 1 |
| Flessa, J | 1 |
| Lindenberg, N | 1 |
| Redel, A | 1 |
| Schneiker, A | 2 |
| Schuierer, G | 2 |
| Graf, B | 2 |
| Silbereisen, V | 1 |
| Lawton, MT | 1 |
| Vates, GE | 1 |
| Nowack, MC | 1 |
| Wolf, H | 1 |
| Kurre, W | 1 |
| Duman, E | 1 |
| Karakoç, F | 1 |
| Pinar, HU | 1 |
| Dogan, R | 1 |
| Fırat, A | 1 |
| Yıldırım, E | 1 |
| Sánchez Arguiano, J | 1 |
| Hernández-Hernández, MA | 1 |
| Jáuregui Solórzano, RA | 1 |
| Maldonado-Vega, S | 1 |
| González Mandly, A | 1 |
| Burón Mediavilla, J | 1 |
| Beez, T | 1 |
| Zazulia, AR | 1 |
| Zhang, C | 1 |
| Zhao, S | 1 |
| Zang, Y | 1 |
| Zhao, W | 1 |
| Song, Q | 1 |
| Feng, S | 1 |
| Hu, L | 1 |
| Gu, F | 1 |
| Tallarico, RT | 1 |
| Pizzi, MA | 1 |
| Turnage, C | 1 |
| Kumar, JS | 1 |
| Kalani, MY | 1 |
| Adami, D | 1 |
| Berkefeld, J | 1 |
| Platz, J | 2 |
| Konczalla, J | 2 |
| Pfeilschifter, W | 1 |
| Weidauer, S | 1 |
| Wagner, M | 1 |
| Samseethong, T | 1 |
| Suansanae, T | 1 |
| Veerasarn, K | 1 |
| Liengudom, A | 1 |
| Suthisisang, C | 1 |
| Paľa, A | 1 |
| Schneider, M | 1 |
| Brand, C | 1 |
| Pedro, MT | 1 |
| Özpeynirci, Y | 1 |
| Schmitz, B | 1 |
| Wirtz, CR | 1 |
| Kapapa, T | 1 |
| König, R | 1 |
| Braun, M | 1 |
| Schmutzhard, E | 1 |
| Faleck, HJ | 4 |
| Saville, BR | 1 |
| Dhandapani, S | 1 |
| Singh, A | 1 |
| Singla, N | 1 |
| Praneeth, K | 1 |
| Aggarwal, A | 2 |
| Sodhi, HB | 1 |
| Pal, SS | 1 |
| Goudihalli, S | 1 |
| Salunke, P | 2 |
| Mohindra, S | 1 |
| Gupta, V | 2 |
| Chhabra, R | 2 |
| Mukherjee, KK | 1 |
| Tewari, MK | 1 |
| Khandelwal, N | 2 |
| Mathuriya, SN | 1 |
| Khosla, VK | 1 |
| Gupta, SK | 1 |
| Gruber, M | 1 |
| Knott, I | 1 |
| Dettmer, K | 1 |
| Oefner, PJ | 1 |
| Tuemmler, S | 1 |
| Eissnert, C | 1 |
| Pop, A | 1 |
| Carbonnel, M | 1 |
| Wang, A | 1 |
| Josserand, J | 1 |
| Auliac, SC | 1 |
| Ayoubi, JM | 1 |
| Qin, Y | 1 |
| Li, G | 1 |
| Sun, Z | 1 |
| Xu, X | 1 |
| Gu, J | 1 |
| Gao, F | 1 |
| Christensen, ST | 1 |
| Johansson, SE | 1 |
| Radziwon-Balicka, A | 1 |
| Warfvinge, K | 1 |
| Haanes, KA | 1 |
| Edvinsson, L | 1 |
| Hajizadeh Barfejani, A | 1 |
| Rabinstein, AA | 1 |
| Wijdicks, EFM | 1 |
| Mitra, R | 1 |
| Dube, SK | 1 |
| Jain, V | 1 |
| Luo, F | 1 |
| Wu, L | 1 |
| Zhang, Z | 2 |
| Zhu, Z | 1 |
| Liu, Z | 1 |
| Guo, B | 1 |
| Li, N | 1 |
| Ju, J | 1 |
| Zhou, Q | 1 |
| Li, S | 1 |
| Mak, S | 1 |
| Han, Y | 1 |
| Sun, Y | 1 |
| Zhang, G | 1 |
| Pierscianek, D | 1 |
| Rölz, R | 1 |
| Darkwah Oppong, M | 1 |
| Kaier, K | 1 |
| Shah, M | 1 |
| Mönninghoff, C | 1 |
| Anand, S | 1 |
| Goel, G | 1 |
| Ponzetto, E | 1 |
| Vinetti, M | 1 |
| Grandin, C | 1 |
| Duprez, T | 1 |
| van Pesch, V | 1 |
| Deggouj, N | 1 |
| Lhommel, R | 1 |
| Hantson, P | 1 |
| Jhang, KM | 1 |
| Lin, CH | 1 |
| Lee, KW | 1 |
| Chen, YY | 1 |
| Jaja, B | 1 |
| Cusimano, MD | 1 |
| Hasan, D | 1 |
| Ilodigwe, D | 1 |
| Lantigua, H | 1 |
| Le Roux, P | 1 |
| Lo, B | 1 |
| Louffat-Olivares, A | 1 |
| Mayer, S | 1 |
| Molyneux, A | 1 |
| Quinn, A | 1 |
| Schenk, T | 1 |
| Spears, J | 1 |
| Todd, M | 1 |
| Torner, J | 1 |
| Vergouwen, MD | 1 |
| Singh, J | 1 |
| Rank, W | 1 |
| Wang, H | 2 |
| James, ML | 1 |
| Venkatraman, TN | 1 |
| Wilson, LJ | 1 |
| Lyuboslavsky, P | 1 |
| Myers, SJ | 1 |
| Lascola, CD | 1 |
| Laskowitz, DT | 2 |
| Ott, S | 1 |
| Jedlicka, S | 1 |
| Wolf, S | 4 |
| Peter, M | 1 |
| Pudenz, C | 1 |
| Merker, P | 1 |
| Schürer, L | 2 |
| Lumenta, CB | 2 |
| Raya, AK | 1 |
| Herzfeld, E | 1 |
| Strauss, C | 1 |
| Simmermacher, S | 1 |
| Bork, K | 1 |
| Horstkorte, R | 1 |
| Dehghani, F | 1 |
| Scheller, C | 1 |
| Sherif, C | 1 |
| Wambacher, B | 1 |
| Loyoddin, M | 1 |
| Karaic, R | 1 |
| Krafft, P | 1 |
| Valentin, A | 1 |
| Tscholakoff, D | 1 |
| Kleinpeter, G | 1 |
| Davis, C | 2 |
| Burton, K | 2 |
| Baker, M | 1 |
| Bastin, MT | 1 |
| Fraser, J | 1 |
| Hessel, E | 1 |
| Heffren, J | 1 |
| McIntosh, AM | 1 |
| Reiter, PD | 1 |
| Aldrich, F | 2 |
| Hoh, BL | 2 |
| Miller, M | 1 |
| Hollingworth, M | 1 |
| Chen, PR | 1 |
| Goddard, AJ | 1 |
| Coulthard, A | 1 |
| Söderman, M | 1 |
| Bulsara, KR | 1 |
| Koskimäki, J | 1 |
| Tarkia, M | 1 |
| Ahtola-Sätilä, T | 1 |
| Saloranta, L | 1 |
| Simola, O | 1 |
| Forsback, AP | 1 |
| Laakso, A | 1 |
| Frantzén, J | 1 |
| Abboud, T | 1 |
| Andresen, H | 1 |
| Koeppen, J | 1 |
| Czorlich, P | 1 |
| Duehrsen, L | 1 |
| Stenzig, J | 1 |
| Westphal, M | 1 |
| Regelsberger, J | 1 |
| Young, AM | 1 |
| Karri, SK | 1 |
| Helmy, A | 1 |
| Budohoski, KP | 1 |
| Kirollos, RW | 1 |
| Bulters, DO | 1 |
| Kirkpatrick, PJ | 1 |
| Ogilvy, CS | 2 |
| Trivedi, RA | 1 |
| Ehlert, A | 1 |
| Schmidt, C | 1 |
| Wölfer, J | 1 |
| Manthei, G | 1 |
| Jacobs, AH | 1 |
| Brüning, R | 1 |
| Heindel, W | 1 |
| Ringelstein, EB | 1 |
| Stummer, W | 1 |
| Pluta, RM | 1 |
| Hesselmann, V | 1 |
| Seker, F | 1 |
| Hesser, J | 1 |
| Brockmann, MA | 2 |
| Neumaier-Probst, E | 1 |
| Groden, C | 1 |
| Schubert, R | 1 |
| Brockmann, C | 1 |
| Proescholdt, MA | 1 |
| Hochreiter, A | 1 |
| Scheitzach, J | 1 |
| Bründl, E | 1 |
| Schödel, P | 1 |
| Brawanski, A | 1 |
| Sandow, N | 1 |
| Diesing, D | 1 |
| Sarrafzadeh, A | 1 |
| Vajkoczy, P | 1 |
| Gölitz, P | 1 |
| Kaschka, I | 1 |
| Lang, S | 1 |
| Roessler, K | 1 |
| Knossalla, F | 1 |
| Doerfler, A | 1 |
| Hockel, K | 2 |
| Diedler, J | 2 |
| Steiner, J | 2 |
| Birkenhauer, U | 2 |
| Danz, S | 1 |
| Ernemann, U | 2 |
| Schuhmann, MU | 2 |
| Bashir, A | 1 |
| Andresen, M | 1 |
| Bartek, J | 1 |
| Cortsen, M | 1 |
| Eskesen, V | 1 |
| Wagner, A | 1 |
| Johnson, M | 1 |
| Peet, MM | 1 |
| Tice, T | 2 |
| Hudson, B | 1 |
| Turner, M | 1 |
| Stella, A | 1 |
| Heshmati, P | 1 |
| Goel, R | 1 |
| Kerz, T | 2 |
| Boor, S | 2 |
| Ulrich, A | 1 |
| Beyer, C | 2 |
| Hechtner, M | 1 |
| Mueller-Forell, W | 1 |
| Brawanski, N | 1 |
| Senft, C | 1 |
| Kashefiolasl, S | 1 |
| Seifert, V | 2 |
| Cho, S | 1 |
| Bales, J | 1 |
| Tran, TK | 1 |
| Korab, G | 1 |
| Joffe, AM | 1 |
| Mohamed, S | 1 |
| Riva, R | 1 |
| Contin, M | 1 |
| Fuest, M | 1 |
| Mueller, M | 1 |
| Vilser, W | 1 |
| Schmidt-Trucksäss, A | 1 |
| Hoellig, A | 1 |
| Seiz, M | 1 |
| Thomé, C | 1 |
| Kotliar, K | 1 |
| Aydin, HE | 1 |
| Bektur, NE | 1 |
| Ozbek, Z | 1 |
| Oner, S | 1 |
| Baycu, C | 1 |
| Kilic, FS | 1 |
| Francoeur, CL | 1 |
| Lee, SH | 2 |
| Yun, SJ | 1 |
| Choi, YH | 1 |
| von der Brelie, C | 1 |
| Doukas, A | 3 |
| Stopfer, A | 1 |
| Larsen, N | 1 |
| Mehdorn, M | 1 |
| Synowitz, M | 1 |
| Jansen, O | 3 |
| Hejčl, A | 1 |
| Cihlář, F | 1 |
| Smolka, V | 1 |
| Vachata, P | 1 |
| Bartoš, R | 1 |
| Procházka, J | 1 |
| Cihlář, J | 1 |
| Sameš, M | 1 |
| Rustemi, O | 1 |
| Carter, BS | 1 |
| Beseoglu, K | 5 |
| Turowski, B | 4 |
| Devlin, MM | 1 |
| Kronvall, E | 1 |
| Undrén, P | 1 |
| Romner, B | 7 |
| Säveland, H | 9 |
| Cronqvist, M | 1 |
| Nilsson, OG | 1 |
| Deshaies, EM | 1 |
| Boulos, AS | 1 |
| Drazin, D | 1 |
| Popp, AJ | 1 |
| Yin, YH | 2 |
| Wang, F | 2 |
| Pan, YH | 1 |
| Luo, QZ | 1 |
| Jiang, JY | 2 |
| Kaneria, MV | 1 |
| Pagar, S | 1 |
| Samant, H | 1 |
| Yeole, S | 1 |
| Patil, S | 1 |
| Koskinen, LO | 1 |
| Olivecrona, M | 1 |
| Rodling-Wahlström, M | 1 |
| Naredi, S | 1 |
| Thomas, S | 1 |
| Herrmann, B | 1 |
| Samii, M | 1 |
| Brinker, T | 1 |
| Eicker, S | 3 |
| Rapp, M | 1 |
| Perrin, J | 2 |
| Nawatny, J | 1 |
| Sommer, C | 2 |
| Al-Shahi Salman, R | 1 |
| Sudlow, CL | 1 |
| Jia, F | 1 |
| Behr, J | 1 |
| Ducros, A | 1 |
| Bousser, MG | 1 |
| Bilginer, B | 3 |
| Onal, MB | 6 |
| Narin, F | 3 |
| Soylemezoglu, F | 2 |
| Ziyal, IM | 1 |
| Ozgen, T | 2 |
| Martin, H | 1 |
| Landscheidt, JF | 1 |
| Rodiek, SO | 1 |
| Zhang, S | 1 |
| Wang, L | 2 |
| Liu, M | 1 |
| Wu, B | 1 |
| Gul, S | 1 |
| Bahadir, B | 1 |
| Hanci, V | 1 |
| Acikgoz, S | 1 |
| Bektas, S | 1 |
| Ugurbas, E | 1 |
| Ankarali, H | 1 |
| Kalayci, M | 1 |
| Acikgoz, B | 1 |
| Pasternak, JJ | 1 |
| Lanier, WL | 1 |
| Weant, KA | 1 |
| Ramsey, CN | 1 |
| Petridis, AK | 2 |
| Barth, H | 2 |
| Mehdorn, HM | 3 |
| Naidech, AM | 1 |
| Liebling, SM | 1 |
| Duran, IM | 1 |
| Ault, ML | 1 |
| Civelek, E | 4 |
| Kircelli, A | 4 |
| Solmaz, I | 4 |
| Ugurel, S | 2 |
| Isikay, I | 1 |
| Yakupoglu, H | 1 |
| Ziyal, MI | 1 |
| Tehli, O | 1 |
| Izci, Y | 2 |
| Erdogan, E | 2 |
| Gonul, E | 3 |
| Temiz, C | 1 |
| Secer, HI | 1 |
| Ongoru, O | 1 |
| Nystoriak, MA | 1 |
| O'Connor, KP | 1 |
| Sonkusare, SK | 1 |
| Brayden, JE | 1 |
| Nelson, MT | 1 |
| Wellman, GC | 1 |
| Musahl, C | 1 |
| Henkes, H | 1 |
| Vajda, Z | 1 |
| Coburger, J | 1 |
| Hopf, N | 1 |
| Samaniego, EA | 1 |
| Dabus, G | 1 |
| Fuentes, K | 1 |
| Linfante, I | 1 |
| Maslehaty, H | 1 |
| Cho, WS | 1 |
| Kang, HS | 1 |
| Kim, JE | 1 |
| Kwon, OK | 1 |
| Oh, CW | 1 |
| Son, YJ | 1 |
| Know, BJ | 1 |
| Jung, C | 1 |
| Hang, MH | 1 |
| Spiriev, T | 1 |
| Kondoff, S | 1 |
| Schaller, B | 1 |
| Liu, GJ | 1 |
| Luo, J | 1 |
| Zhang, LP | 1 |
| Wang, ZJ | 1 |
| Xu, LL | 1 |
| He, GH | 1 |
| Zeng, YJ | 1 |
| Wang, YF | 1 |
| Zhao, J | 2 |
| Zhou, D | 2 |
| Guo, J | 2 |
| Ren, Z | 2 |
| Zhou, L | 2 |
| Wang, S | 2 |
| Zhang, Y | 1 |
| Xu, B | 3 |
| Zhao, K | 1 |
| Wang, R | 2 |
| Mao, Y | 1 |
| Soppi, V | 2 |
| Karamanakos, PN | 1 |
| Koivisto, T | 2 |
| Kurki, MI | 1 |
| Vanninen, R | 1 |
| Jaaskelainen, JE | 1 |
| Rinne, J | 2 |
| Choi, HA | 1 |
| Ko, SB | 1 |
| Chen, H | 1 |
| Gilmore, E | 1 |
| Carpenter, AM | 1 |
| Lee, D | 1 |
| Claassen, J | 1 |
| Schmidt, JM | 1 |
| Lee, K | 1 |
| Connelly, ES | 1 |
| Paik, M | 1 |
| Badjatia, N | 1 |
| Welschehold, S | 1 |
| Schuessler, A | 1 |
| Oertel, J | 1 |
| Cook, DJ | 1 |
| Kan, S | 1 |
| Ai, J | 1 |
| Kasuya, H | 1 |
| Zhao, WJ | 1 |
| Wu, C | 1 |
| Koenig, MA | 1 |
| Leung, M | 1 |
| Aburto-Murrieta, Y | 1 |
| Marquez-Romero, JM | 1 |
| Bonifacio-Delgadillo, D | 1 |
| López, I | 1 |
| Hernández-Curiel, B | 1 |
| Kamp, MA | 1 |
| Heiroth, HJ | 1 |
| Bege, N | 2 |
| Macht, S | 1 |
| Frauenknecht, K | 1 |
| Kissel, T | 2 |
| Ko, CN | 1 |
| Lee, IW | 1 |
| Cho, SY | 1 |
| Park, SU | 1 |
| Koh, JS | 1 |
| Park, JM | 1 |
| Kim, GK | 1 |
| Bae, HS | 1 |
| Wartenberg, KE | 1 |
| Renette, T | 1 |
| Endres, T | 1 |
| Beck-Broichsitter, M | 1 |
| Dorsch, NW | 5 |
| Rosengart, A | 1 |
| Huo, D | 1 |
| Karrison, T | 1 |
| LeStrange, DG | 1 |
| Sun, BL | 1 |
| Zhang, SM | 1 |
| Xia, ZL | 1 |
| Yang, MF | 1 |
| Yuan, H | 1 |
| Zhang, J | 1 |
| Xiu, RJ | 1 |
| Brown, G | 1 |
| Carley, S | 1 |
| Subramani, K | 1 |
| Ghrew, M | 1 |
| Kumar, S | 1 |
| Nandigam, K | 1 |
| Stiefel, MF | 1 |
| Heuer, GG | 1 |
| Abrahams, JM | 1 |
| Bloom, S | 1 |
| Smith, MJ | 1 |
| Maloney-Wilensky, E | 1 |
| Grady, MS | 1 |
| LeRoux, PD | 1 |
| Wanke, I | 1 |
| Gizewski, E | 1 |
| Dörfler, A | 1 |
| Stolke, D | 1 |
| Hui, C | 1 |
| Lau, KP | 1 |
| Nemec, K | 1 |
| Greif, R | 1 |
| Poon, WS | 1 |
| Li, LL | 1 |
| Feng, N | 1 |
| Wang, XL | 1 |
| Sakowitz, OW | 1 |
| Unterberg, AW | 1 |
| Biondi, A | 1 |
| Le Jean, L | 1 |
| Puybasset, L | 2 |
| Laslo, AM | 1 |
| Eastwood, JD | 1 |
| Chen, FX | 1 |
| Lee, TY | 1 |
| Jacobi, C | 1 |
| Schwark, C | 1 |
| Kress, B | 1 |
| Hug, A | 1 |
| Storch-Hagenlocher, B | 1 |
| Schwaninger, M | 1 |
| Schmid-Elsaesser, R | 1 |
| Kunz, M | 1 |
| Zausinger, S | 1 |
| Prueckner, S | 1 |
| Briegel, J | 1 |
| Straube, A | 1 |
| Plendl, H | 1 |
| Bruening, R | 1 |
| Mesis, RG | 1 |
| Lombard, FW | 1 |
| Yates, R | 1 |
| Vitek, MP | 1 |
| Borel, CO | 1 |
| Warner, DS | 1 |
| Sen, J | 1 |
| Belli, A | 1 |
| van den Bergh, WM | 2 |
| Mees, SM | 1 |
| Rinkel, GJ | 4 |
| Kokki, H | 1 |
| Lehtonen, M | 1 |
| Helin-Tanninen, M | 1 |
| Lehtola, S | 1 |
| Przewlocki, T | 1 |
| Pieniazek, P | 1 |
| Kablak-Ziembicka, A | 1 |
| Motyl, R | 1 |
| Moczulski, Z | 1 |
| Tracz, W | 1 |
| Dorhout Mees, SM | 1 |
| Feigin, VL | 2 |
| Algra, A | 2 |
| Vermeulen, M | 4 |
| van Gijn, J | 4 |
| Keyrouz, SG | 1 |
| Tavernier, B | 1 |
| Decamps, F | 1 |
| Vega, E | 1 |
| Poidevin, P | 1 |
| Verdin, M | 1 |
| Riegel, B | 2 |
| Abdennour, L | 1 |
| Lejean, L | 1 |
| Bonneville, F | 1 |
| Boch, AL | 1 |
| Neuschmelting, V | 1 |
| Graupner, T | 1 |
| Jakob, SM | 1 |
| Fandino, J | 1 |
| Yong, M | 1 |
| Allen, GS | 3 |
| Ahn, HS | 1 |
| Preziosi, TJ | 1 |
| Battye, R | 2 |
| Boone, SC | 2 |
| Chou, SN | 1 |
| Kelly, DL | 1 |
| Weir, BK | 3 |
| Crabbe, RA | 1 |
| Lavik, PJ | 1 |
| Rosenbloom, SB | 1 |
| Dorsey, FC | 1 |
| Ingram, CR | 1 |
| Mellits, DE | 1 |
| Bertsch, LA | 1 |
| Boisvert, DP | 1 |
| Hundley, MB | 1 |
| Johnson, RK | 1 |
| Strom, JA | 1 |
| Transou, CR | 1 |
| Auer, LM | 8 |
| Voldby, B | 3 |
| Petersen, OF | 1 |
| Buhl, M | 1 |
| Jakobsen, P | 3 |
| Ostergaard, R | 1 |
| Espinosa, F | 2 |
| Weir, B | 6 |
| Overton, T | 3 |
| Castor, W | 1 |
| Grace, M | 3 |
| Boisvert, D | 3 |
| Shnitka, T | 1 |
| Russegger, L | 1 |
| Kostron, H | 3 |
| Twerdy, K | 2 |
| Grunert, V | 2 |
| Powell, MP | 1 |
| Silver, IA | 1 |
| Coakham, HB | 1 |
| Walters, FJ | 1 |
| Grotenhuis, JA | 3 |
| Bettag, W | 2 |
| Fiebach, BJ | 1 |
| Dabir, K | 1 |
| Svendgaard, NA | 4 |
| Brismar, J | 2 |
| Delgado, T | 3 |
| Egund, N | 1 |
| Owman, C | 3 |
| Rodacki, MA | 1 |
| Sahlin, C | 3 |
| Salford, LG | 3 |
| Hijdra, A | 1 |
| Wijdicks, EF | 1 |
| Tanaka, K | 1 |
| Gotoh, F | 1 |
| Muramatsu, F | 1 |
| Fukuuchi, Y | 1 |
| Okayasu, H | 1 |
| Suzuki, N | 1 |
| Kobari, M | 1 |
| Trembly, B | 1 |
| Ohman, J | 7 |
| Tonks, AM | 1 |
| Hannequin, D | 1 |
| Langlois, O | 1 |
| Freger, P | 3 |
| Creissard, P | 3 |
| Hauerberg, J | 2 |
| Rasmussen, G | 2 |
| Juhler, M | 1 |
| Gjerris, F | 1 |
| Golfinos, JG | 1 |
| Thompson, BG | 1 |
| Zabramski, JM | 1 |
| Spetzler, RF | 2 |
| Brandt, L | 13 |
| Pickard, JD | 4 |
| Walker, V | 1 |
| Zygmunt, S | 1 |
| Smythe, J | 1 |
| Kakarieka, A | 4 |
| Schakel, EH | 2 |
| Fritze, J | 1 |
| Fritschi, J | 1 |
| Seiler, RW | 4 |
| Boecher-Schwarz, HG | 1 |
| Ungersboeck, K | 1 |
| Ulrich, P | 1 |
| Fries, G | 1 |
| Wild, A | 1 |
| Perneczky, A | 2 |
| Braakman, R | 2 |
| Nash, SD | 1 |
| Patt, MV | 1 |
| Hongo, K | 1 |
| Kobayashi, S | 1 |
| MacDonald, L | 1 |
| Mercier, P | 1 |
| Alhayek, G | 1 |
| Rizk, T | 1 |
| Fournier, D | 1 |
| Menei, P | 1 |
| Guy, G | 1 |
| Hütter, BO | 1 |
| Gilsbach, JM | 5 |
| Compton, JS | 1 |
| Tapaninaho, A | 1 |
| Hernesniemi, J | 1 |
| Vapalahti, M | 1 |
| Niskanen, M | 1 |
| Kari, A | 1 |
| Luukkonen, M | 1 |
| Puranen, M | 1 |
| Rousseaux, P | 1 |
| Gomis, P | 1 |
| Bazin, A | 1 |
| Peruzzi, P | 1 |
| Scherpereel, B | 1 |
| Bernard, MH | 1 |
| Bertault, R | 1 |
| Graftieaux, JP | 1 |
| Kumana, CR | 1 |
| Kou, M | 1 |
| Yu, YL | 1 |
| Fong, KY | 1 |
| Fung, CF | 1 |
| Chang, CM | 1 |
| Mück, W | 1 |
| Lauder, IJ | 1 |
| Steinmeier, R | 2 |
| Laumer, R | 2 |
| Bondár, I | 1 |
| Priem, R | 2 |
| Fahlbusch, R | 2 |
| Gönner, F | 1 |
| Vogtmann, T | 1 |
| Ryba, M | 2 |
| Pastuszko, M | 2 |
| Dziewiecki, C | 2 |
| Andrychowski, J | 1 |
| Bojarski, P | 1 |
| Barczewska, M | 1 |
| Popovic, EA | 1 |
| Danks, RA | 1 |
| Siu, KH | 1 |
| Barker, FG | 1 |
| Karadimov, D | 1 |
| Ekelund, A | 1 |
| Harders, A | 4 |
| Porchet, F | 1 |
| Chioléro, R | 1 |
| de Tribolet, N | 1 |
| Melon, E | 1 |
| Rimaniol, JM | 1 |
| Schaller, C | 1 |
| Raueiser, B | 1 |
| Hassler, W | 1 |
| Lindsberg, PJ | 1 |
| Lehto, T | 1 |
| Karjalainen-Lindsberg, ML | 1 |
| Paetau, A | 1 |
| Wuorimaa, T | 1 |
| Carpén, O | 1 |
| Kaste, M | 3 |
| Meri, S | 1 |
| Murray, GD | 3 |
| Teasdale, GM | 4 |
| Schmitz, H | 1 |
| Rosenørn, J | 1 |
| Skriver, EB | 1 |
| Piek, J | 1 |
| Haley, EC | 1 |
| Kassell, NF | 1 |
| Apperson-Hansen, C | 1 |
| Maile, MH | 1 |
| Alves, WM | 1 |
| Dennis, GC | 1 |
| Welch, B | 1 |
| Cole, AN | 1 |
| Mendoza, R | 1 |
| Morgan, J | 1 |
| Epps, J | 1 |
| Bernard, E | 1 |
| St Louis, P | 1 |
| Radhakrishnan, D | 1 |
| Menon, DK | 1 |
| Cunitz, G | 1 |
| Carteri, A | 1 |
| Billeci, D | 1 |
| Copetti, E | 1 |
| Toyota, BD | 1 |
| Bergholdt, B | 1 |
| Dalh, B | 1 |
| Sunde, N | 1 |
| Cold, G | 1 |
| Di Mascio, R | 1 |
| Marchioli, R | 1 |
| Tognoni, G | 1 |
| Stroobandt, G | 1 |
| Lambert, O | 1 |
| Menard, E | 1 |
| Selman, WR | 1 |
| Karinen, P | 1 |
| Koivukangas, P | 1 |
| Ohinmaa, A | 1 |
| Koivukangas, J | 1 |
| Carvi y Nievas, MN | 1 |
| Patel, HC | 1 |
| Hutchinson, PJ | 1 |
| Matula, C | 2 |
| Wanner-Olsen, H | 1 |
| Gaarskaer, FB | 1 |
| Mikkelsen, EO | 1 |
| Devlin, JW | 1 |
| Coplin, WM | 1 |
| Murry, KR | 1 |
| Rengachary, SS | 1 |
| Wilson, RF | 1 |
| Haralanov, L | 1 |
| Klissurski, M | 1 |
| Stamenova, P | 1 |
| Roos, YB | 1 |
| Levi, M | 1 |
| Carroll, TA | 1 |
| Beenen, LF | 1 |
| Egge, A | 1 |
| Waterloo, K | 1 |
| Sjøholm, H | 1 |
| Solberg, T | 1 |
| Ingebrigtsen, T | 1 |
| Corsten, L | 1 |
| Raja, A | 1 |
| Guppy, K | 1 |
| Roitberg, B | 1 |
| Misra, M | 1 |
| Alp, MS | 1 |
| Charbel, F | 1 |
| Debrun, G | 1 |
| Ausman, J | 1 |
| Schoeggl, A | 1 |
| Stachura, K | 1 |
| Danilewicz, B | 1 |
| Origitano, TC | 1 |
| Reichman, OH | 1 |
| Anderson, DE | 1 |
| Tadie, M | 3 |
| Rickels, E | 1 |
| Zumkeller, M | 1 |
| Hillman, J | 4 |
| Edner, G | 1 |
| Jakobsson, KE | 1 |
| Algers, G | 1 |
| Lovell, AT | 1 |
| Smith, M | 1 |
| Toni, D | 1 |
| Frontoni, M | 1 |
| Argentino, C | 1 |
| Sacchetti, ML | 1 |
| De Michele, M | 1 |
| Fieschi, C | 1 |
| Bynke, O | 1 |
| Westergren, H | 1 |
| Mourier, KL | 1 |
| George, B | 1 |
| Raggueneau, JL | 1 |
| Tran Dinh, YR | 1 |
| Lot, G | 1 |
| Boissonnet, H | 1 |
| Cophignon, J | 1 |
| Ryman, T | 4 |
| Brørs, O | 1 |
| Levesque, H | 1 |
| Sevrain, L | 2 |
| Courtois, H | 1 |
| Ljunggren, B | 9 |
| Fodstad, H | 1 |
| Servo, A | 2 |
| Heiskanen, O | 4 |
| Juvela, S | 2 |
| Grieb, P | 1 |
| Bidzinski, J | 1 |
| Iwanska, K | 1 |
| Nirkko, AC | 1 |
| Bracard, S | 1 |
| Picard, L | 1 |
| Marchal, JC | 2 |
| Ducrocq, X | 2 |
| Per, A | 1 |
| Czorny, A | 1 |
| Islak, C | 1 |
| Roy, D | 1 |
| Roland, J | 1 |
| Lepoire, J | 2 |
| Tettenborn, D | 4 |
| Dycka, J | 2 |
| Sosnowski, C | 1 |
| Illingworth, R | 2 |
| Shaw, MD | 2 |
| Foy, PM | 2 |
| Humphrey, PR | 2 |
| Lang, DA | 2 |
| Nelson, R | 2 |
| Richards, P | 2 |
| Davies, C | 1 |
| Keogh, A | 1 |
| Robinson, MJ | 1 |
| Adams, HP | 2 |
| Mathiesen, T | 1 |
| Lindquist, C | 1 |
| Teasdale, G | 1 |
| Mendelow, AD | 1 |
| Graham, DI | 1 |
| Harper, AM | 1 |
| McCulloch, J | 1 |
| Wroński, J | 1 |
| Abraszko, R | 1 |
| Berny, W | 1 |
| Mierzwa, J | 1 |
| Rabehenoina, C | 1 |
| Hattab, N | 1 |
| Clavier, E | 1 |
| Thiebot, J | 1 |
| Laissy, JP | 1 |
| Gutknecht, JL | 1 |
| Irthum, B | 1 |
| Cavaroc, G | 1 |
| Halberstadt, J | 1 |
| Planchon, E | 1 |
| Greil, P | 1 |
| Berard, JP | 1 |
| Childs, M | 2 |
| Jomin, M | 2 |
| Fesard, P | 1 |
| Robiquet, P | 1 |
| Hund, E | 1 |
| Aschoff, A | 1 |
| Tronnier, V | 1 |
| Hampl, J | 1 |
| Kunze, S | 1 |
| Procházka, M | 1 |
| Gazdíková, K | 1 |
| Cigánek, L | 1 |
| Koprdová, I | 1 |
| Chang, JY | 1 |
| Hillbom, M | 1 |
| Seligman, M | 1 |
| Yasuda, SU | 1 |
| Tietze, KJ | 1 |
| Texier, JJ | 1 |
| Lepetit, JM | 1 |
| Moreau, JJ | 1 |
| Ravon, R | 1 |
| Feiss, P | 1 |
| Girard, A | 1 |
| Auque, J | 1 |
| Burdin, D | 1 |
| Pincemaille, B | 1 |
| Hepner, H | 1 |
| Desbordes, JM | 1 |
| Ades, PE | 2 |
| Guggiari, M | 3 |
| DiPalma, JR | 1 |
| Rimpel, J | 1 |
| Branston, NM | 1 |
| Harris, RJ | 1 |
| Bentivoglio, P | 1 |
| Symon, L | 1 |
| Fabre, M | 1 |
| Aesch, B | 1 |
| Rieant, JF | 1 |
| Buchet, S | 1 |
| Lamotte, C | 1 |
| Jan, M | 2 |
| Harders, AG | 2 |
| Grolimund, P | 2 |
| Zurbruegg, HR | 1 |
| Reulen, HJ | 2 |
| Huber, P | 1 |
| Ebeling, U | 2 |
| Gilsbach, J | 2 |
| Frerebeau, P | 1 |
| Janny, P | 1 |
| Taquoi, G | 2 |
| Besson, G | 1 |
| Buchheit, F | 1 |
| Houtteville, JP | 1 |
| Pecker, J | 1 |
| Rodriguez, R | 1 |
| Baena, Y | 1 |
| Gaetani, P | 2 |
| Grignani, G | 1 |
| Pacchiarini, L | 1 |
| Rodriguez y Baena, R | 1 |
| Silvani, V | 1 |
| Spanu, G | 1 |
| Marzatico, F | 1 |
| Biller, J | 1 |
| Godersky, JC | 1 |
| von Essen, C | 2 |
| Leszniewski, W | 2 |
| Hoffmann, B | 1 |
| Ackermann, L | 1 |
| Grupe, H | 1 |
| Feldges, A | 1 |
| Laursen, J | 1 |
| Jensen, F | 1 |
| Mikkelsen, E | 1 |
| Petruk, KC | 1 |
| West, M | 1 |
| Mohr, G | 1 |
| Benoit, BG | 1 |
| Gentili, F | 1 |
| Disney, LB | 1 |
| Khan, MI | 1 |
| Holness, RO | 1 |
| Mee, E | 2 |
| Dorrance, D | 2 |
| Lowe, D | 2 |
| Neil-Dwyer, G | 2 |
| Lee, KS | 1 |
| Lee, KC | 1 |
| Choi, JU | 1 |
| Welty, TE | 1 |
| Porto, L | 1 |
| Strugo, V | 1 |
| Andersson, KE | 4 |
| Sonesson, B | 1 |
| Eggert, HR | 1 |
| Hornyak, ME | 1 |
| Lewis, PJ | 1 |
| Nosko, MG | 1 |
| Tanabe, T | 1 |
| Grace, MG | 1 |
| Vinge, E | 3 |
| Johansson, I | 1 |
| Pellettieri, L | 1 |
| Bolander, H | 1 |
| Carlsson, H | 1 |
| Sjölander, U | 1 |
| Van der Werf, AJ | 2 |
| Philippon, J | 1 |
| Grob, R | 1 |
| Dagreou, F | 1 |
| Rivierez, M | 1 |
| Viars, P | 1 |
| Tucker, WS | 1 |
| Messeter, K | 2 |
| Algotsson, L | 1 |
| Ryding, E | 1 |
| Torrealba, G | 1 |
| Sharp, A | 1 |
| Soto, B | 1 |
| Müller, H | 1 |
| Marck, P | 1 |
| Gips, H | 1 |
| Börner, U | 1 |
| Otto, O | 1 |
| Adams, HA | 1 |
| Hempelmann, G | 1 |
| Nosko, M | 3 |
| Norris, SL | 1 |
| King, EG | 1 |
| Schneider, GH | 1 |
| Auer, T | 1 |
| Govoni, S | 1 |
| Trabucchi, M | 1 |
| Battaini, F | 1 |
| Magnoni, MS | 1 |
| Paoletti, R | 1 |
| Nilsson, LG | 1 |
| Rosendal-Helgesen, S | 1 |
| Groeger, U | 1 |
| Oppel, F | 1 |
| Saeveland, H | 1 |
| Guggenberger, H | 1 |
| Kottler, B | 1 |
| Heuser, D | 1 |
| Nowak, G | 1 |
| Arnold, H | 1 |
| Winkler, D | 1 |
| Freckmann, N | 1 |
| Gioia, AE | 1 |
| White, RP | 1 |
| Bakhtian, B | 1 |
| Robertson, JT | 1 |
| Zabramski, J | 1 |
| Bonstelle, C | 1 |
| Krueger, C | 2 |
| Cook, D | 2 |
| Norris, S | 2 |
| Stullken, EH | 1 |
| Balestrieri, FJ | 1 |
| Prough, DS | 1 |
| McWhorter, JM | 1 |
| Kazner, E | 1 |
| Sprung, C | 1 |
| Adelt, D | 1 |
| Ammerer, HP | 1 |
| Karnick, R | 1 |
| Baumann, H | 1 |
| Böker, DK | 3 |
| Jaksche, H | 2 |
| Istaitih, AR | 1 |
| Koos, WT | 1 |
| Gaab, M | 1 |
| Meinig, G | 1 |
| Muizelaar, JP | 1 |
| Solymosi, L | 1 |
| Wassmann, H | 1 |
| Rämsch, KD | 1 |
| Ahr, G | 1 |
| Volberg, E | 1 |
| Düdden, P | 1 |
| Ausman, JI | 1 |
| Diaz, FG | 1 |
| Malik, GM | 1 |
| Fielding, AS | 1 |
| Son, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Correlation of Various Laboratory Parameters With Outcome in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage - Prospective Case Series[NCT05403970] | 300 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| Endovascular Treatment of Wide Neck Saccular Cerebral Aneurysms[NCT05796986] | 40 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Multicenter, Controlled, Randomized, Safety and Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage[NCT02893826] | Phase 1 | 6 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Based on DMC recommendation to discontinue EG-01-1962-03) | ||
| Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial[NCT04148105] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| An Evaluation of Effectiveness and Safety of the CorPath® GRX System in Endovascular Embolization Procedures of Cerebral Aneurysms[NCT04236856] | 120 participants (Actual) | Interventional | 2020-08-21 | Completed | |||
| Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage[NCT02790632] | Phase 3 | 374 participants (Anticipated) | Interventional | 2016-07-31 | Terminated (stopped due to DMC review concluded study has a low probability of meeting its primary endpoint) | ||
| Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimod[NCT01893190] | Phase 1/Phase 2 | 73 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effect of Superior Cervical Sympathetic Block Versus Stellate Ganglion Block to Treat Cerebral Vasospasm in Patients With Refractory Post-traumatic Subarachnoid Hemorrhage.[NCT06134583] | 60 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| Inter- and Intra-Observer Variability in Transcranial Doppler (TCD) Technique in Neurocritical Care Patients[NCT04583163] | 12 participants (Anticipated) | Observational | 2020-09-22 | Recruiting | |||
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Through Treatment With Intravenous Autologous Cerebrospinal Fluid - a Pilot Trial.[NCT04490161] | 20 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
| IVIG in Acute Ischemic Stroke: A Pilot Study[NCT01628055] | Phase 1 | 0 participants (Actual) | Interventional | 2013-03-31 | Withdrawn (stopped due to difficult recruitment and new black box warning for IVIG) | ||
| The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study[NCT01996436] | Phase 4 | 330 participants (Anticipated) | Interventional | 2016-08-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
75 reviews available for nimodipine and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
Nimodipine in Clinical Practice: A Pharmacological Update.
Topics: Calcium Channel Blockers; Clinical Protocols; Humans; Nimodipine; Pharmacogenetics; Subarachnoid Hem | 2022 |
Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2022 |
Therapeutic Approaches for Cerebrovascular Dysfunction After Aneurysmal Subarachnoid Hemorrhage: An Update and Future Perspectives.
Topics: Brain Injuries; Brain Ischemia; Cerebral Infarction; Humans; Nimodipine; Quality of Life; Subarachno | 2022 |
Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Topics: Adult; Brain Ischemia; Cilostazol; Humans; Magnesium; Morbidity; Network Meta-Analysis; Nicardipine; | 2022 |
A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Network Meta-Analysis; Nimodipine; Randomized Controlle | 2022 |
Delayed cerebral ischemia after meningioma resection: Literature review and illustrative case.
Topics: Brain Ischemia; Humans; Meningeal Neoplasms; Meningioma; Middle Aged; Nimodipine; Paresis; Platelet | 2022 |
Cerebral Vasospasm: Practical Review of Diagnosis and Management.
Topics: Brain Injuries; Humans; Nimodipine; Subarachnoid Hemorrhage; Treatment Outcome; Vasospasm, Intracran | 2023 |
Efficacy of nimodipine in the treatment of subarachnoid hemorrhage: a meta-analysis.
Topics: Glasgow Coma Scale; Humans; Nimodipine; Stroke; Subarachnoid Hemorrhage; Treatment Outcome | 2022 |
Cortical Spreading Depolarization and Delayed Cerebral Ischemia; Rethinking Secondary Neurological Injury in Subarachnoid Hemorrhage.
Topics: Autonomic Nervous System Diseases; Brain; Brain Ischemia; Cerebral Infarction; Humans; Nimodipine; S | 2023 |
The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis.
Topics: Administration, Intravenous; Bayes Theorem; Brain Ischemia; Cerebral Infarction; Humans; Network Met | 2023 |
Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage.
Topics: Administration, Oral; Adult; Brain Ischemia; Calcium Channel Blockers; Cytochrome P-450 Enzyme Syste | 2019 |
Treatment of Spontaneous Subarachnoid Hemorrhage: Guidelines and Gaps.
Topics: Endovascular Procedures; Humans; Intensive Care Units; Nimodipine; Practice Guidelines as Topic; Sub | 2020 |
Treatment of Spontaneous Subarachnoid Hemorrhage: Guidelines and Gaps.
Topics: Endovascular Procedures; Humans; Intensive Care Units; Nimodipine; Practice Guidelines as Topic; Sub | 2020 |
Treatment of Spontaneous Subarachnoid Hemorrhage: Guidelines and Gaps.
Topics: Endovascular Procedures; Humans; Intensive Care Units; Nimodipine; Practice Guidelines as Topic; Sub | 2020 |
Treatment of Spontaneous Subarachnoid Hemorrhage: Guidelines and Gaps.
Topics: Endovascular Procedures; Humans; Intensive Care Units; Nimodipine; Practice Guidelines as Topic; Sub | 2020 |
Non-steroidal anti-inflammatory drugs in the pathophysiology of vasospasms and delayed cerebral ischemia following subarachnoid hemorrhage: a critical review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Double-Blind Method; Humans; Nimodipine; Ra | 2021 |
Nimodipine Pharmacokinetic Variability in Various Patient Populations.
Topics: Animals; Biological Variation, Population; Drug Interactions; Epidemiologic Factors; Humans; Nimodip | 2020 |
Side effects of continuous intra-arterial infusion of nimodipine for management of resistant cerebral vasospasm in subarachnoid hemorrhage patients: A systematic review.
Topics: Humans; Infusions, Intra-Arterial; Nimodipine; Retrospective Studies; Subarachnoid Hemorrhage; Vasos | 2021 |
Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta‑analysis and systematic review.
Topics: Cardiovascular Agents; Cilostazol; Humans; Intracranial Aneurysm; Network Meta-Analysis; Neuroprotec | 2021 |
Subarachnoid Hemorrhage.
Topics: Adolescent; Aneurysm, Ruptured; Angiography; Brain; Calcium Channel Blockers; Endovascular Procedure | 2017 |
Pharmacological targeting of secondary brain damage following ischemic or hemorrhagic stroke, traumatic brain injury, and bacterial meningitis - a systematic review and meta-analysis.
Topics: Brain Damage, Chronic; Brain Injuries, Traumatic; Brain Ischemia; Cerebral Hemorrhage; Dexamethasone | 2017 |
Aneurysmal Subarachnoid Hemorrhage: Strategies for Preventing Vasospasm in the Intensive Care Unit.
Topics: Calcium Channel Blockers; Delayed-Action Preparations; Humans; Intensive Care Units; Intracranial An | 2017 |
Investigational drugs for vasospasm after subarachnoid hemorrhage.
Topics: Animals; Brain Ischemia; Drug Design; Drugs, Investigational; Humans; Neuroprotective Agents; Nimodi | 2018 |
SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials.
Topics: Antioxidants; Brain Infarction; Calcium Channel Blockers; Critical Care; Dioxanes; Drug Therapy, Com | 2013 |
Treatment of subarachnoid hemorrhage.
Topics: Brain Ischemia; Female; Humans; Intracranial Aneurysm; Male; Nimodipine; Practice Guidelines as Topi | 2014 |
Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Delayed-Action Preparations; Drug Delivery Systems; Humans; Injections, Spinal; Micr | 2015 |
Management of delayed cerebral ischemia after subarachnoid hemorrhage.
Topics: Brain Ischemia; Calcium Channel Blockers; Disease Management; Humans; Hyponatremia; Hypotension; Hyp | 2016 |
Evidence-based pharmacotherapy for cerebral vasospasm.
Topics: Animals; Cardiovascular Agents; Enoxaparin; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-C | 2009 |
Reversible cerebral vasoconstriction syndrome.
Topics: Age of Onset; Cerebral Angiography; Female; Humans; Male; Nimodipine; Sex Factors; Stroke; Subarachn | 2009 |
Tirilazad for aneurysmal subarachnoid haemorrhage.
Topics: Brain Ischemia; Humans; Neuroprotective Agents; Nimodipine; Pregnatrienes; Randomized Controlled Tri | 2010 |
Neuroanesthesiology update.
Topics: Anesthesia; Anesthesiology; Animals; Anticonvulsants; Brain; Calcium Channel Blockers; Electroenceph | 2010 |
Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2010 |
Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage.
Topics: Humans; Nimodipine; Randomized Controlled Trials as Topic; Subarachnoid Hemorrhage; Treatment Outcom | 2011 |
Management of delayed cerebral ischemia after subarachnoid hemorrhage.
Topics: Angioplasty, Balloon; Brain Ischemia; Calcium Channel Blockers; Cardiovascular Agents; Cerebral Angi | 2012 |
Intracranial drug delivery for subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug De | 2012 |
Therapeutic approaches to vasospasm in subarachnoid hemorrhage.
Topics: Angioplasty, Balloon; Blood Volume; Calcium Channel Blockers; Fibrinolytic Agents; Fluid Therapy; He | 2002 |
Best evidence topic reports. Does nimodipine reduce mortality and secondary ischaemic events after subarachnoid haemorrhage?
Topics: Adult; Brain Ischemia; Calcium Channel Blockers; Evidence-Based Medicine; Humans; Male; Nimodipine; | 2004 |
[Treatment following aneurysmal subarachnoid hemorrhage].
Topics: Animals; Calcium Channel Blockers; Drug Interactions; Humans; Nimodipine; Subarachnoid Hemorrhage | 2005 |
Detecting and treating microvascular ischemia after subarachnoid hemorrhage.
Topics: Antihypertensive Agents; Cerebrovascular Circulation; Hemodilution; Humans; Hypoxia-Ischemia, Brain; | 2006 |
Calcium antagonists for aneurysmal subarachnoid haemorrhage.
Topics: Calcium Channel Blockers; Humans; Intracranial Aneurysm; Nimodipine; Randomized Controlled Trials as | 2007 |
Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage.
Topics: Angioplasty, Balloon; Calcium Channel Blockers; Cerebral Angiography; Endothelin-1; Humans; Hydroxym | 2007 |
Clinical potential for the use of neuroprotective agents. A brief overview.
Topics: Animals; Brain Diseases; Brain Injuries; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular D | 1995 |
[Treatment of subarachnoid hemorrhage].
Topics: Calcium Channel Blockers; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Nimodipine; Sub | 1994 |
Clinical experiences with nimodipine in cerebral ischemia.
Topics: Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Craniocerebral Trauma; Humans; | 1994 |
Calcium antagonists for the treatment of vasospasm following subarachnoid haemorrhage.
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Circulation; Diltiazem; Humans; Ischemic Attack, | 1993 |
Cerebral vasospasm.
Topics: Aneurysm, Ruptured; Blood Pressure; Blood Volume; Brain Ischemia; Catheterization; Cerebral Infarcti | 1993 |
[Neurosurgical therapy of subarachnoid hemorrhage. Microsurgical techniques--early postoperative nimodipine administration].
Topics: Aged; Aneurysm, Ruptured; Combined Modality Therapy; Drug Administration Schedule; Humans; Intracran | 1993 |
Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis.
Topics: Brain Ischemia; Calcium Channel Blockers; Cerebral Infarction; Humans; Ischemic Attack, Transient; N | 1996 |
[Pharmacological treatment of vasospasm in subarachnoid hemorrhage].
Topics: Antioxidants; Humans; Ischemic Attack, Transient; Lipid Peroxides; Male; Nicardipine; Nimodipine; Pa | 1996 |
Nimodipine in traumatic subarachnoid haemorrhage: a re-analysis of the HIT I and HIT II trials.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Injuries; Calcium Channel Blockers; Female; Gl | 1996 |
Review on traumatic subarachnoid hemorrhage.
Topics: Calcium Channel Blockers; Craniocerebral Trauma; Humans; Nimodipine; Subarachnoid Hemorrhage; Wounds | 1997 |
Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Humans; Intracranial Aneury | 1998 |
[Prospective pharmacologic treatments for subarachnoid hemorrhage].
Topics: Calcium Channel Blockers; Humans; Nimodipine; Subarachnoid Hemorrhage | 1998 |
From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders.
Topics: Animals; Brain Ischemia; Cause of Death; Cerebrovascular Disorders; Controlled Clinical Trials as To | 1994 |
The effect and management of delayed vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Aneurysm, Ruptured; Calcium Channel Blockers; Dose-Response Relationship, Drug; Female; Humans; Isch | 1998 |
The association of tranexamic acid and nimodipine in the pre-operative treatment of ruptured intracranial aneurysms.
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Antifibrinolytic Agents; Antihypertensive Agents | 1998 |
Poor-grade subarachnoid hemorrhage patients: the use of nimodipine and other optional treatments.
Topics: Aneurysm, Ruptured; Clinical Trials as Topic; Humans; Intracranial Aneurysm; Nimodipine; Subarachnoi | 1999 |
Traumatic subarachnoid haemorrhage.
Topics: Calcium Channel Blockers; Craniocerebral Trauma; Humans; Ischemic Attack, Transient; Nimodipine; Ris | 1999 |
Subarachnoid hemorrhage and cerebral vasospasm--facts and perspectives.
Topics: Adolescent; Adult; Age Factors; Austria; Calcium Channel Blockers; Drug Therapy, Combination; Female | 2000 |
Subarachnoid haemorrhage: diagnosis, causes and management.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Antihypertensive Agents; Brain Ischemia; Ce | 2001 |
Cerebral protection before, during and after neurosurgical procedures.
Topics: Amino Acids; Brain Damage, Chronic; Calcium Channel Blockers; Clinical Trials as Topic; Cognition Di | 2000 |
[Cerebral vasospasm after subarachnoid hemorrhage. Current possibilities of prevention and treatment].
Topics: Aneurysm, Ruptured; Humans; Neuroprotective Agents; Nimodipine; Pregnatrienes; Subarachnoid Hemorrha | 2002 |
Nimodipine for delayed cerebral ischaemia after subarachnoid haemorrhage.
Topics: Brain Ischemia; Humans; Nimodipine; Subarachnoid Hemorrhage | 1992 |
Update on calcium antagonists in cerebrovascular diseases.
Topics: Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Disorders; Humans; Nimodipine; Randomized | 1991 |
[Value of the measurement of cerebral blood flow before and after diamox injection in predicting clinical vasospasm and final outcome in aneurysmal subarachnoid hemorrhage].
Topics: Acetazolamide; Cerebrovascular Circulation; Female; Humans; Intracranial Aneurysm; Male; Nimodipine; | 1991 |
Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Double-Blind Method; Humans; Intracranial Aneurysm; Meta-Analysis as Topic; Nimodipi | 1990 |
Calcium antagonists in the management of subarachnoid haemorrhage.
Topics: Brain Ischemia; Calcium Channel Blockers; Clinical Trials as Topic; Humans; Nimodipine; Randomized C | 1990 |
Calcium antagonists in the management of patients with aneurysmal subarachnoid hemorrhage: a review.
Topics: Calcium Channel Blockers; Cerebral Infarction; Humans; Intracranial Aneurysm; Ischemic Attack, Trans | 1990 |
Efficacy of nimodipine in cerebral ischemia or hemorrhage.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Humans; Ischemic Attack, Transient; Nimodipine | 1990 |
[Epidemiology of meningeal hemorrhage caused by aneurysmal rupture (report of 600 cases)].
Topics: Adult; Age Factors; Female; Follow-Up Studies; Glasgow Coma Scale; Health Surveys; Humans; Intracran | 1990 |
Nimodipine in the treatment of subarachnoid hemorrhage.
Topics: Animals; Humans; Nimodipine; Subarachnoid Hemorrhage | 1989 |
Nimodipine in subarachnoid hemorrhage.
Topics: Brain Ischemia; Humans; Nimodipine; Subarachnoid Hemorrhage | 1989 |
Haemodynamic effectiveness of nimodipine on spastic brain vessels after subarachnoid haemorrhage evaluated by the transcranial Doppler method. A review of clinical studies.
Topics: Blood Flow Velocity; Dose-Response Relationship, Drug; Double-Blind Method; Hemodynamics; Humans; Is | 1988 |
Nimodipine in the prevention of ischaemic deficits after aneurysmal subarachnoid haemorrhage. An analysis of recent clinical studies.
Topics: Brain; Clinical Trials as Topic; Humans; Injections, Intravenous; Intracranial Aneurysm; Ischemic At | 1988 |
Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage.
Topics: Humans; Ischemic Attack, Transient; Nimodipine; Subarachnoid Hemorrhage | 1987 |
Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine.
Topics: Brain Ischemia; Clinical Trials as Topic; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; | 1987 |
[Vascular spasm and cerebral ischemia after meningeal hemorrhage caused by rupture of an aneurysm].
Topics: Brain Ischemia; Calcium Channel Blockers; Cerebral Angiography; Electroencephalography; Fibrin Fibri | 1986 |
Cerebral arterial spasm.
Topics: Blood Platelets; Calcium; Cerebral Arterial Diseases; Humans; Muscle Contraction; Nervous System Dis | 1985 |
62 trials available for nimodipine and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
Clinical Outcome in Cerebral Vasospasm Patients Treated with and without Intra-Arterial Nimodipine Infusion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Middle Aged; Nimodipine; Prospective Studies; Re | 2022 |
Effect of Locally Delivered Nimodipine Microparticles on Spreading Depolarization in Aneurysmal Subarachnoid Hemorrhage.
Topics: Brain; Brain Ischemia; Electrocorticography; Humans; Nimodipine; Subarachnoid Hemorrhage; Vasospasm, | 2021 |
NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Antihypertensive Agents; Delayed-Action Preparations; Female; Humans; Hyaluronic Acid; Inject | 2020 |
Efficacy and safety of cilostazol-nimodipine combined therapy on delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: a prospective, randomised, double-blinded, placebo-controlled trial protocol.
Topics: Brain Ischemia; Cilostazol; Humans; Multicenter Studies as Topic; Nimodipine; Prospective Studies; Q | 2020 |
Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
Topics: Aortic Aneurysm, Abdominal; Blood Vessel Prosthesis Implantation; Brain Injuries; Endovascular Proce | 2021 |
Magnesium sulfate in combination with nimodipine for the treatment of subarachnoid hemorrhage: a randomized controlled clinical study.
Topics: Adult; Brain Ischemia; Cerebral Infarction; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimo
Topics: Adult; Aged; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Method; Female; Gla | 2019 |
NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
Topics: Adolescent; Adult; Aged; Aneurysm, Ruptured; Calcium Channel Blockers; Clinical Protocols; Delayed-A | 2015 |
Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage.
Topics: Administration, Intravenous; Administration, Oral; Aged; Female; Humans; Male; Middle Aged; Nimodipi | 2015 |
Long-Term, Continuous Intra-Arterial Nimodipine Treatment of Severe Vasospasm After Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Cohort Studies; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, | 2016 |
Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid
Topics: Adult; Aged; Calcium Channel Blockers; Cohort Studies; Delayed-Action Preparations; Female; Humans; | 2017 |
Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Endpoint Determination; Female; Follow-Up Stud | 2009 |
A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm.
Topics: Adult; Aged; Calcium Channel Blockers; Combined Modality Therapy; Female; Humans; Male; Middle Aged; | 2009 |
Continuous intra-arterial infusion of nimodipine at the onset of resistant vasospasm in aneurysmal subarachnoidal haemorrhage. Technical report.
Topics: Antihypertensive Agents; Coronary Angiography; Female; Humans; Infusions, Intra-Arterial; Male; Midd | 2011 |
Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain Ischemia; Calcium Channel Blockers | 2011 |
A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Adult; Aged; Brain Damage, Chronic; Calcium Channel Blockers; Cerebral Angiogr | 2012 |
Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2003 |
The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage.
Topics: Aged; Brain; Calcium Channel Blockers; Female; Humans; Intracranial Aneurysm; Intracranial Pressure; | 2004 |
Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Topics: Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Cerebral Angiography; Cerebral Infarction; Fe | 2006 |
Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Brain Ischemia; Female; Humans; Male; Middle A | 2006 |
Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Calcium Channel Blockers; Female; Humans; Infusion | 2007 |
Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Circulation; Female; Humans; Injections, Intra-Arter | 2008 |
Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Fe | 1983 |
[Clinical experiences with nimodipine (Bay e 9736)].
Topics: Calcium Channel Blockers; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Nicotinic A | 1984 |
Clinical significance of the finding of subarachnoid blood on CT scan after head injury.
Topics: Adult; Brain Damage, Chronic; Brain Injuries; Disability Evaluation; Dose-Response Relationship, Dru | 1994 |
A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. The European Study Group on Nimodipine in Severe Head Injury.
Topics: Adult; Brain Injuries; Female; Humans; Male; Nimodipine; Placebos; Radiography; Subarachnoid Hemorrh | 1994 |
Experience with nimodipine in aneurysmal subarachnoid haemorrhage.
Topics: Brain Ischemia; Double-Blind Method; Humans; Intracranial Aneurysm; Middle Aged; Nimodipine; Prospec | 1993 |
Traumatic subarachnoid hemorrhage and its treatment with nimodipine. German tSAH Study Group.
Topics: Adult; Blood Pressure; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nimodipine; Subarachnoi | 1996 |
Nimodipine in traumatic subarachnoid haemorrhage: a re-analysis of the HIT I and HIT II trials.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Injuries; Calcium Channel Blockers; Female; Gl | 1996 |
A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
Topics: Administration, Oral; Anticonvulsants; Calcium Channel Blockers; Cerebral Angiography; Clinical Prot | 1997 |
Haemodynamic effects of intravenous nimodipine following aneurysmal subarachnoid haemorrhage: implications for monitoring.
Topics: Adult; Aged; Calcium Channel Blockers; Cardiac Catheterization; Hemodynamics; Humans; Hypotension; I | 1997 |
Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery.
Topics: Adolescent; Adult; Aged; Aneurysm, Ruptured; Combined Modality Therapy; Cost-Benefit Analysis; Doubl | 1999 |
Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage.
Topics: Fibrinolysis; Humans; Netherlands; Nimodipine; Plasminogen Activator Inhibitor 1; Plasminogen Activa | 2001 |
Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study.
Topics: Aged; Brain; Brain Ischemia; Cognition Disorders; Echoencephalography; Female; Fluid Therapy; Follow | 2001 |
[Effect of nimodipine on vasospasm of cortical arteries. Experimental study].
Topics: Animals; Cerebral Arteries; Cerebral Cortex; Disease Models, Animal; Dogs; Drug Evaluation; Female; | 1992 |
Raised plasma endothelin in aneurysmal subarachnoid haemorrhage.
Topics: Endothelins; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Nimodipine; Peptides; Prospe | 1990 |
Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery.
Topics: Adolescent; Adult; Aged; Cause of Death; Cerebral Infarction; Double-Blind Method; Female; Humans; I | 1991 |
Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Double-Blind Method; Humans; Intracranial Aneurysm; Meta-Analysis as Topic; Nimodipi | 1990 |
Oral nimodipine and cerebral ischaemia following subarachnoid haemorrhage.
Topics: Brain Ischemia; Double-Blind Method; Humans; Nimodipine; Randomized Controlled Trials as Topic; Suba | 1990 |
Calcium antagonists in the management of patients with aneurysmal subarachnoid hemorrhage: a review.
Topics: Calcium Channel Blockers; Cerebral Infarction; Humans; Intracranial Aneurysm; Ischemic Attack, Trans | 1990 |
Effect of nimodipine on platelet function in patients with subarachnoid hemorrhage.
Topics: Adult; Blood Platelets; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Nimo | 1990 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Nimodipine for cerebral vasospasm after subarachnoid hemorrhage.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Infusions, Intravenous; Intracranial Aneurys | 1989 |
[Intravenous nimodipine in the treatment of cerebral vasospasm following subarachnoid hemorrhage caused by aneurysm rupture: a comparative multicenter study].
Topics: Adult; Double-Blind Method; Female; Humans; Infusions, Intravenous; Intracranial Aneurysm; Ischemic | 1989 |
Prevention of symptomatic vasospasm after SAH by constant venous infusion of nimodipine.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Nimo | 1986 |
Timing of operation for ruptured supratentorial aneurysms: a prospective randomized study.
Topics: Adolescent; Adult; Aged; Brain Ischemia; Circle of Willis; Evaluation Studies as Topic; Humans; Intr | 1989 |
Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Intracranial Aneurys | 1988 |
Haemodynamic effectiveness of nimodipine on spastic brain vessels after subarachnoid haemorrhage evaluated by the transcranial Doppler method. A review of clinical studies.
Topics: Blood Flow Velocity; Dose-Response Relationship, Drug; Double-Blind Method; Hemodynamics; Humans; Is | 1988 |
Nimodipine in the prevention of ischaemic deficits after aneurysmal subarachnoid haemorrhage. An analysis of recent clinical studies.
Topics: Brain; Clinical Trials as Topic; Humans; Injections, Intravenous; Intracranial Aneurysm; Ischemic At | 1988 |
[Treatment of vasospasm in aneurysmal meningeal hemorrhage using intravenous nimodipine. Multicenter cooperative study].
Topics: Double-Blind Method; Female; Humans; Injections, Intravenous; Intracranial Aneurysm; Ischemic Attack | 1988 |
[Therapy of aneurysm-induced subarachnoid hemorrhage].
Topics: Follow-Up Studies; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Nimodipine; Postoperat | 1988 |
Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Cerebral Angiography; Cerebral Inf | 1988 |
Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aged; Cardiovascular System; Cerebrovascular Circulation; Clinical Trials as Topi | 1988 |
Clinical trial of a calcium channel blocker in patients with aneurysmal subarachnoid hemorrhage--prevention of delayed ischemic deficits.
Topics: Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Nimodipine; Prospective Studies; Subar | 1987 |
Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Double-Blind Method; Humans; | 1987 |
Aneurysmal subarachnoid hemorrhage: prevention of delayed ischemic dysfunction with intravenous nimodipine.
Topics: Brain Ischemia; Clinical Trials as Topic; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; | 1987 |
Early intervention with nimodipine in subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cerebral Angiography; Cerebrovascular Circulation; Double-B | 1987 |
Cerebral vasospasm and calcium channel blockade. Nimodipine treatment in patients with aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Internal; Clinical Trials as Topic; Humans; | 1986 |
Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine.
Topics: Adolescent; Adult; Aged; Cerebral Angiography; Clinical Trials as Topic; Double-Blind Method; Humans | 1986 |
The relationship between timing of surgery and operative complications in aneurysmal subarachnoid hemorrhage.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Intracranial Aneurysm; Middle Aged; Nimodipin | 1987 |
Role of calcium antagonists in cerebral arterial spasm.
Topics: Animals; Calcium Channel Blockers; Cerebral Arteries; Clinical Trials as Topic; Dogs; Double-Blind M | 1985 |
Preventive nimodipine and acute aneurysm surgery. Heading for the control of complications after aneurysmal subarachnoid hemorrhage.
Topics: Animals; Arteries; Brain Ischemia; Calcium Channel Blockers; Cats; Cerebral Revascularization; Clini | 1985 |
263 other studies available for nimodipine and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
Radiation exposure in the intra-arterial nimodipine therapy of subarachnoid hemorrhage related cerebral vasospasm.
Topics: Humans; Nimodipine; Radiation Exposure; Retrospective Studies; Subarachnoid Hemorrhage; Treatment Ou | 2022 |
Influence of nimodipine combined with ulinastatin on neurological function and inflammatory reaction in patients with cerebral vasospasm after subarachnoid hemorrhage.
Topics: Adult; Blood Flow Velocity; Cerebral Arteries; Drug Therapy, Combination; Female; Glycoproteins; Hum | 2021 |
Early cisternal fibrinolysis is more effective than rescue spasmolysis for the prevention of delayed infarction after subarachnoid haemorrhage.
Topics: Cerebral Infarction; Fibrinolysis; Humans; Nimodipine; Parasympatholytics; Retrospective Studies; Su | 2022 |
Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage.
Topics: Female; Humans; Male; Middle Aged; Nimodipine; Outcome Assessment, Health Care; Prospective Studies; | 2022 |
Continuous intra-arterial nimodipine infusion as rescue treatment of severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Humans; Infusions, Intra-Arterial; Nimodipine; Quality of Life; Retrospective Studies; Subarachnoid | 2022 |
Nimodipine Attenuates Early Brain Injury by Protecting the Glymphatic System After Subarachnoid Hemorrhage in Mice.
Topics: Animals; Brain; Brain Injuries; Glymphatic System; Humans; Mice; Nimodipine; Rats; Rats, Sprague-Daw | 2022 |
Large practice variations in diagnosis and treatment of delayed cerebral ischemia after subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Nimodipine; Subarachnoid Hemorrhage; Vasospasm, Intracr | 2022 |
Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Hemodynamics; Humans; Hypertension; Milrinone; Nimodipine; Nore | 2022 |
Analysis of Angiographic Treatment Response to Intra-Arterial Nimodipine Bolus Injection in Patients with Medically Refractory Cerebral Vasospasm After Spontaneous Subarachnoid Hemorrhage.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Humans; Infarction; Nimodipine; Retrospective Studies; Su | 2022 |
Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Milrinone; Nimodipine; Subarachnoid Hemorrhage; Vasospa | 2022 |
Intravenous Nimodipine Versus Enteral Nimodipine: The Meta-analysis Paradox.
Topics: Administration, Intravenous; Calcium Channel Blockers; Humans; Infusions, Intravenous; Meta-Analysis | 2022 |
Treatment and outcomes of non-aneurysmal perimesencephalic subarachnoid haemorrhage: A 5 year retrospective study in a tertiary care centre.
Topics: Humans; Nimodipine; Retrospective Studies; Subarachnoid Hemorrhage; Tertiary Care Centers; Treatment | 2022 |
Current management of subarachnoid hemorrhage in a northern urban Chinese population: a multi-center surveillance study.
Topics: Aged; Aneurysm, Ruptured; Case-Control Studies; Female; Humans; Intracranial Aneurysm; Middle Aged; | 2023 |
Dantrolene Significantly Improves Cerebral Blood Flow in a Rat Model of Hemorrhagic Vasospasms.
Topics: Animals; Cerebrovascular Circulation; Dantrolene; Nimodipine; Rats; Rats, Sprague-Dawley; Subarachno | 2023 |
Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study.
Topics: Calcium Channel Blockers; Enteral Nutrition; Humans; Hypotension; Nimodipine; Retrospective Studies; | 2023 |
Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage.
Topics: Blood Pressure; Brain Ischemia; Cerebral Infarction; Humans; Hypotension; Nimodipine; Norepinephrine | 2023 |
Vasodilatory effects of tadalafil in an animal model of cerebral vasospasm: Comparative analysis with oral nimodipine.
Topics: Animals; Humans; Models, Animal; Nimodipine; Rabbits; Subarachnoid Hemorrhage; Tadalafil; Treatment | 2023 |
Evaluation of DeGIR registry data on endovascular treatment of cerebral vasospasm in Germany 2018-2021: an overview of the current care situation.
Topics: Endovascular Procedures; Female; Humans; Male; Nimodipine; Papaverine; Retrospective Studies; Routin | 2023 |
Nimodipine Reduces Microvasospasms After Experimental Subarachnoid Hemorrhage.
Topics: Animals; Humans; Male; Mice; Mice, Inbred C57BL; Microcirculation; Microvessels; Nimodipine; Subarac | 2023 |
Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage?
Topics: Adult; Aged; Aged, 80 and over; Arterial Pressure; Brain Ischemia; Catecholamines; Cerebrovascular C | 2019 |
Mass spectrometry-based method for quantification of nimodipine and glutamate in cerebrospinal fluid. Pilot study with patients after aneurysmal subarachnoid haemorrhage.
Topics: Adult; Aged; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Female; Glutamic Acid; | 2020 |
May levosimendan be safe and effective in refractory vasospasm despite adequate treatment with repeated angiography and milrinone infusion after subarachnoid haemorrhage?
Topics: Aneurysm, Ruptured; Cardiotonic Agents; Cerebral Angiography; Cerebrospinal Fluid Leak; Computed Tom | 2019 |
Transluminal balloon angioplasty for cerebral vasospasm after spontaneous subarachnoid hemorrhage: A single-center experience.
Topics: Adult; Angioplasty, Balloon; Brain Infarction; Brain Ischemia; Cerebral Angiography; Endovascular Pr | 2020 |
Symptomatic Cerebral Vasospasm after Spontaneous Subarachnoid Hemorrhage: Comparison of Single and Multiple Intra-arterial Treatment with Respect to the Functional Outcome.
Topics: Aged; Angioplasty; Female; Humans; Male; Middle Aged; Nimodipine; Prognosis; Retrospective Studies; | 2020 |
Impact of Stereotactic Ventriculocisternostomy on Delayed Cerebral Infarction and Outcome After Subarachnoid Hemorrhage.
Topics: Aged; Aneurysm, Ruptured; Cerebral Infarction; Female; Fibrinolytic Agents; Humans; Intracranial Ane | 2020 |
Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage.
Topics: Aged, 80 and over; Antihypertensive Agents; Bradycardia; Cytochrome P-450 CYP3A; Female; Humans; Nim | 2020 |
The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage.
Topics: Administration, Oral; Adult; Aged; Brain Ischemia; Drug Administration Schedule; Enteral Nutrition; | 2020 |
Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis.
Topics: Animals; Antihypertensive Agents; Cognitive Dysfunction; Disease Models, Animal; Down-Regulation; Ma | 2020 |
Early strategy of scepter XC balloon angioplasty and simultaneous Nimodipine infusion for vasospasm following ruptured aneurysm.
Topics: Adult; Aged; Aneurysm, Ruptured; Angioplasty, Balloon; Computed Tomography Angiography; Female; Huma | 2020 |
Takotsubo syndrome after nimodipine-induced hypotension treated with norepinephrine in a female with subarachnoid hemorrhage.
Topics: Aged; Female; Humans; Hypotension, Controlled; Nimodipine; Norepinephrine; Subarachnoid Hemorrhage; | 2020 |
Enantioselective assay of nimodipine in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, Liquid; Humans; Linear Models; Nimodipine; Reproducibility of Results; Sensitivity a | 2021 |
Use of Nimodipine in a Neonate With Cerebral Vasospasm With Delayed Ischemia From Subarachnoid Hemorrhage in the Posterior Fossa.
Topics: Angiography, Digital Subtraction; Brain Ischemia; Cerebral Angiography; Cranial Fossa, Posterior; Hu | 2020 |
Nimodipine after aneurysmal subarachnoid hemorrhage: Fourteen-day course for patients that meet criteria for early hospital discharge.
Topics: Adult; Aged; Drug Administration Schedule; Female; Follow-Up Studies; Hospitalization; Humans; Male; | 2021 |
[Continuous intra arterial nimodipine for vasospasm secondary to subarachnoid hemorrhage. Report of one case].
Topics: Adult; Angiography; Coma; Computed Tomography Angiography; Humans; Male; Nimodipine; Subarachnoid He | 2019 |
Vasorelaxing cell permeant phosphopeptide mimetics for subarachnoid hemorrhage.
Topics: Animals; Cell Adhesion Molecules; Cyclic GMP-Dependent Protein Kinases; Down-Regulation; Drug Design | 2021 |
The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats.
Topics: Animals; Calcium Channel Blockers; Dantrolene; Diabetes Mellitus, Experimental; Drug Therapy, Combin | 2021 |
Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid haemorrhage - neurological and radiological outcome.
Topics: Humans; Nimodipine; Retrospective Studies; Subarachnoid Hemorrhage; Treatment Outcome; Vasodilator A | 2022 |
Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment.
Topics: Aged; Cerebral Cortex; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Humans; Mal | 2017 |
Is intra arterial nimodipine really beneficial in vasospasm following aneurysmal subarachnoid hemorrhage?
Topics: Humans; Nimodipine; Subarachnoid Hemorrhage; Vasodilator Agents; Vasospasm, Intracranial | 2017 |
Comment: The Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients.
Topics: Calcium Channel Blockers; Humans; Intracranial Aneurysm; Nimodipine; Subarachnoid Hemorrhage | 2017 |
Evaluation function of transcranial two-dimensional and color Doppler ultrasonography (TCCS) for patients with different degrees of cerebral vasospasm before and after the nimodipine treatment.
Topics: Adult; Aged; Blood Flow Velocity; Female; Hemodynamics; Humans; Male; Middle Aged; Middle Cerebral A | 2017 |
Side Effects of Long-Term Continuous Intra-arterial Nimodipine Infusion in Patients with Severe Refractory Cerebral Vasospasm after Subarachnoid Hemorrhage.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intra-Arterial; M | 2018 |
Topics: Adult; Cerebral Angiography; Computed Tomography Angiography; Diagnosis, Differential; Headache Diso | 2018 |
Higher dose intra-arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a rescue therapy for refractory cerebral vasospasm.
Topics: Angiography, Digital Subtraction; Cerebral Angiography; Computed Tomography Angiography; Drug Therap | 2017 |
Stellate ganglion block as rescue therapy in refractory vasospasm after subarachnoid hemorrhage.
Topics: Anesthetics, Local; Aneurysm, Ruptured; Arm; Bupivacaine; Humans; Intracranial Aneurysm; Middle Aged | 2019 |
Dangers of outpatient nimodipine use after spontaneous subarachnoid hemorrhage in accordance with the Comprehensive Stroke Center guidelines.
Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Humans; Hypotension; Male; Nimodipine; Outpatients; | 2018 |
Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk?
Topics: Adult; Aged; Angioplasty; Aortic Dissection; Cerebral Infarction; Combined Modality Therapy; Female; | 2019 |
Impact of Early Versus Late Intravenous Followed by Oral Nimodipine Treatment on the Occurrence of Delayed Cerebral Ischemia Among Patients With Aneurysm Subarachnoid Hemorrhage.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Brain Ischemia; Drug Administration | 2018 |
The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia-continuous selective intracarotid nimodipine therapy in awake patients without sedation.
Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Carotid Arteries; Feasibility Studies; Female; Human | 2019 |
Has Outcome of Subarachnoid Hemorrhage Changed With Improvements in Neurosurgical Services?
Topics: Adult; Databases, Factual; Developing Countries; Female; Fluid Therapy; Glasgow Outcome Scale; Human | 2018 |
Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Femal | 2019 |
A novel rescue therapy for cerebral vasospasm: Cisternal Nimodipine application via stereotactic catheter ventriculocisternostomy.
Topics: Catheters; Cerebral Infarction; Female; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Nimod | 2019 |
Posterior reversible encephalopathy syndrome associated with reversible cerebral vasoconstriction syndrome in a patient presenting with postpartum eclampsia: A case report.
Topics: Adult; Cerebral Arterial Diseases; Eclampsia; Female; Headache; Humans; Nimodipine; Posterior Leukoe | 2019 |
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze | 2019 |
MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats.
Topics: Animals; Butadienes; Calcium Channel Blockers; Cerebral Arteries; Disease Models, Animal; Male; Mito | 2019 |
Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Drug Administration Sch | 2019 |
Isolated diastolic hypotension: A unique complication of intra-arterial nimodipine infusion!!
Topics: Aged; Angiography, Digital Subtraction; Anterior Cerebral Artery; Blood Pressure; Diastole; Electroc | 2020 |
The dual-functional memantine nitrate MN-08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models.
Topics: Animals; Brain Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; HEK293 Cells; Hum | 2019 |
Endovascular treatment of cerebral vasospasm after subarachnoid hemorrhage: More is more.
Topics: Adult; Aged; Angioplasty, Balloon; Arterial Pressure; Brain Ischemia; Endovascular Procedures; Femal | 2019 |
Continuous intra-arterial dilatation with nimodipine and milrinone for refractory cerebral vasospasm.
Topics: Angioplasty, Balloon; Cerebral Angiography; Dilatation; Drug Resistance; Female; Humans; Infusions, | 2014 |
In brief: nimodipine oral solution (Nymalize).
Topics: Administration, Oral; Aneurysm, Ruptured; Calcium Channel Blockers; Drug Approval; Humans; Intracran | 2013 |
Partly reversible central auditory dysfunction induced by cerebral vasospasm after subarachnoid hemorrhage.
Topics: Angioplasty; Auditory Diseases, Central; Female; Humans; Middle Aged; Middle Cerebral Artery; Nimodi | 2013 |
Bath-related thunderclap headache associated with subarachnoid and intracerebral hemorrhage.
Topics: Baths; Cerebral Hemorrhage; Female; Headache Disorders, Primary; Humans; Magnetic Resonance Angiogra | 2013 |
Using nimodipine for patients with aneurysmal subarachnoid hemorrhage.
Topics: Calcium Channel Blockers; Humans; Intracranial Aneurysm; Nimodipine; Practice Guidelines as Topic; R | 2014 |
pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH.
Topics: Animals; Behavior, Animal; Calcium Channel Blockers; Disease Models, Animal; Hydrogen-Ion Concentrat | 2014 |
Continuous selective intra-arterial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Cerebrovascular Circulation; Female; Glasgow Outcome Scale; Humans; Infusions, Intra-Ar | 2014 |
Investigation of the neuroprotective impact of nimodipine on Neuro2a cells by means of a surgery-like stress model.
Topics: Animals; Cell Death; Cell Line; Ethanol; Hot Temperature; Neurons; Neuroprotective Agents; Nimodipin | 2014 |
Repeated combined endovascular therapy with milrinone and nimodipine for the treatment of severe vasospasm: preliminary results.
Topics: Adult; Combined Modality Therapy; Endovascular Procedures; Female; Follow-Up Studies; Humans; Male; | 2015 |
Hypoxemia associated with nimodipine in a patient with an aneurysmal subarachnoid hemorrhage.
Topics: Calcium Channel Blockers; Humans; Hypoxia; Male; Middle Aged; Nimodipine; Subarachnoid Hemorrhage; V | 2015 |
Nimodipine for the prevention of cerebral vasospasm after subarachnoid hemorrhage in 12 children.
Topics: Adolescent; Cerebral Angiography; Child; Child, Preschool; Female; Humans; Male; Nimodipine; Retrosp | 2015 |
Results of an International Survey on the Investigation and Endovascular Management of Cerebral Vasospasm and Delayed Cerebral Ischemia.
Topics: Adult; Australasia; Brain Ischemia; Disease Management; Endovascular Procedures; Europe; Female; Hea | 2015 |
Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model.
Topics: Animals; Delayed-Action Preparations; Disease Models, Animal; Dogs; Intracranial Aneurysm; Nimodipin | 2015 |
Pharmacologic Management of Subarachnoid Hemorrhage.
Topics: Adrenal Cortex Hormones; Animals; Anticoagulants; Apoptosis; Brain Ischemia; Calcium Channel Blocker | 2015 |
Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Drug Therapy, Combinat | 2016 |
Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.
Topics: Computer Simulation; Humans; Injections, Intra-Arterial; Metabolic Clearance Rate; Models, Cardiovas | 2017 |
Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results.
Topics: Adult; Calcium Channel Blockers; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nimod | 2015 |
Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Calcium Channel Blockers; Cerebral Infarction; Female; Humans; Intracranial Aneurysm; Male; M | 2016 |
Real-Time, In Vivo Monitoring, and Quantitative Assessment of Intra-Arterial Vasospasm Therapy.
Topics: Adult; Angiography, Digital Subtraction; Cerebrovascular Circulation; Female; Humans; Infusions, Int | 2016 |
Intra-arterial nimodipine for cerebral vasospasm after subarachnoid haemorrhage: Influence on clinical course and predictors of clinical outcome.
Topics: Female; Humans; Injections, Intra-Arterial; Male; Middle Aged; Nimodipine; Prognosis; Radiography; R | 2016 |
A Site-Specific, Sustained-Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage.
Topics: Animals; Brain; Delayed-Action Preparations; Dogs; Female; Infusion Pumps, Implantable; Male; Nimodi | 2016 |
Is intra arterial nimodipine really beneficial in vasospasm following aneurysmal subarachnoid haemorrhage?
Topics: Adult; Aged; Female; Humans; Infusions, Intra-Arterial; Intracranial Aneurysm; Male; Middle Aged; Ni | 2016 |
Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage.
Topics: Adult; Aged; Angioplasty, Balloon; Cerebral Arteries; Endovascular Procedures; Female; Humans; Injec | 2016 |
Aneurysm Location as a Prognostic Outcome Factor After Subarachnoid Hemorrhage From Internal Carotid Artery Aneurysms and Potential Impact for Further Experimental Subarachnoid Hemorrhage Models.
Topics: Adult; Aged; Aneurysm, Ruptured; Carotid Artery Diseases; Female; Humans; Male; Middle Aged; Multiva | 2016 |
Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients.
Topics: Adult; Aged; Calcium Channel Blockers; Dose-Response Relationship, Drug; Drug Utilization; Female; H | 2016 |
Simple and validated UHPLC-MS/MS analysis of nimodipine in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage.
Topics: Calcium Channel Blockers; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Limit of De | 2016 |
Retinal Vessel Analysis (RVA) in the Context of Subarachnoid Hemorrhage - A Proof of Concept Study.
Topics: Adult; Aged; Aneurysm; Brain Ischemia; Case-Control Studies; Cerebrovascular Circulation; Female; Hu | 2016 |
Comparison of the Effects and Mechanism of the Curcumin with Different Drugs in Experimental Vasospasm After Subarachnoid Hemorrhage.
Topics: Animals; Apoptosis; Basilar Artery; Cerebellum; Cerebral Cortex; Curcumin; Interleukin-1beta; Interl | 2017 |
Reversible cerebral vasoconstriction syndrome presenting as subarachnoid hemorrhage: A rare cause of postpartum seizure.
Topics: Adult; Calcium Channel Blockers; Female; Humans; Magnetic Resonance Imaging; Neuroimaging; Nimodipin | 2017 |
Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm.
Topics: Cerebral Angiography; Chronic Disease; Disease Progression; Echoencephalography; Female; Humans; Inf | 2017 |
Chemical angioplasty with spasmolytics for vasospasm after subarachnoid hemorrhage.
Topics: Adult; Angioplasty; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nimodipine; Subara | 2017 |
Effect of Intra-Arterial and Intravenous Nimodipine Therapy of Cerebral Vasospasm After Subarachnoid Hemorrhage on Cerebrovascular Reactivity and Oxygenation.
Topics: Adult; Aged; Cerebrovascular Circulation; Female; Homeostasis; Humans; Infusions, Intra-Arterial; In | 2017 |
Letter by Rustemi Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery Whil
Topics: Delayed-Action Preparations; Humans; Maximum Tolerated Dose; Nimodipine; Subarachnoid Hemorrhage; Va | 2017 |
Response by Hänggi and Macdonald to Letter Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles
Topics: Delayed-Action Preparations; Humans; Maximum Tolerated Dose; Nimodipine; Subarachnoid Hemorrhage; Va | 2017 |
Editorial. Nimodipine treatment.
Topics: Hearing; Humans; Neuroma, Acoustic; Nimodipine; Pilot Projects; Subarachnoid Hemorrhage | 2017 |
Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy.
Topics: Adult; Angiography, Digital Subtraction; Calcium Channel Blockers; Cerebral Angiography; Cerebral In | 2008 |
Nimodipine: test your drug IQ.
Topics: Adult; Calcium Channel Blockers; Drug Interactions; Humans; Nimodipine; Patient Education as Topic; | 2008 |
Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Topics: Administration, Topical; Animals; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Dis | 2009 |
Subarachnoid haemorrhage: possibly caused by the illegitimate use of sildenafil citrate.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Humans; Male; Middle Aged; Naprox | 2008 |
Prostacyclin treatment normalises the MCA flow velocity in nimodipine-resistant cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Cerebral Arteries; Cerebrovascular Circula | 2009 |
Experimental subarachnoid hemorrhage in the rat: influences of nimodipine.
Topics: Animals; Brain Injuries; Disease Models, Animal; Fibrinolytic Agents; Glial Fibrillary Acidic Protei | 2008 |
Dose-related efficacy of a continuous intracisternal nimodipine treatment on cerebral vasospasm in the rat double subarachnoid hemorrhage model.
Topics: Animals; Antihypertensive Agents; Cerebral Angiography; Dose-Response Relationship, Drug; Drug Conta | 2009 |
Case fatality after subarachnoid haemorrhage: declining, but why?
Topics: Age Distribution; Calcium Channel Blockers; Embolization, Therapeutic; Humans; Meta-Analysis as Topi | 2009 |
Effects of topical administration of nimodipine on cerebral blood flow following subarachnoid hemorrhage in pigs.
Topics: Administration, Topical; Animals; Brain; Cerebrovascular Circulation; Disease Models, Animal; Male; | 2013 |
The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model.
Topics: Animals; Basilar Artery; Cilostazol; Disease Models, Animal; Drug Therapy, Combination; Injections, | 2009 |
Continuous selective intraarterial infusion of nimodipine for therapy of refractory cerebral vasospasm.
Topics: Adult; Anticoagulants; Calcium Channel Blockers; Cerebral Angiography; Drug Therapy, Combination; Em | 2010 |
Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats.
Topics: Analysis of Variance; Animals; Antioxidants; Azoles; Brain; Drug Administration Schedule; Female; In | 2010 |
Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage.
Topics: Adult; Aged; Blood Preservation; Cerebral Infarction; Coma; Erythrocyte Aging; Erythrocyte Transfusi | 2011 |
Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Administration, Oral; Analysis of Variance; Angiography, Digital Subtraction; Animals; Basilar Arter | 2011 |
Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Analysis of Variance; Animals; Basilar Artery; Calcium Channel Blockers; Cilostazol; Disease Models, | 2011 |
Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Angiography, Digital Subtraction; Animals; Basilar Artery; Benzhydryl Compounds; Calcium Channel Blo | 2011 |
Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits.
Topics: Angiography, Digital Subtraction; Animals; Basilar Artery; Calcium Channel Blockers; Disease Models, | 2011 |
The effects of intrathecal nicergoline and nimodipine in cerebral vasospasm: an experimental study in rabbits.
Topics: Adrenergic alpha-Antagonists; Angiography, Digital Subtraction; Animals; Basilar Artery; Calcium Cha | 2011 |
Fundamental increase in pressure-dependent constriction of brain parenchymal arterioles from subarachnoid hemorrhage model rats due to membrane depolarization.
Topics: Animals; Arterioles; Blood Pressure; Brain; Calcium; Calcium Channels, L-Type; Endothelium, Vascular | 2011 |
Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage.
Topics: Adult; Cerebral Angiography; Cerebrovascular Circulation; Female; Humans; Infusions, Intra-Arterial; | 2011 |
Endovascular treatment of severe vasospasm in nonaneurysmal perimesencephalic subarachnoid hemorrhage.
Topics: Adult; Angiography, Digital Subtraction; Angioplasty, Balloon; Blood Flow Velocity; Calcium Channel | 2011 |
Resistant vasospasm in subarachnoid hemorrhage treated with continuous intraarterial nimodipine infusion.
Topics: Calcium Channel Blockers; Cerebral Angiography; Humans; Infusions, Intra-Arterial; Nimodipine; Retro | 2011 |
Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Topics: Adult; Calcium Channel Blockers; Cerebral Angiography; Female; Follow-Up Studies; Humans; Infusions, | 2011 |
Cardiovascular changes after subarachnoid hemorrhage initiated by the trigeminocardiac reflex-first description of a case series.
Topics: Antihypertensive Agents; Blood Pressure; Female; Heart Rate; Hemodynamics; Humans; Intracranial Pres | 2011 |
Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients.
Topics: Adult; Aged; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Critical Care; Energy Met | 2012 |
Effect of intraarterial papaverine or nimodipine on vessel diameter in patients with cerebral vasospasm after subarachnoid hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Brain Ischemia; Capillaries; Carotid Artery, I | 2012 |
Cisternal sustained release dihydropyridines for subarachnoid hemorrhage.
Topics: Animals; Delayed-Action Preparations; Dihydropyridines; Disease Models, Animal; Dogs; Female; Macaca | 2012 |
Nimodipine attenuation of early brain dysfunctions is partially related to its inverting acute vasospasm in a cisterna magna subarachnoid hemorrhage (SAH) model in rats.
Topics: Animals; Blood-Brain Barrier; Cerebrovascular Circulation; Cisterna Magna; Disease Models, Animal; M | 2012 |
Endovascular treatment: balloon angioplasty versus nimodipine intra-arterial for medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage.
Topics: Adult; Angiography, Digital Subtraction; Angioplasty, Balloon; Chi-Square Distribution; Female; Huma | 2012 |
Local delivery of nimodipine by prolonged-release microparticles-feasibility, effectiveness and dose-finding in experimental subarachnoid hemorrhage.
Topics: Angiography, Digital Subtraction; Animals; Brain; Calcium-Binding Proteins; Delayed-Action Preparati | 2012 |
Acupuncture for cerebral vasospasm after subarachnoid hemorrhage: a retrospective case-control study.
Topics: Acupuncture Therapy; Adult; Aged; Aneurysm, Ruptured; Case-Control Studies; Cerebral Angiography; Co | 2013 |
[Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: prevention, diagnostics and therapy].
Topics: Angioplasty, Balloon; Brain Ischemia; Combined Modality Therapy; Critical Care; Humans; Nimodipine; | 2012 |
In situ forming nimodipine depot system based on microparticles for the treatment of posthemorrhagic cerebral vasospasm.
Topics: Delayed-Action Preparations; Microspheres; Nimodipine; Subarachnoid Hemorrhage; Treatment Outcome; V | 2013 |
The pharmacologic treatment of vasospasm after subarachnoid hemorrhage: a case study.
Topics: Adult; Blood Pressure; Brain; Cardiotonic Agents; Dobutamine; Female; Fluid Therapy; Hemodilution; H | 2003 |
The effects of nimodipine on regional cerebral blood flow, brain water and electrolyte contents in rats with subarachnoid hemorrhage.
Topics: Animals; Body Water; Brain Chemistry; Brain Ischemia; Calcium; Calcium Channel Blockers; Cations; Ce | 2003 |
Severe myocardial depression following intravenous nimodipine for aneurysmal subarachnoid haemorrhage.
Topics: Cardiomyopathies; Female; Humans; Infusions, Intravenous; Middle Aged; Nimodipine; Subarachnoid Hemo | 2004 |
Nimodipine in severe head injury.
Topics: Calcium Channel Blockers; Craniocerebral Trauma; Humans; Nimodipine; Randomized Controlled Trials as | 2004 |
Role of nimodipine in severe diffuse head injury.
Topics: Calcium Channel Blockers; Craniocerebral Trauma; Humans; Nimodipine; Randomized Controlled Trials as | 2004 |
[Stenting plus coiling: dangerous or helpful?].
Topics: Acute Disease; Aneurysm, Ruptured; Angiography, Digital Subtraction; Aspirin; Calcium Channel Blocke | 2005 |
Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhage.
Topics: Adult; Aged; Blood Pressure; Cerebral Angiography; Female; Heart Rate; Humans; Infusions, Intra-Arte | 2005 |
Use of phenytoin and other anticonvulsant prophylaxis in patients with aneurysmal subarachnoid hemorrhage.
Topics: Cognition Disorders; Drug Interactions; Humans; Intracranial Aneurysm; Nimodipine; Phenytoin; Seizur | 2005 |
[A simple and repeatable model of subarachnoid hemorrhage in rats].
Topics: Animals; Behavior, Animal; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Mod | 2005 |
Clinical experience of selective intra-arterial nimodipine treatment for cerebral vasospasm following subarachnoid hemorrhage.
Topics: Calcium Channel Blockers; Humans; Infusions, Intra-Arterial; Nimodipine; Subarachnoid Hemorrhage; Va | 2006 |
Dynamic CT perfusion imaging in subarachnoid hemorrhage-related vasospasm.
Topics: Angiography; Animals; Cerebrovascular Circulation; Nimodipine; Rabbits; Subarachnoid Hemorrhage; Tom | 2006 |
Subarachnoid hemorrhage due to Borrelia burgdorferi-associated vasculitis.
Topics: Animals; Anti-Bacterial Agents; Bites and Stings; Cefuroxime; Cerebral Angiography; Female; Humans; | 2006 |
[Idiopathic thunderclap headache: reversible vasospasm of the Arteria basilaris].
Topics: Adult; Angiography, Digital Subtraction; Cerebral Angiography; Diagnosis, Differential; Headache Dis | 2006 |
Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage.
Topics: Animals; Antihypertensive Agents; Apolipoproteins E; Behavior, Animal; Calcium Channel Blockers; Dis | 2006 |
Nimodipine for traumatic [corrected] subarachnoid haemorrhage: the end of the road or better trials?
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Humans; Nimodipine; Subarachnoid Hemorrhage; Tre | 2006 |
Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Topics: Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Cerebral Angiography; Cerebral Infarction; Fe | 2006 |
Subarachnoid hemorrhage after carotid artery stenting.
Topics: Aged; Carotid Artery, Internal; Carotid Stenosis; Headache; Humans; Infusions, Intravenous; Ischemic | 2007 |
[Systemic treatments of the vasospasm].
Topics: Hemodilution; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hy | 2007 |
[Endovascular treatment of vasospasm following subarachnoid aneurysmal haemorrhage].
Topics: Calcium Channel Blockers; Humans; Intracranial Aneurysm; Nicardipine; Nimodipine; Nitroprusside; Pap | 2007 |
Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo.
Topics: Animals; Basilar Artery; Cerebral Angiography; Female; Injections, Spinal; Male; Nimodipine; Nitric | 2008 |
Acute operation and preventive nimodipine improve outcome in patients with ruptured cerebral aneurysms.
Topics: Adult; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Intraoperative Complications; Ische | 1984 |
Reversal of cerebral arterial spasm by intrathecal administration of a calcium antagonist (nimodipine).
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Dogs; Female; Injections, Spinal; Intracranial Pr | 1984 |
A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings.
Topics: Animals; Collateral Circulation; Double-Blind Method; Drug Evaluation, Preclinical; Female; Ischemic | 1984 |
A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 2: Pathological findings.
Topics: Animals; Cerebral Arteries; Double-Blind Method; Drug Evaluation, Preclinical; Female; Macaca fascic | 1984 |
Intraoperative monitoring of cortical surface oxygen in subarachnoid haemorrhage.
Topics: Brain; Cerebrovascular Circulation; Electrodes; Humans; Intraoperative Care; Nicotinic Acids; Nimodi | 1984 |
Intracarotid slow bolus injection of nimodipine during angiography for treatment of cerebral vasospasm after SAH. A preliminary report.
Topics: Adolescent; Adult; Carotid Arteries; Cerebral Angiography; Female; Humans; Injections, Intra-Arteria | 1984 |
Late cerebral arterial spasm: the cerebrovascular response to hypercapnia, induced hypertension and the effect of nimodipine on blood flow autoregulation in experimental subarachnoid hemorrhage in primates.
Topics: Animals; Calcium Channel Blockers; Cerebral Angiography; Cerebrovascular Circulation; Electroencepha | 1983 |
Nimodipine for cerebral arterial spasm in subarachnoid hemorrhage.
Topics: Humans; Ischemic Attack, Transient; Nicotinic Acids; Nimodipine; Subarachnoid Hemorrhage; Vasodilato | 1983 |
Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarachnoid hemorrhage in cats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cats; Female; Ischemic Attack, Transient; Male; N | 1982 |
Nimodipine levels in breast milk.
Topics: Adult; Aneurysm, Ruptured; Cesarean Section; Combined Modality Therapy; Female; Humans; Milk, Human; | 1995 |
Causes of morbidity and mortality after ruptured aneurysm surgery in a series of 230 patients. The importance of control angiography.
Topics: Adolescent; Adult; Aged; Aneurysm, Ruptured; Brain Ischemia; Cerebral Angiography; Cerebral Hemorrha | 1995 |
The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat.
Topics: Animals; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Infarction; Homeostasis; Male; Nimodip | 1995 |
Are the calcium antagonists really useful in cerebral aneurysmal surgery? A retrospective study.
Topics: Brain Ischemia; Calcium Channel Blockers; Humans; Intracranial Aneurysm; Neuropsychological Tests; N | 1994 |
Which are the major determinants for outcome in aneurysmal subarachnoid hemorrhage? A prospective total management study from a strictly unselected series.
Topics: Adult; Aged; Aneurysm, Ruptured; Brain Ischemia; Cause of Death; Disability Evaluation; Female; Foll | 1994 |
Effect of intraventricular haemorrhage and rebleeding following subarachnoid haemorrhage on CSF eicosanoids.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Brain Damage, Chronic; Cerebral Ventricles; Dexamethasone; Di | 1994 |
Current pattern of in-hospital aneurysmal rebleeds. Analysis of a series treated with individually timed surgery and intravenous nimodipine.
Topics: Adult; Aged; Aneurysm, Ruptured; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Neurologi | 1994 |
Transcranial Doppler diagnosis of cerebral vasospasm following subarachnoid haemorrhage: correlation and analysis of results in relation to the age of patients.
Topics: Adult; Age Factors; Aged; Aneurysm, Ruptured; Blood Flow Velocity; Cerebrovascular Circulation; Dose | 1994 |
Sinus arrest after nimodipine treatment for a head injury.
Topics: Adult; Arrhythmia, Sinus; Electrocardiography; Heart Arrest; Humans; Ischemic Attack, Transient; Mal | 1994 |
Are the calcium antagonists really useful in cerebral aneurysmal surgery? A retrospective study.
Topics: Activities of Daily Living; Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Cerebral Angiogra | 1994 |
Which neuropsychological deficits are hidden behind a good outcome (Glasgow = I) after aneurysmal subarachnoid hemorrhage?
Topics: Adult; Age Factors; Aphasia; Cognition Disorders; Female; Follow-Up Studies; Glasgow Coma Scale; Hum | 1993 |
Treatment of symptomatic vasospasm with nimodipine.
Topics: Adolescent; Adult; Aged; Cause of Death; Female; Glasgow Coma Scale; Humans; Infusions, Intravenous; | 1993 |
Shunt-dependent hydrocephalus after subarachnoid haemorrhage and aneurysm surgery: timing of surgery is not a risk factor.
Topics: Adult; Aneurysm, Ruptured; Cerebrospinal Fluid Shunts; Combined Modality Therapy; Female; Humans; Hy | 1993 |
New developments in the treatment of SAH-induced cerebral vasospasm.
Topics: Humans; Ischemic Attack, Transient; Lipid Peroxides; Nimodipine; Pregnatrienes; Subarachnoid Hemorrh | 1993 |
[Comparison of 2 consecutive series of aneurysmal subarachnoid hemorrhage with or without nimodipine and study of the temperature curve].
Topics: Adult; Female; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Male; Middle Aged; Nimodip | 1993 |
Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Asian People; Biological Availability; | 1993 |
Cerebral hemodynamics in subarachnoid hemorrhage evaluated by transcranial Doppler sonography. Part 2. Pulsatility indices: normal reference values and characteristics in subarachnoid hemorrhage.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Flow Velocity; Brain Ischemia; Caroti | 1993 |
Cerebral hemodynamics in subarachnoid hemorrhage evaluated by transcranial Doppler sonography. Part 1. Reliability of flow velocities in clinical management.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Brain Ischemia; Cerebral Arteries; | 1993 |
A strategy for analyzing multiple parameters with application to aneurysmal SAH patients all of them clipped but treated with and without cyclosporine.
Topics: Adult; Aged; Aneurysm, Ruptured; Cyclosporine; Drug Therapy, Combination; Female; Glasgow Coma Scale | 1993 |
[Controlled hypotension against a background of nimodipine during an operation on neurosurgical patients with hypertension].
Topics: Adolescent; Adult; Anesthesia, General; Antihypertensive Agents; Hemodynamics; Humans; Hypertension; | 1995 |
Is transcranial Doppler sonography useful in detecting late cerebral ischaemia after aneurysmal subarachnoid haemorrhage?
Topics: Adult; Aged; Calcium Channel Blockers; Cerebral Arteries; Humans; Intracranial Aneurysm; Ischemic At | 1996 |
Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage.
Topics: Administration, Oral; Adult; Aged; Aneurysm, Ruptured; Blood Pressure; Brain; Calcium Channel Blocke | 1995 |
Cerebral vasospasm after subarachnoid haemorrhage of unknown aetiology: a clinical and transcranial Doppler study.
Topics: Adult; Aged; Blood Flow Velocity; Brain; Calcium Channel Blockers; Combined Modality Therapy; Critic | 1996 |
Complement activation in the central nervous system following blood-brain barrier damage in man.
Topics: Adult; Aneurysm, Ruptured; Anti-Inflammatory Agents; Betamethasone; Blood-Brain Barrier; Brain; Chem | 1996 |
Does nimodipine influence sex difference in outcome after aneurysmal subarachnoid haemorrhage?
Topics: Administration, Oral; Adolescent; Adult; Aged; Aneurysm, Ruptured; Brain Damage, Chronic; Brain Isch | 1996 |
Traumatic subarachnoid hemorrhage.
Topics: Craniocerebral Trauma; Humans; Nimodipine; Subarachnoid Hemorrhage; Treatment Outcome | 1997 |
Subarachnoid hemorrhage in the African-American population: a cooperative study.
Topics: Aminocaproates; Antifibrinolytic Agents; Black People; Brain Ischemia; Calcium Channel Blockers; Coh | 1997 |
Early management of head injury.
Topics: Analgesics, Opioid; Anesthetics, Inhalation; Anti-Anxiety Agents; Antihypertensive Agents; Benzodiaz | 1997 |
The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Length of Stay; Male; Middle | 1999 |
Effect of nimodipine on cerebral blood flow and cerebrovascular reactivity after subarachnoid haemorrhage.
Topics: Adult; Blood Gas Monitoring, Transcutaneous; Brain; Brain Ischemia; Calcium Channel Blockers; Cerebr | 1999 |
Nimodipine in subarachnoid hemorrhage.
Topics: Brain Ischemia; Glasgow Coma Scale; Humans; Ischemic Attack, Transient; Nimodipine; Retrospective St | 1999 |
Studies on concentration-time profiles of nimodipine enantiomers following intravenous and oral administration of nimodipine in patients with subarachnoid hemorrhage.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Injections, | 2000 |
Nimodipine-induced acute hypoxemia: case report.
Topics: Acute Disease; Calcium Channel Blockers; Drug Administration Schedule; Humans; Hydrocephalus; Hypoxi | 2000 |
Functional methods for evaluation the occurrence of delayed ischemic deficit in patients with subarachnoid hemorrhage.
Topics: Adult; Aphasia, Wernicke; Basilar Artery; Brain; Brain Ischemia; Cerebrovascular Circulation; Evoked | 2001 |
Contemporary management of subarachnoid hemorrhage and vasospasm: the UIC experience.
Topics: Algorithms; Angioplasty, Balloon; Calcium Channel Blockers; Catheterization; Cerebral Angiography; D | 2001 |
Prophylactic hypervolemia without calcium channel blockers in early aneurysm surgery.
Topics: Blood Volume; Brain; Hemodilution; Humans; Intracranial Aneurysm; Nimodipine; Postoperative Complica | 1992 |
Vasospasm after experimentally induced subarachnoid haemorrhage and treatment with nimodipine.
Topics: Animals; Brain; Calcium; Disease Models, Animal; Endothelium, Vascular; Ischemic Attack, Transient; | 1992 |
Overall outcome in aneurysmal subarachnoid hemorrhage. A prospective study from neurosurgical units in Sweden during a 1-year period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Hemodilution; Humans; Hydrocephalus; Intr | 1992 |
Pulmonary vasoconstriction following intravenous nimodipine.
Topics: Humans; Hypertension, Pulmonary; Male; Middle Aged; Nimodipine; Pulmonary Artery; Subarachnoid Hemor | 1992 |
Nimodipine evoked dilation of cerebral arteries early during the development of late vasospasm in subarachnoid hemorrhage.
Topics: Aged; Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Male; Neurolo | 1991 |
Does nimodipine eliminate arterial hypertension as a prognostic risk factor in subarachnoid haemorrhage?
Topics: Adolescent; Adult; Aged; Female; Humans; Hypertension; Intracranial Aneurysm; Ischemic Attack, Trans | 1991 |
[Subarachnoid hemorrhage. Treatment with nimodipine--a new calcium antagonist of dihydropyridine type].
Topics: Humans; Nimodipine; Subarachnoid Hemorrhage | 1991 |
Advances in the management of victims struck by ruptured intracranial aneurysms.
Topics: Aged; History, 19th Century; History, 20th Century; History, Ancient; Humans; Intracranial Aneurysm; | 1990 |
Unfavorable outcome following early surgical repair of ruptured cerebral aneurysms--a critical review of 238 patients.
Topics: Aged; Cerebral Hemorrhage; Female; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Male; | 1991 |
Subarachnoid haemorrhage.
Topics: Brain Ischemia; Humans; Intracranial Aneurysm; Nimodipine; Referral and Consultation; Rupture, Spont | 1991 |
Angiographic vasospasm and release of platelet thromboxane after subarachnoid hemorrhage.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cerebral Angiography; Female; Humans; Intracranial An | 1991 |
Cyclosporine A for the prevention of neurological deficit following subarachnoid hemorrhage.
Topics: Animals; Cyclosporins; Dogs; Humans; Ischemic Attack, Transient; Nimodipine; Plasma Substitutes; Ste | 1991 |
Effect of nimodipine on cerebrovascular response to CO2 in asymptomatic individuals and patients with subarachnoid hemorrhage: a transcranial Doppler ultrasound study.
Topics: Adolescent; Adult; Aged; Blood Flow Velocity; Carbon Dioxide; Cerebral Arteries; Cerebrovascular Cir | 1990 |
Role of angioplasty in the treatment of symptomatic vascular spasm occurring in the post-operative course of intracranial ruptured aneurysms.
Topics: Adult; Angiography; Angioplasty, Balloon; Circle of Willis; Female; Humans; Intracranial Aneurysm; I | 1990 |
Nimodipine: the use of calcium antagonists to prevent vasospasm following subarachnoid hemorrhage.
Topics: Humans; Ischemic Attack, Transient; Nimodipine; Patient Care Planning; Subarachnoid Hemorrhage | 1990 |
Nimodipine and cerebral ischaemia following subarachnoid haemorrhage.
Topics: Brain Ischemia; Humans; Injections, Intravenous; Nimodipine; Subarachnoid Hemorrhage | 1990 |
Delayed brainstem ischemia following rupture of a basilar artery aneurysm and its reversal by nimodipine.
Topics: Adult; Basilar Artery; Brain Ischemia; Brain Stem; Female; Humans; Intracranial Aneurysm; Nimodipine | 1990 |
Clinical experiences with nimodipine treatment in patients after SAH and aneurysm surgery.
Topics: Adolescent; Adult; Aged; Female; Humans; Infusions, Intravenous; Intracranial Aneurysm; Ischemic Att | 1990 |
[The value of a computer tomography scanner and controlled arteriography in the study of the results of aneurysm surgery. A series of 100 consecutive cases].
Topics: Adult; Aged; Aneurysm; Angiography; Carotid Artery Diseases; Cerebral Angiography; Cerebral Hemorrha | 1990 |
[Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume].
Topics: Adolescent; Adult; Aged; Cerebral Arterial Diseases; Child; Child, Preschool; Clinical Protocols; Fe | 1990 |
Nimodipine: evidence for clinically significant gastrointestinal side-effects.
Topics: Colonic Diseases; Humans; Intestinal Pseudo-Obstruction; Male; Middle Aged; Nimodipine; Subarachnoid | 1990 |
[Prophylactic treatment of vasospasm with nimodipine in subarachnoid hemorrhage].
Topics: Adult; Aged; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Nimodipine; Subarachnoid | 1990 |
Changes in contractile response and effect of a calcium antagonist, nimodipine, in isolated intracranial arteries of baboon following experimental subarachnoid hemorrhage.
Topics: Animals; Calcium Channel Blockers; Cerebral Arteries; Female; In Vitro Techniques; Male; Muscle Cont | 1990 |
Comment: nimodipine in treatment of subarachnoid hemorrhage.
Topics: Humans; Nimodipine; Subarachnoid Hemorrhage | 1989 |
[Nimodipine and cerebrovascular circulation. Initial results apropos of 4 cases of subarachnoid hemorrhage].
Topics: Cerebrovascular Circulation; Female; Humans; Male; Middle Aged; Nimodipine; Subarachnoid Hemorrhage; | 1989 |
[Value of transcranial Doppler in the monitoring of aneurysmal subarachnoid hemorrhage treated with calcium inhibitors].
Topics: Brain; Follow-Up Studies; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Nimodipine; Sub | 1989 |
[Nimodipine for subarachnoid hemorrhage].
Topics: Humans; Ischemic Attack, Transient; Nimodipine; Subarachnoid Hemorrhage | 1989 |
An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage.
Topics: Acute Disease; Animals; Blood Pressure; Cerebrovascular Circulation; Disease Models, Animal; Evoked | 1989 |
[Use of calcium inhibitors in subarachnoid hemorrhage].
Topics: Double-Blind Method; Humans; Ischemic Attack, Transient; Nimodipine; Random Allocation; Subarachnoid | 1989 |
[Does nimodipine improve the outcome of perioperative complications of aneurysm rupture? Results of systematic treatment].
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Ischemic Attack, | 1989 |
Nimodipine and cerebral ischaemia following subarachnoid haemorrhage.
Topics: Brain Ischemia; Humans; Nimodipine; Subarachnoid Hemorrhage | 1989 |
Morbidity and mortality after early aneurysm surgery--a prospective study with nimodipine prevention.
Topics: Adult; Aged; Brain Ischemia; Cerebral Arteries; Cerebral Hemorrhage; Cerebral Infarction; Combined M | 1989 |
Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study.
Topics: Adult; Aged; Blood Flow Velocity; Cerebrovascular Circulation; Female; Humans; Intracranial Aneurysm | 1987 |
Outcome of aneurysmal subarachnoid hemorrhage in a hospital population: a prospective study including early operation, intravenous nimodipine, and transcranial Doppler ultrasound.
Topics: Adolescent; Adult; Aged; Cerebrovascular Circulation; Female; Humans; Intracranial Aneurysm; Male; M | 1988 |
Effect of nimodipine on arachidonic acid metabolites after subarachnoid hemorrhage.
Topics: 6-Ketoprostaglandin F1 alpha; Arachidonic Acid; Arachidonic Acids; Humans; Nimodipine; Prostaglandin | 1987 |
Effect of nimodipine on mitochondrial respiration in different rat brain areas after subarachnoid haemorrhage.
Topics: Animals; Brain; Male; Mitochondria; Nimodipine; Oxygen Consumption; Rats; Rats, Inbred Strains; Suba | 1988 |
Management of aneurysmal subarachnoid hemorrhage.
Topics: Aminocaproic Acid; Humans; Intracranial Aneurysm; Nervous System Diseases; Nicardipine; Nimodipine; | 1988 |
Results of treatment for cerebral saccular aneurysms in a small neurosurgical unit--evaluation of early operation and nimodipine treatment.
Topics: Humans; Intracranial Aneurysm; Nimodipine; Rupture, Spontaneous; Subarachnoid Hemorrhage | 1988 |
Prevention and treatment of delayed ischaemic dysfunction in patients with subarachnoid haemorrhage. An update.
Topics: Animals; Brain Ischemia; Humans; Nimodipine; Subarachnoid Hemorrhage | 1988 |
The calcium entry blocker nimodipine improves the quality of life of patients operated on for cerebral aneurysms. A 5-year follow-up analysis.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Infusions, I | 1988 |
Nimodipine treatment of subarachnoid hemorrhage.
Topics: Adult; Blood Pressure; Cerebrovascular Circulation; Drug Administration Schedule; Female; Humans; Hy | 1988 |
Does intravenous nimodipine treatment influence cognition in patients subjected to early aneurysm operation?
Topics: Adult; Aged; Cognition Disorders; Humans; Injections, Intravenous; Middle Aged; Neuropsychological T | 1988 |
Early aneurysm surgery: a 7 year clinical practice report.
Topics: Cerebral Angiography; Cerebrospinal Fluid Shunts; Humans; Hydrocephalus; Intracranial Aneurysm; Isch | 1988 |
Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm.
Topics: Animals; Cerebral Angiography; Chronic Disease; Female; Injections, Spinal; Ischemic Attack, Transie | 1988 |
Thromboxane B2 levels in serum during continuous administration of nimodipine to patients with aneurysmal subarachnoid hemorrhage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Intracranial Aneurysm; Nimodipine; Subarachnoid Hem | 1988 |
Significance of "ultra-early" rebleeding in subarachnoid hemorrhage.
Topics: Female; Hematoma; Humans; Intracranial Aneurysm; Male; Mental Disorders; Middle Aged; Nervous System | 1988 |
Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results.
Topics: Adolescent; Adult; Brain Ischemia; Child; Child, Preschool; Follow-Up Studies; Humans; Hypertension; | 1988 |
Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation.
Topics: Adult; Brain Ischemia; Cerebrovascular Circulation; Female; Humans; Intracranial Aneurysm; Male; Mid | 1987 |
Nimodipine-treated subarachnoid hemorrhage associated with acute pseudo-obstruction of the colon.
Topics: Acute Disease; Colonic Pseudo-Obstruction; Female; Humans; Intestinal Pseudo-Obstruction; Middle Age | 1987 |
[Effect of the calcium antagonist nimodipine on hemodynamics, gas exchange and endocrine parameters in opiate anesthesia].
Topics: Anesthesia, General; Cerebrovascular Circulation; Fentanyl; Hemodynamics; Hormones; Humans; Infusion | 1987 |
Nimodipine and chronic vasospasm in monkeys: Part 3. Cardiopulmonary effects.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Dose-Response Relationship, Drug; | 1986 |
Computerized tomography and prognosis in early aneurysm surgery.
Topics: Cerebral Angiography; Follow-Up Studies; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; | 1986 |
[Vascular and neuronal mechanisms of calcium antagonists. Significance in neurological therapy].
Topics: Blood-Brain Barrier; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Circulation; Humans; | 1986 |
Prognosis in ruptured cerebral aneurysms with early operation and nimodipine prophylaxis.
Topics: Adult; Aged; Cisterna Magna; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Injections; I | 1986 |
Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.
Topics: Administration, Oral; Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Female; Humans; Infusio | 1986 |
Nimodipine and early aneurysm operation in good condition SAH patients.
Topics: Administration, Topical; Adolescent; Adult; Aged; Female; Follow-Up Studies; Humans; Infusions, Pare | 1986 |
[Cardiorespiratory problems in the use of calcium antagonists for vasospasm prophylaxis in subarachnoid hemorrhage].
Topics: Adult; Calcium Channel Blockers; Heart Diseases; Hemodynamics; Humans; Ischemic Attack, Transient; N | 1986 |
[Aneurysms of the auditory artery at the internal acoustic meatus].
Topics: Arteries; Cerebellum; Combined Modality Therapy; Ear, Inner; Humans; Intracranial Aneurysm; Male; Mi | 1986 |
Cerebrovascular and metabolic changes during the delayed vasospasm following experimental subarachnoid hemorrhage in baboons, and treatment with a calcium antagonist.
Topics: Animals; Blood Flow Velocity; Cerebral Angiography; Cerebral Arteries; Disease Models, Animal; Femal | 1987 |
Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm.
Topics: Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Dogs; Female; Injections | 1985 |
Early aneurysm operation and vasospasm. Intracranial Doppler findings.
Topics: Adult; Calcium Channel Blockers; Circle of Willis; Female; Humans; Intracranial Aneurysm; Ischemic A | 1985 |
Chronic cerebral vasospasm: effect of calcium antagonists.
Topics: Animals; Cerebral Angiography; Chronic Disease; Disease Models, Animal; Dogs; Injections; Ischemic A | 1986 |
Delayed ischemic deterioration in patients with early aneurysm operation and intravenous nimodipine.
Topics: Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Arterial Diseases; Combi | 1986 |
Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Female; Ischemic Attack, Transient; Macac | 1985 |
Nimodipine and chronic vasospasm in monkeys: Part 2. Pharmacological studies of vessels in spasm.
Topics: Animals; Calcium Channel Blockers; Cerebral Arteries; In Vitro Techniques; Ischemic Attack, Transien | 1985 |
The hemodynamic effects of nimodipine in patients anesthetized for cerebral aneurysm clipping.
Topics: Anesthesia, General; Blood Pressure; Calcium Channel Blockers; Hemodynamics; Humans; Intracranial An | 1985 |
Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhage.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Female; Heart Rate; Humans; Hypertension; Intracran | 1985 |
Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage. Clinical results of a multicenter study.
Topics: Adult; Aged; Brain Ischemia; Drug Interactions; Female; Humans; Intracranial Aneurysm; Ischemic Atta | 1985 |
Immediate postangiographic intraarterial treatment of cerebral vasospasm after subarachnoid hemorrhage with nimodipine. Report on 3 cases.
Topics: Adult; Calcium Channel Blockers; Cerebral Angiography; Female; Humans; Injections, Intra-Arterial; I | 1985 |
Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage.
Topics: Administration, Oral; Calcium Channel Blockers; Female; Half-Life; Humans; Infusions, Parenteral; In | 1985 |
Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage.
Topics: Arrhythmias, Cardiac; Blood Pressure; Brain Ischemia; Calcium Channel Blockers; Heart Rate; Humans; | 1985 |
Current management of cerebral aneurysms: is it based on facts or myths?
Topics: Adult; Age Factors; Aged; Antifibrinolytic Agents; Cerebral Angiography; Humans; Hypotension, Contro | 1985 |